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Male genital schistosomiasis (MGS) is a specific chronic manifestation of schistosomiasis 
associated with schistosome eggs and related pathologies in the genital system of men inhabiting or 
visiting endemic areas. Despite description of the first recognised MGS patient by Madden in 1911, 
the epidemiology, diagnostic testing and case management of MGS are not well described owing to 
limited research and diminishing focus over several decades. Furthermore, as the human 
immunodeficiency virus (HIV) epidemic expands across sub-Saharan Africa (SSA), there is renewed 
interest in MGS owing to plausible but as of yet under-explored interactions with HIV.    
To shed new light on MGS, a longitudinal cohort study was conducted among fishermen 
along the southern shoreline of Lake Malawi, an endemic area in SSA to investigate the prevalence 
of MGS, its associated knowledge, attitudes and practices (KAP), and determine the potential 
increase of viral shedding in semen of HIV-positive men with MGS.  A systematic review conducted 
prior to the onset of the research fieldwork describing the MGS epidemiology, clinico-pathological 
manifestations, diagnostic techniques and treatment outlined and informed the current approach to 
the body of research presented here.  
Fishermen aged 18+ years were recruited into the study after providing informed written 
consent and individual questionnaires were administered to assess their KAP associated with MGS. 
Thereafter, participants submitted urine, semen, and blood for point-of-care (POC) field 
parasitological tests, and later laboratory-based molecular polymerase chain reaction (PCR), and HIV 
VL analyses.  In addition, transabdominal and scrotal ultrasonography to assess the pathological 
effects of MGS on their genital organs were performed. Praziquantel therapy was provided to all 
participants, together with the follow-up diagnoses and treatment dates after 1, 3, 6 and 12-months’ 
intervals. 
376 fishermen (320 HIV-negative and 56 HIV-positive on Antiretroviral therapy (ART)) aged 
between 18 and 70 years (median: 30.0 years), were recruited into the study, and had 
questionnaires interviews.  At baseline, prevalence of UGS (S. haematobium eggs in urine) was 
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17.1% (n = 210, median: 2.3 per 10 ml, range: 0.1 – 186.0), 3.8% had a positive point-of-care 
circulating cathodic antigen (POC-CCA) indicative of intestinal S. mansoni infection, while MGS 
prevalence was 10.4% by semen microscopy (n = 114, median: 5.0, range: 0.1 – 30.0) and 26.5% by 
real-time PCR (n = 65, Ct value range: 18.8 – 36.6).  More participants (66.7%) with schistosome eggs 
in semen were observed to not have any eggs in their urine. 6.9% of participants (n = 130) were 
observed to have pathological lesions in their genital organs on ultrasonography.  For 15 HIV-MGS 
cases and 16 HIV-only controls who submitted paired blood and semen samples during the 
longitudinal study, more cases than controls had detectable and quantifiable VL, which regressed 
with PZQ.  Similarly, the results of the diagnostic tests improved, with negative schistosome egg, 
real-time PCR in semen and pathological resolution on follow-up.  
In conclusion, MGS has been observed, via parasitological, molecular and radiological 
examinations, to be common in local male inhabitants (fishermen) of endemic areas along the south 
shoreline of Lake Malawi in the SSA region and shown to respond to standard PZQ treatment.  
Improving availability and accessibility for all people in these areas to PZQ, diagnostic tools for MGS, 
and combined HIV and schistosomiasis control interventions are advocated to reduce morbidity and 












Schistosomiasis, also known as Bilharzia, is a prevalent parasitic disease with the highest 
burden among 17 recognised neglected tropical diseases (NTDs) (Christinet et al., 2016) and  
endemic in 78 low-and-middle income countries (LMICs) of tropical and subtropical regions. This 
freshwater snail-borne disease affects over 200 million people globally, 85% in sub-Saharan Africa 
(SSA) with 20 million suffering from the severe urogenital and intestinal complications of the disease 
(Engels et al., 2002; WHO, 2018b). Each year, 200,000 people are estimated to die annually from the 
disease (van der Werf et al., 2003; Colley et al., 2014). 
Urogenital schistosomiasis (UGS) caused by Schistosoma haematobium is responsible for 
most of the global schistosomiasis burden, infecting over 112 million people annually (WHO, 2013b) 
and causing chronic urinary bladder calcification, carcinoma, obstructive uropathy, renal 
hydronephrosis and genital complications (Butterworth et al., 2013; Squire and Stothard, 2014). 
However, much emphasis of UGS has been on urinary pathology, overlooking the genital 
complications especially in men.  Male genital schistosomiasis (MGS) is a specific gender 
manifestation of schistosomiasis, associated with presence of schistosome eggs and pathologies in 
the genital fluids and organs, which was first described in 1911 (Madden, 1911).  
Despite several case reports and research studies describing MGS since the first case 
description (Gelfand et al., 1970; Corachan et al., 1994; Leutscher et al., 2000), there has been little 
knowledge on its current burden and morbidity among local inhabitants  in endemic areas of SSA. In 
the last decade, UGS has gained much attention in SSA for morbidity control through the preventive 
chemotherapy programmes with mass drug administration (MDA) of Praziquantel (PZQ), a mainstay 
pyrazinoisoquinole antihelminth for schistosomiasis (Knopp et al., 2013).  
In addition, the epidemic of Human immunodeficiency virus (HIV) infection in SSA has been 
observed to overlap with that of schistosomiasis (Ndeffo Mbah et al., 2013), highlighting the possible 
interactions between the two diseases. While women with female genital schistosomiasis (FGS) have 
shown to have an increased risk of HIV acquisition (Kjetland et al., 2006; Jourdan et al., 2011), men 
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whose semen harbours Schistosoma eggs have been observed with increased levels of inflammatory 
cells and immunological mediators associated with HIV infection, highlighting the possible risk to HIV 
acquisition and transmission (Leutscher et al., 2005; Leutscher et al., 2008b). Reduction of viral load 
in semen have been demonstrated after PZQ treatment in HIV positive men coinfected with UGS 
(Midzi et al., 2017), which suggest the need for further research studies to explore the role of PZQ 
treatment as one of the HIV control interventions in schistosomiasis-endemic areas.  
1.2. Justification and rationale of the present study 
Malawi (Figure 1) is a land-locked country in SSA where both urogenital S. haematobium and 
intestinal S. mansoni are prevalent and focally distributed along lakes, rivers and other water bodies 
(Teesdale and Chitsulo, 1985; Makaula et al., 2014). The shorelines along Lake Malawi, third largest 
lake in Africa and a renowned tourist destination (NSO and ICF, 2011), has high prevalence of S. 
haematobium infection, with evidence of frequent re-infection episodes especially in children 
(Madsen et al., 2011). Very little is known about the burden of MGS in these schistosomiasis-
endemic areas in SSA. 
Furthermore, Malawi has a generalised HIV epidemic whose prevalence is high among adults 
aged 15 – 49 years, estimated at 10.0% in 2016 (Ministry of Health, 2017), and the communities on 
the shoreline of Lake Malawi like Mangochi district have higher prevalence at 11.8% in 2014, 
compared to other non-endemic areas in the country (NSO and ICF, 2011; UNAIDS, 2014). Fishermen 
are among the high-risk occupational groups in Malawi with higher HIV prevalence, which was 11.5% 
in 2014 (NSO, 2014; NAC, 2015), despite the many control efforts to reduce HIV incidence and 
mortality.  
The current control interventions of schistosomiasis and HIV, running parallel in dual-
epidemic regions, are also leaving out sexually-active men, women and girls who are also at high-risk 
of both conditions, thereby slowing down efforts of arresting the burden of both diseases (Hotez, 
Fenwick and Kjetland, 2009; Rollinson et al., 2013; Stothard, Bustinduy and Montresor, 2014; 
Stecher et al., 2015). The multidisciplinary research studies on MGS test the hypotheses that PZQ 
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treatment reduces the prevalence and morbidity of MGS as well as the potential risk of HIV 
transmission through viral load shedding in semen of adult fishermen living in schistosomiasis-
endemic areas along Lake Malawi. 
 
Figure 1: Map of Malawi showing Mangochi District in the Southern region 
and Lake Malawi 




1.3. My research aspirations for the study 
In order to determine the current prevalence and morbidity of MGS in a schistosomiasis-
endemic area in SSA, I conducted multidisciplinary cohort research studies among high-risk 
population of local fishermen along south shoreline of Lake Malawi in Mangochi district. The cohort 
studies were further set to evaluate the extent of relationship between MGS and HIV-1 VL through 
potential increase of viral shedding in semen of HIV-positive men with MGS in these fishing 
communities.  
1.4. Context of the study  
The research study was conducted among local fishermen aged 18 years and above, dwelling 
in specific fishing villages (communities) identified and selected along the south shoreline of Lake 
Malawi in Mangochi district, which is endemic for schistosomiasis. Fishermen just like children and 
women, have high frequency of contact with infested lake water when carrying out their daily 
household and income-generating activities, posing themselves at huge risk to schistosomiasis 
infection, and its complications like MGS. Hence, selection of this population in order to investigate 
MGS and its potential impact of HIV infection. 
As misconceptions or cultural perceptions regarding the nature of the research including 
semen collection were anticipated to affect implementation of the research, adequate awareness 
and sensitisation meetings with local traditional leaders, healthcare personnel and individual 
fishermen were conducted to describe the research objectives and address their concerns, using the 
experiences and lessons from recent studies with similar methodology in the district (Kipandula and 
Lampiao, 2015). All participants were offered PZQ treatment in accordance with the national 
guidelines.   
1.5. Thesis layout  
The chapters of this PhD thesis have been presented in the following structure: 
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Chapter 1 General overview: Provides the general overview of the thesis, rationale, research 
aspirations and context of the MGS cohort studies. 
Chapter 2 General Introduction: Provides the background knowledge of urogenital 
schistosomiasis, current literature review on MGS, HIV co-infection, existing gaps, specific aims and 
objectives of the MGS cohort studies. 
Chapter 3 Systematic review on MGS: Provides the updated systematic review of MGS, 
describing the current epidemiology, clinico-pathological descriptions, diagnostic techniques, 
treatments and management of MGS. 
Chapter 4 Description of the Cohort studies: Provides the general description of the 
fishermen cohort recruited at baseline and followed up at 1-, 3-, 6- and 12-months’ time-points of 
the study as well as the methodology used for data collection. 
Chapter 5 Baseline prevalence of MGS and associated knowledge, attitudes and practices: 
Provides the baseline prevalence of MGS in the cohort and describes the knowledge, attitudes and 
practices associated with MGS. 
Chapter 6 Molecular diagnosis of MGS and progression after treatment: Provides the results 
of the novel diagnosis of MGS using advanced molecular technique, real-time PCR on semen and 
compared to the traditional semen microscopy and urine filtration. It also reports on the results of 
the study follow-up at 1-, 3-, 6- and 12-months’ time-points after PZQ treatment. 
Chapter 7 Morbidity of MGS described by ultrasonography: Provides the results of the 
transabdominal and scrotal ultrasonography conducted to describe the morbidity of MGS and 
subsequent regression after PZQ treatment during the follow-up at 1-, 3-, 6- and 12-months’ time-
points. 
Chapter 8 Seminal HIV-1 RNA detection among HIV-positive in men with MGS: Provides the 
results of the novel pilot HIV-1 RNA detection in semen and blood plasma among men with MGS and 
HIV co-infection compared with HIV-positive men without MGS, and followed up at all time-points of 
the cohort studies. 
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Chapter 9 General Discussion: Provides discussion on the results of the MGS longitudinal 
cohort studies in Malawi, implications to the schistosomiasis control in Malawi and region, possible 











2.1. Summary  
This chapter provides detailed background knowledge on schistosomiasis, with emphasis on 
urogenital schistosomiasis (UGS), its life cycle, clinic-pathological features, diagnosis, treatment, 
control and prevention. In addition, one of the complications particularly in men, male genital 
schistosomiasis (MGS) is further described, highlighting the current literature review, HIV co-
infection, existing gaps, and research focus, with specific aims and objectives of the multidisciplinary 
MGS cohort studies. 
The section on the diagnosis of schistosomiasis was published in Parasitology journal 
(https://doi.org/10.1017/S0031182019000969) as cited:  
Kayuni S.A., Corstjens P.L., LaCourse E.J., Bartlett K.E., Fawcett J., Shaw A., Makaula P., 
Lampiao F., Juziwelo L., de Dood C.J., Hoekstra P.T., Verweij J.J., Leutscher P.D.C., van Dam G.J., van 
Lieshout L. and Stothard J.R. (2009). How can schistosome circulating antigen assays be best 
applied for diagnosing male genital schistosomiasis (MGS): an appraisal using exemplar MGS cases 
from a longitudinal cohort study among fishermen on the south shoreline of Lake Malawi. 
Parasitology, Volume 146, Issue 14, pages 1785-95. (Received: 20 February 2019, revised: 30 June 
2019, accepted: 3 July 2019, published online: 27 August 2019). 
My contribution to this manuscript is that I conducted the literature review on MGS and the 
research fieldwork along south shoreline of Lake Malawi. Thereafter, I wrote the manuscript and 
made all the changes suggested by the co-authors and journal referees.  
35 
 
2.2. Background  
Schistosomiasis is among five of the most common NTDs which include: lymphatic filariasis 
(LF), onchocerciasis, soil-transmitted helminths (STH) and trachoma (Hotez et al., 2007). These 
diseases affect poor people in LMICs and contribute to significant morbidity and considerable 
mortality in the world. Schistosomiasis is a parasitic disease which remains a major public health 
concern as children, young women and other vulnerable populations are disproportionately affected 
in most rural and deprived urban localities. Such areas have low socio-economic status, poor 
sanitation, inadequate access to clean and safe potable water, with limited medical resources, 
consequently depriving them of normal development and potential (Figure 2) (Molyneux, Hopkins 
and Zagaria, 2004; Tchuente, 2012).  
Furthermore, significant proportion of infected children and adults usually harbour more 
than one parasite, making polyparasitism a norm in the developing world, as such the control 
strategies on NTDs should focus on integrated approach for cost-effectiveness and streamlined 
efficiency. However, the highest priority of the international health community is on the ‘big three’ 
diseases, HIV/AIDS, tuberculosis and malaria, while burden of NTDs is estimated to be a quarter of 
that of HIV and half of malaria, resulting in less attention on huge morbidity of schistosomiasis and 
other NTDs, compared to the big three’s higher mortality  (Molyneux, Hotez and Fenwick, 2005). 
 
Figure 2: Women, children and men in their daily activities along south Lake Malawi shores  
Photo credit: Mohammad H. Alharbi, LSTM, U.K. November 2017. 
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Schistosomiasis is caused by digenetic trematodes (schistosomes) of Schistosoma genus and 
remains one of the commonest NTDs in Africa region (Engels et al., 2002; Hotez, Fenwick and 
Kjetland, 2009). In 1851, Theodor Bilharz first reported and described these human parasites after 
discovering adult schistosome worms in post-mortems conducted in Egypt (Ross et al., 2002; Squire 
and Stothard, 2014). This trematode was initially termed as Distomum haematobium and later 
changed to Schistosoma haematobium (Rollinson et al., 1997; Rollinson, 2009). He did not realise 
presence of Schistosoma mansoni worms in the post-mortems too. Schistosome eggs were 
recovered in Chinese and Egyptian mummies demonstrating the presence of infection in early 
civilisation. 
Schistosomes belong to Phylum Platyhelminthes (flatworms), Class Trematoda (flukes / 
schistosomes) (Figure 3), with 24 species of schistosomes currently recognised, six of which cause 
disease in humans namely, S. haematobium, S. mansoni, S. japonicum, S. intercalatum, S. mekongi 
and S. guineensis. Some species have particular veterinary importance, namely S. bovis, S. mattheii 
and S. curassoni, however, hybridization between animal and human species has been reported, 
highlighting potential emergence of zoonotic infections (Huyse et al., 2009; Leger and Webster, 
2017; Webster et al., 2019). Interestingly, S. japonicum has highest zoonotic potential, infecting 
humans and animals (both wild and domestic) such as cattle, dogs, pigs, water buffaloes, rodents 
(Knopp et al., 2013). 
Only three schistosome species are responsible for majority of human disease, with different 
geographical distribution, morbidity trends, intermediate hosts and clinico-pathological 
presentations (Squire and Stothard, 2014), namely urogenital schistosomiasis caused by S. 
haematobium, endemic throughout Africa, parts of Arabia, the Near East, Madagascar, Mauritius 
and recently reported in Corsica, France (Berry et al., 2014; Gautret et al., 2015; Moné et al., 2015); 
gastrointestinal-hepatosplenic schistosomiasis caused by S. mansoni in Africa, Madagascar, Arabia, 
South America and Caribbean, and S. japonicum in China, Philippines, Sulawesi and Thailand. The 
eggs of each species are distinct and useful in parasitological diagnosis, while the schistosome worm 
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burden is measured by the number of eggs / ova excreted which can also be correlated to 
morbidities in the urinary tract or gastrointestinal-hepatosplenic systems (Andrade et al., 2017). 
 
Figure 3: Order of the main schistosome parasites affecting human globally 
2.3. Life cycle of schistosomes 
The Life cycle of schistosomes (Figure 4) was clearly described by the father of modern 
helminthology, Robert T. Leiper (1881-1969) between 1915 and 1916 in Egypt (Garnham, 1970; 
Willmott, 1981; Stothard et al., 2016). Schistosomiasis is distributed along freshwater bodies which 
create habitats for their particular intermediate snail hosts, namely aquatic sinistral turreted Bulinus 
snails for S. haematobium (also S. intercalatum and S. guineensis); flat ramshorn Biomphalaria snails 
for S. mansoni or small amphibious operculate turreted Oncomelania snails for S. japonicum. These 
freshwater habitats are areas where both intermediate snails and people come together, mostly 
those with low-level sanitation, contaminated with urine or faeces harbouring Schistosoma ova. 
The eggs expelled from the human body through urine or faeces, contain ciliated miracidia 
which hatch out once in these freshwater habitats and swim in search for suitable specific snail hosts 
which they penetrate. Thereafter, the miracidia undergoes asexual replication cycle through two 
generations of sporocysts (mother and daughter sporocysts) resulting in release of minute fork-
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tailed cercariae into water 4-6 weeks later (Knopp et al., 2013; Colley et al., 2014). This snail’s ability 
to develop miracidia is usually affected by environmental factors such as high temperature and 
water chemistry. Once exposed to light, the snails shed hundreds to thousands of infective cercariae 
into water for several weeks, which survive for 24 – 72 hours unless a suitable host is found.  
 
Figure 4: Life cycle of schistosomiasis  




Once the cercaria comes into contact with human skin, it penetrates and sheds its tail, 
becoming a schistosomulum and enters capillary blood or lymph vessels. This penetration may cause 
itchy maculopapular “swimmer’s or fisherman’s” skin rash, commonly experienced among visitors 
and migrants on their first exposure in high endemic areas especially in S. japonicum infection than 
S. haematobium and S. mansoni (Ross et al., 2002). The schistosomula develop while following 
circulatory or lymphatic system and through the lungs by passive intravascular migration, causing 
cough and wheezing, before reaching the liver as juvenile male and female worms, where they 
reside in the intrahepatic portal vessels. In host circulation, maturing worms survives hostile immune 
environment due to their ability of regenerating their outer tegument (Colley and Secor, 2014; Ross 
and Yuesheng, 2017).   
The juvenile worms in the liver develops further and mature in 1 – 3 months into adult 
schistosomes, 1-2 cm long, which are actively motile and pair up in perpetual copulatory position 
with the female being held in the male copulo (gynecorphoric canal).  They can live in humans 
normally for 3 - 10 years but up to 40 years has been reported. The worms feed on erythrocytes, 
releases energy from glucose metabolism or fatty acid oxidation for egg production (Colley et al., 
2014). The schistosomes have no anus as their gut has a blind end, so they regurgitate their waste 
into blood stream, which is useful for development of blood and urine-based diagnostic assays. 
Thereafter, the matured paired worms migrate to final habitat in specific venous plexuses, vesical 
(bladder) for S. haematobium and mesenteric for S. mansoni and other species, with some possibly 
migrating to genital vessels where they are responsible for causing genital schistosomiasis.  
The adult male and female worms mate to fertilise the eggs which the female lays in the 
terminal venules of preferred tissues. The eggs are impeded from escaping into circulation by the 
adult worms obstructing the vessels. The eggs then penetrate the vessel walls and enter tissues of 
the particular neighbouring organs. The parasite and host adapt to the ova presence which aids 
rhythmic excretion, with the peak before mid-day (Rollinson, 2009). In addition, movement of the 
organs propels the eggs towards the lumen of the organ from where they escape into the outside 
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world through urine or stool.  About half of the eggs get trapped in the tissues and die within 2 
weeks, causing bulk of pathologies described as chronic schistosomiasis in the next sections (Colley 
et al., 2014).  
Some requirements for transmission of schistosomiasis include contaminated water with 
viable eggs expelled from human hosts, presence of suitable specific snail hosts in the water, 
suitable environmental conditions of asexual schistosome development in the snails and human 
exposure to infested water containing infective cercariae. Therefore, targeted interventions towards 
these areas are critical in achieving prevention and control of schistosomiasis. 
2.4. Epidemiology of schistosomiasis in Africa 
At least 17% of world’s population is located in Africa, whose population is estimated at 1.3 
billion and regarded as the fastest growing continent (UN, 2019). Most of the people live in SSA 
which experiences diverse weather conditions and has the highest burden of tropical and infectious 
diseases in the world including HIV and NTDs.  Schistosomiasis is endemic in 78 countries globally 
and the majority of affected people live in poor and rural communities along rivers, dams and lakes 
in SSA (WHO, 2018b). 
At least 779 million people are at risk of the disease in SSA with over 200 million people are 
infected, making it one of the commonest NTD (Tchuente, 2012; McManus et al., 2018). The global 
burden of schistosomiasis in 2016 was estimated to be 2.5 million disease-adjusted life years 
(DALYs),  with Africa contributing to 2.2 million DALYs, second largest after malaria among the 
parasitic and vector-borne diseases (WHO, 2018a). Urogenital schistosomiasis (UGS) affects more 
people in SSA compared to intestinal schistosomiasis, with 436 million people estimated to be at risk 
of S. haematobium and 112 million are infected, while 393 million are at risk of S. mansoni and 54 
million are infected. Other species causing intestinal schistosomiasis in Africa include S. 
guineensis and S. intercalatum in rainforest areas of Central Africa.  
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Schistosomiasis mostly affects children (pre-school aged (PSAC) and school aged (SAC)), 
adolescents, women, fishermen, farmers, irrigation workers and other people when they expose 
themselves frequently to infective cercariae during their routine domestic chores, recreational or 
professional activities in infested water. Lack of access to adequate, safe and clean water, poor 
sanitation and inadequate hygiene make local inhabitants living near infested freshwater bodies, 
vulnerable to schistosome infection. PSAC and SAC have been observed to harbour the greatest 
number of worms in endemic areas (Tchuente, 2012; Stothard et al., 2016) and morbidity trends 
rises to a peak during adolescent age (10-15 years) and falls down steadily to lower levels in 
adulthood. Heavily infected persons suffer most of the clinical consequences of the infection and are 
also the major sources of infection for the rest of the community (WHO, 2002).  
In highly endemic areas, transmission patterns commonly show that 60% to 80% of SAC are 
infected while 20% to 40% of adults remain actively infected (Colley and Secor, 2014). The S. 
haematobium infection is commonest and heaviest in children aged between 5 and 15 years who, 
with highest egg output and frequent exposure to freshwater bodies, are more likely to contaminate 
the water, being the most important reservoir group of the infection (Montresor et al., 1998; 
Gryseels et al., 2006). Age-associated decline in infection rates in the adults of endemic population 
result from antiparasitic immunity rather than reduced contact with infested water (Colley et al., 
2014).  
2.4.1. Schistosomiasis in Malawi 
Malawi is located south of Equator in SSA, bordered by United Republic of Tanzania, 
People’s Republic of Mozambique and Republic of Zambia (Figure 1), with 118,484 square kilometres 
of land (80%) and water (20%) mostly Lake Malawi, the third largest African lake and renowned 
tourist destination (NSO and ICF, 2011). Its population of 17.6 million comprise of more women 
(52%), younger people (51% are aged less than 18 years), majority living in rural areas (84%) and 
below poverty line (52%) (NSO, 2019).  
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Schistosomiasis has been reported in Malawi since early 1900s where both S. haematobium 
and S. mansoni have been observed to be prevalent and highly focal in distribution along water 
bodies (Doumenge et al., 1987). Schistosoma haematobium has been highly prevalent throughout 
the country especially shores of Lake Malawi and Shire river, with prevalences of between 32% to 
94% in southern and central areas, 75% in northern areas and almost 100% along Lake Malawi since 
1980s (Teesdale and Chitsulo, 1985; Makaula et al., 2014). On the other hand, S. mansoni 
predominates Lower Shire river basin, southern highlands, plains of Central and Northern regions, 
with lower prevalences of mostly less than 40%. Frequent exposures to infested water contributes to 
reinfections which have been noted along the shores of Lake Malawi with S. haematobium infection 
with rates of 30% to 40% (Madsen et al., 2011). 
Bulinus and Biomphalaria snail species have been found in Malawi to be responsible for 
active transmission of schistosomiasis. Bulinus globosus and B. nyassanus have been observed 
especially along shores of Lake Malawi causing high transmission and prevalence of S. haematobium 
infections, with subsequent rise in their population recently due to overfishing, thereby reducing 
molluscivorous fishes which predate on the snails, apart from ecological changes, cyclonic events 
and migration (Stauffer et al., 1997; Madsen et al., 2011). Biomphalaria snails have been observed in 
swamps, rivers and other water bodies away from Lake Malawi until the recent discovery in the 
southern part of Lake Malawi in Mangochi District with S. mansoni and autochthonous transmission 
of intestinal schistosomiasis among SAC in the area (Alharbi et al., 2019).   
2.5. Clinical and pathological features of schistosomiasis 
Schistosomiasis infection has been associated with various clinical and pathological features 
in infected people. Much of the pathological features are primarily due to egg deposition following 
their entrapment in various tissues, triggering immune response with the human host (Colley and 
Secor, 2014). A large proportion of infected people in endemic areas remain asymptomatic while 
heavily infected persons suffer most of the clinical consequences of the infection (Samuel et al., 
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2000; WHO, 2002). Clinical features can be categorised as immediate phase, acute phase and 
chronic phase of schistosomiasis (Ross et al., 2002; Squire and Stothard, 2014). 
2.5.1. Immediate phase of schistosomiasis 
This occurs soon after penetration of cercariae into the skin, characterised with cutaneous 
maculopapular rash which can be itchy, also known as swimmer’s itch. This is mostly associated with 
avian and animal schistosomiasis but seldom with human schistosomiasis. Usually, the rash is clinical 
diagnosis, self-limiting and resolves with a few days without treatment. 
2.5.2.  Acute phase of schistosomiasis 
Acute schistosomiasis (also known as Katayama fever) occurs usually at least 2 weeks 
following contact with contaminated water (Squire and Stothard, 2014). This is rarely seen in 
residents of endemic area but commonly experienced by visitors during their initial infection with 
schistosomes. When the worms start laying eggs, soluble antigens leak out of the eggs triggering a 
Th-1 immune response (Colley and Secor, 2014), antibody production and antigen-antibody (Ag-Ab) 
complexes formation, resulting in the classical Katayama fever. Other symptoms include urticaria, 
eosinophilia, fatigue, generalised myalgia, diarrhoea, hepatomegaly, splenomegaly and cachexia.  
The eggs migrate from circulation through the tissues to urinary bladder lumen in order 
escape out of the body. As they move into the bladder, they cause pain (dysuria) and ulcers with 
blood loss. As they escape, they cause haematuria, dysuria or little blood in stool, which are 
frequently noted 2 to 3 months after the infection (Samuel et al., 2000). In endemic African 
countries, S. haematobium is the commonest cause of haematuria in children (Figure 5).  In both 
PSAC and SAC, the infections usually result in anaemia, malnutrition, detrimental effects on cognitive 
development, affecting school attendance and education performance; as well as increased 






Furthermore, schistosome eggs retained in the tissues (Figure 6) trigger intense immune and 
inflammatory reactions with the host due to the leakage of proteases, soluble egg antigens (SEA) 
and other potentially toxic moieties once they die in the tissues. This result in granulomata 
formation, which is characterised by lymphocytes, eosinophils, activated macrophages, foreign body 
giant cells, plasma cells, Langerhans cells, fibroblasts and multinucleated histiocytes (Ross et al., 
2002; Yuesheng and Ross, 2017; McManus et al., 2018).  Such immune-mediated response can lead 
to necrosis and damage to tissues in the liver, gastrointestinal and genitourinary organs among 
others (Bustinduy and King, 2014; Colley et al., 2014; Squire and Stothard, 2014). 
Figure 5: Haematuria with UGS infection caused by S. haematobium eggs expelled in urine 
A, B and C. urine without haematuria; while D, E and F. urine with increasing intensity of haematuria. 
Image courtesy of J. Russell Stothard, LSTM, August 2019.  




Some eggs can penetrate some genital organs in both males and females, causing specific 
pathologies which are described in the subsequent sections. 
2.5.3. Chronic phase of schistosomiasis 
Chronic schistosomiasis arise from more eggs being trapped in the tissues, stimulating 
further repeated Th-2 immune reactions from released SEA (Colley and Secor, 2014; Squire and 
Stothard, 2014; Olveda and Ross, 2017). Continued SEA exposure induces downregulating 
mechanisms, resulting in granuloma formation, hundred times more than the ova, containing 
epithelioid and giant cells, anti-IgE antibodies, lymphocytes, eosinophils and other cells. This 
granulomatous response can cause anatomical and functional obstruction of organs which is 
reversible after anti-schistosomal chemotherapy (Samuel et al., 2000). 
Further granulomatous reactions result in calcification and fibrous tissue development in the 
affected tissues, whose pathology becomes irreversible even with anti-schistosomal chemotherapy. 
Some features of chronic schistosomiasis include urinary bladder calcification and carcinoma, 
obstructive uropathy, renal hydronephrosis and genital schistosomiasis (for S. haematobium); colon 
Figure 6: S. haematobium eggs trapped in a urinary bladder seen on biopsy, stained with H&E. 





pseudopolyposis, liver ‘Symmer’s pipestem’ fibrosis, portal hypertension, hepatosplenomegaly and 
varices (S. mansoni, S. japonicum); and neuroschistosomiasis (ectopy of schistosome eggs into the 
nervous system (Ross et al., 2012)). 
Urinary bladder cancers are the most commonly diagnosed malignancy in many S. 
haematobium endemic areas, commonly in men (Rollinson, 2009). The common cancer pathology 
associated with chronic S. haematobium infection is squamous cell carcinoma. Mechanism of the 
carcinogens remain still unclear, however S. haematobium infection is strongly associated with 
higher risk for cytological abnormality characterising the malignancy. Early diagnosis and treatment 
are very important in preventing chronic inflammation and its consequences including fibrosis, 
malignancy and even death, described above (Samuel and Taylor, 2015).  
2.6. Female genital schistosomiasis (FGS) 
As described already, women and girls are disproportionately affected by schistosomiasis 
infection due to their close contact with contaminated water bodies during numerous domestic 
activities in the community (washing, bathing, water-drawing for their household needs), putting 
them at risk of schistosome infection.  
Female genital schistosomiasis (FGS), defined as infection associated with presence of 
Schistosoma ova in genital organs of women, was first described in 1899 with a papillomatous mass 
in the submucosa tissue of the vagina of a younger married woman in Egypt, containing numerous 
ova but none in her urine (Madden, 1899). Since then, schistosomiasis has been observed to be one 
of the commonest causes of genital lesions in endemic areas, affecting over half of the adult female 
population(Kjetland et al., 2008).  
Up to 75% of women infected with S. haematobium in urine living in endemic areas have 
reported abnormal lesions, nodules and ulcers in genital organs such as cervix, vulva and vagina, 
which sometimes has been mistaken as sexually-transmitted infections (Samuel and Taylor, 2015), 
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polyps or malignancy. As much as 23% will have FGS without ova in the urine. There are 9 to 13 
million women with FGS globally with the commonest sites in the body being cervix and vagina.  
A study conducted in rural Zimbabwe showed that 58% of women with S. haematobium ova 
in urine had FGS, but 41% with FGS had no detectable ova in their urine (Kjetland et al., 2005). Those 
with FGS had characteristic grainy sandy patches, abnormal blood vessels, neovascularised and 
friable mucosa on their cervix(Colley et al., 2014). The women also experienced stress incontinence 
and pollakiuria among other problems. Genital itching, malodorous and abnormally coloured vaginal 
discharge were significantly associated with S. haematobium infection in the women (Kjetland et al., 
2008). 
Serious complications caused by FGS are ectopic pregnancy, subfertility and infertility, which 
also contribute to chronic physical and psychosocial consequences to affected women (Rollinson, 
2009) like family disputes and divorce. Other consequences associated with FGS include 
dyspareunia, contact bleeding, menstrual disorders, chronic abdominal pains, chronic cervicitis, 
vaginal or cervical polyps, spontaneous miscarriages, preterm and low birthweight babies, ascites 
among more (Talaat et al., 2004; Kjetland, Leutscher and Ndhlovu, 2012; Christinet et al., 2016). 
Women with genital schistosomiasis have been observed to have a higher HIV prevalence 
than others, and also FGS enhance risk of having HIV by 3-fold which highlight the link between FGS 
and HIV. The sandy patches on the cervix have been suggested as an important risk factor for both 
acquisition and transmission of HIV (Kjetland et al., 2005; Kjetland et al., 2008; Kjetland, Leutscher 
and Ndhlovu, 2012; Christinet et al., 2016). In addition, the calcified S. haematobium ova in genital 
tissues increase the density of HIV receptive CD4+ cells, hence lesions around the ova provide entry 
point for HIV (Jourdan et al., 2011).  
Praziquantel treatment among FGS patients result in parasitological cure and stops excretion 
of new ova in urine and genital tract. Provision of such treatment in to young girls including SAC will 
prevent FGS development, which represent an innovative preventive AIDS strategy in endemic areas 
of HIV and schistosomiasis, like SSA (Hotez, Fenwick and Kjetland, 2009). As the cost of 
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implementing Praziquantel MDA is relatively low, estimated at US$0.32 per person, there’s need for 
women with FGS have access to regular PZQ treatment in endemic areas, in order to avert around 
120,000 new HIV cases in the next decade. 
2.7. Male genital schistosomiasis (MGS) 
Male genital schistosomiasis (MGS) is a chronic manifestation of schistosomiasis,  associated 
with presence of schistosome eggs in genital fluids and tissues and related pathologies in the male 
genital system (WHO, 2018b). This was first described in 1911 when a lesion seen in spermatic cord 
of a young Egyptian man was mistaken for a tuberculous lesion (Madden, 1911).  MGS is usually 
underreported and unknown in most endemic areas, despite S. haematobium infection causing UGS 
previously observed to produce characteristic pathologies in reproductive organs (Poggensee and 
Feldmeier, 2001). Schistosome eggs which pass through or entrapped in tissues of prostate, seminal 
vesicles, vas deferens, epididymis and testis (Figure 7), trigger immune reactions and granulomata 
formation resulting in classical symptoms and pathologies, associated with MGS.  
 
Figure 7: Male genital organs affected by schistosome eggs are passing through or trapped 




The symptoms associated with MGS include pelvic pain, especially of the genital organs, 
coital or ejaculatory pain, haemospermia (presence of blood in the semen), abnormal ejaculates 
(Figure 8), occasional spermaturia (presence of spermatozoa in urine), infertility and abnormal 
enlarged organs (Butterworth et al., 2013; Bustinduy and King, 2014; Squire and Stothard, 2014). 
Although haemospermia is seldom reported in most medical textbooks describing schistosomiasis in 
tropical countries (Squire and Stothard, 2014), it has been observed in some patients presenting in 
early stages of MGS (Barlow and Meleney, 1949; Gelfand et al., 1970; Corachan et al., 1994; 
Feldmeier et al., 1999; Schwartz et al., 2002) and even at a young age (Rambau et al., 2011).   
Also post-mortem and histopathological studies have shown that those affected with S. 
haematobium had their seminal vesicles and prostrate frequently affected by the egg-induced 
lesions similar to urinary bladder, such as granulomatous infiltration, fibrosis and calcifications 
(Edington et al., 1970; Gelfand et al., 1970; Patil and Elem, 1988). Remarkable genital pathologies 
have been observed on radiological examinations of those affected with MGS, highlighting the role 
of ultrasonography and other radiological techniques which can be utilised in endemic areas (Vilana 




One of the recent research studies in the last decade was conducted by Leutscher et. al. 
among local inhabitants in endemic areas in Madagascar where S. haematobium ova were detected 
in urine and semen samples (Leutscher et al., 2000). Further studies in the same areas observed that 
increased levels of cytokines and inflammatory markers like eosinophil cationic protein (ECP) in 
males with schistosome eggs in their semen, suggesting that frequent genital organ infection occur 
with schistosomiasis (Leutscher et al., 2005). S. haematobium infection has been hypothesized to 
cause increased viral shedding into semen of HIV-infected men as a result of egg-induced 
inflammation in seminal vesicles and prostate (Leutscher et al., 2005; Leutscher et al., 2008a; 
Leutscher et al., 2008b; Stecher et al., 2015; Midzi et al., 2017). However, MGS remains 
underdiagnosed and underreported in local male inhabitants of most endemic areas especially in 
SSA, with limited research interest on this important infection in the last decade. 
Figure 8: S. haematobium egg in semen of a man who swam in Lake Malawi. 




2.8. Diagnosis of schistosomiasis 
A range of parasitological, immunological and molecular methods have been used for 
detection of UGS (Stothard et al., 2014). The operational gold standard of diagnosing UGS is direct 
microscopy of filtered urine (Peters et al., 1976), which has been widely used in high transmission 
areas to estimate the morbidity upon enumeration of eggs in 10 ml of urine (i.e. ≥50 eggs per 10 m). 
However, it lacks diagnostic sensitivity in light infections when the number of eggs shed in urine is 
very few (counting less than 1 egg in 10 ml) and repeated urine samples may need to be inspected. 
Other less expensive methods that can complement this test include the use of questionnaires in 
high risk areas for recognition of macrohematuria (presence of red urine), and urine reagent test 
strips for microhaematuria as a diagnostic indicator and marker of bladder pathology, although 
these suffer from poor rates of sensitivity (< 75 %) and cannot detect sub-clinical or acute infections 
(Stothard et al., 2014; Le and Hsieh, 2017). 
Antibody-based tests such as enzyme-linked immunosorbent assay (ELISA) for IgG titres 
against schistosome soluble egg antigen (SEA) present in human serum have been widely used for 
diagnosis (Le and Hsieh, 2017). Serological methods have much higher sensitivities than filtration 
and microscopy, especially in travellers originating from non-endemic regions, however they cannot 
distinguish active from past infections, nor discriminate between species of schistosome. Alternative 
highly sensitive approaches based on detection of schistosome glycan antigens in blood or urine 
have been developed to diagnose active Schistosoma infections (Utzinger et al., 2015; Le and Hsieh, 
2017), which are described below. Nucleic acid amplification tests (NAAT) have increasingly been 
used as highly sensitive and specific diagnostic tools, utilising several clinical specimens (i.e. stool, 
urine or tissue biopsy) in diagnosing the infection (Utzinger et al., 2015). Currently NAAT are not 
widely available, owing to the need for skilled personnel, laboratory equipment and infrastructure 
which make roll out, especially in endemic areas, difficult. Newer approaches based on loop-
mediated isothermal amplification (LAMP), POC magnetic bio-capture probes and microfluidic 
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devices are being developed for resource poor settings (Minetti et al., 2016; Candido et al., 2018; 
Poulton and Webster, 2018). 
2.8.1. Glycobiology of schistosome antigens and their applications 
A number of different schistosome antigens are excreted and secreted into the human 
circulation, namely cercarial antigens, gut-associated antigens from living juvenile and adult worms 
and antigens secreted from eggs (van Lieshout, Polderman and Deelder, 2000). Most of the 
described circulating genus specific antigens in humans are from gut-associated tissues of feeding 
worms, namely circulating cathodic antigen (CCA) and circulating anodic antigen (CAA). Both CCA 
and CAA, see Figure 9A, are detectable in the host’s serum as well as in urine although relative 
concentrations can differ and these are thought to have immunomodulating effects within the 
parasitized host (van Dam et al., 1996; van Dam and Deelder, 1996; van Diepen et al., 2012; Hokke 
and van Diepen, 2017).  
 
Glycoproteins containing CCA are produced by the gut epithelium of schistosomes 
presumably for its protection and are regurgitated into the human bloodstream upon digestion of 
the blood meal as worms have a blind-end gut. The structure of these positively-charged antigens 
consists of multiple trisaccharide units (Lewis-X) containing fucose, galactose and N-acetyl-
Figure 9: Structures of schistosome CCA and CAA with prototype dual urine dipstick 
A. Schematic outline of the chemical and polymeric glycan structures of the two most common schistosome glycoproteins 
(CCA and CAA) using in rapid urine-antigen detection dipsticks. B. An illustration of future developments in POC diagnostics 
with a prototype dual antigen urine-dipstick detecting each antigen separately (LHS CCA, RHS CAA). Having a dual design could 
detect and differentiate urogenital and intestinal schistosomiasis co-infection simulatenously, however, this prototype has 
inadequate sensitivity for detection of urine-CAA and needs reformulation. (Figure reproduced from (Kayuni et al., 2019b)). 
53 
 
galactosamine, Figure 9. In addition, CCA epitopes are also present on Schistosoma egg secretions. 
They also evoke high titres of specific IgM/IgG antibodies, which may be responsible for the mild-
moderate neutropenia during schistosome infection arising from an inhibitory factor in their sera, 
causing delay in the maturation of neutrophils in the bone marrow and spleen (van Dam et al., 
1996). 
Making use of CCA, POC urine-based lateral-flow assays have been developed since the late 
90s and have been commercially available since 2002 in the form of reagent dipsticks or cassettes, 
with carbon- or gold-labelled monoclonal antibodies and interpreted visually (van Dam et al., 2004; 
Le and Hsieh, 2017). Detectable CCA-levels typically correlate with active schistosome infection, 
which become undetectable after successful praziquantel treatment. However, upon comparison 
with intestinal schistosomiasis (caused by S. mansoni) these tests perform poorly for UGS see Table 
1, hence combining it with urine filtration is needed, and can help with simultaneous detection of 
co-infected cases (i.e. S. haematobium and S. mansoni). Since the first use of POC-CCA tests, they 
have been subject to many evaluations of their performance, with WHO now endorsing these tests 
as appropriate for estimating prevalence thresholds for intestinal schistosomiasis to guide 
preventive chemotherapy (Colley, Andros and Campbell, 2017; Bärenbold et al., 2018). Current 
developments in POC testing include a prototype dual antigen cassette with both CCA and CAA strips 
included, enabling detection and discrimination of intestinal and urogential schistosomiasis 
simultaneously see Figure 9B. (see https://freebily.eu/about/). 
Table 1: Sensitivity and specificity of urine POC-CCA tests to diagnose S. haematobium infection, in 
comparison to urine filtration and microscopy as the gold standard 
Source N Prevalence (%) Sensitivity (%) (95% CI) Specificity (%) (95% CI) 
Stothard et al., 2009 150 31 - Moderate 9 (2 – 21) 98 (93 – 100) 
Ayele et al., 2008 206 48 - Moderate 52 (42 – 62) 64 (54 – 73) 
Midzi et al., 2009 265 40 - Moderate 79 (70 – 86) 44 (36 – 52) 
Ashton et al., 2011 373 26 - Moderate 37 (26 – 49) 79 (72 – 84) 
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Obeng et al., 2008* 
153 Not stated (Case-
control study) 
41 (Not stated) 91 (Not stated) 
El-Ghareeb et al., 2016* 600 5 88 (Not stated) 96 (Not stated) 
Sanneh et al., 2017* 1,954 23 48 (Not stated) 76 (Not stated) 
Rubaba et al., 2018* 380 40 68 (Not stated) 46 (Not stated) 
Range  5 – 48 9 – 88 44 – 98 
Data adapted from (Ochodo et al., 2015), where intensities of infection are classed as ‘moderate’. 
Additional sources marked by “ * ”. Where data is missing this is marked as ‘Not stated’. (Table 
reproduced from (Kayuni et al., 2019b)). 
 
The alternative CAA antigens are also gut-associated glycoproteins but are negatively 
charged. The structure of CAA is made up of carbohydrate chains which consist of multiple 
disaccharide units containing N-acetyl-galactosamine and glucuronic acid (Figure 9). It binds to the 
collagen-like stalk of first complement component C1q, probably preventing host complement from 
attacking the schistosome gut (van Dam et al., 1993). CAA is also present in urine or serum of 
actively infected people as shown by monoclonal antibody-based antigen detection ELISA’s and 
more recently up-converting phosphor-lateral flow assay (UCP-LF CAA) (Corstjens et al., 2008). This 
assay has shown to be more sensitive and specific especially in low transmission areas but is unable 
to differentiate between urogenital and intestinal schistosomiasis (Corstjens et al., 2015; Knopp et 
al., 2015). The UCP-LF-CAA test therefore has future application in the general monitoring of 
schistosomiasis as disease control programmes move towards interruption of transmission or 
endgame scenarios (Corstjens et al., 2017; Stothard et al., 2017).  
2.8.2. Focus on male genital schistosomiasis 
Substantial progress has been made in developing a gold standard technique for a definite 
FGS diagnosis, namely colposcopy in gynaecological clinics (WHO, 2015a) often with genital tissue 
biopsy for histopathology in the hospital laboratory. Conversely, MGS remains largely undefined, an 
orphan within disease syndromic triage (Kayuni et al., 2019a). At present, semen microscopy is 
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considered as a standard technique for diagnosing active MGS infection and assessing its severity, 
since the schistosome eggs are directly visualized. Urine filtration has been used as diagnostic proxy 
markers in the presence of MGS symptoms; however, there have been reports of seminal 
schistosome eggs in urine negative patients (Schwartz et al., 2002; van Delft et al., 2007).  In 
addition, genital tissue biopsy and ultrasonography can be applied as diagnostic tools relevant in 
diagnosing MGS through observation of pathologies associated with the disease in the absence of 
other genital diseases, which have successfully been studied and reported (Leutscher et al., 2008b). 
2.9. Treatment, control and prevention of schistosomiasis 
Treatment of all forms of schistosomiasis including MGS is achieved by single dose of a safe 
and effective anti-helminth drug, PZQ, a pyrazinoisoquinole derivative which remains the drug of 
choice, with egg-reduction rates of at least 98.7% and cure rates of 63-100%, seen up to 3 months 
after treatment (Knopp et al., 2013). PZQ is effective on adult stages only and not young developing 
stages of the schistosomes (Rollinson, 2009; Knopp et al., 2013). It works on the calcium ions 
channels by binding to actin in the worms’ muscles, causing its rapid influx and disrupting 
homeostasis, which induces intense contractions of muscles and tegumentum, thus exposing the 
surface membranes to host immune defence mechanisms, Th2, which contributes to the spastic 
paralysis and killing of the worms (Rollinson, 2009; Knopp et al., 2013). PZQ induces a switch from a 
predominantly IgA-specific antibody response to a IgG response within 12 weeks, which may be 
driven by alternations in cytokines levels in response to antigens released by paralysed or dead 
parasites (Samuel et al., 2000). However, PZQ does not kill juvenile immature worms, prevent re-
infection, or reduce transmission of the infection. 
Single dose of PZQ is effective in treatment and prevention of schistosomiasis especially in 
high-risk population living in heavy infested, endemic areas. Significant improvements in language 
and memory development occur with provision of appropriate treatment to infected children (WHO, 
2013b). In addition, impact of PZQ chemotherapy has shown good evidence for reversal of organ 
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pathology experienced with urogenital schistosomiasis. Furthermore, PZQ has no detrimental effects 
to humans, as shown from experimental animals  who experienced no effects acutely or chronically 
when given higher doses than routinely given to humans (Olds, 2003). As such WHO recommends 
PZQ treatment should be given to all children and adults including pregnant and lactating women at 
any stage. Since polyparasitism is common in endemic areas, co-administration of PZQ and other 
anti-helminth drugs such as albendazole and ivermectin where necessary has been reported to be 
safe (WHO, 2002; Mohammed et al., 2008), as a strategy to successfully treat and control prevalent 
NTDs. 
The prevalence, intensity and potential for control of schistosomiasis are largely functions of 
interactions of social, cultural, behavioural, geographical and economic factors in a given area with 
local and regional ecological and environmental factors. Furthermore, global control efforts of 
schistosomiasis has shifted from transmission reduction (snail control) before 1970s to morbidity 
control  (development of diagnostics and effective PZQ chemotherapy) after 1970s (Kloos, 1995; 
Fenwick, Keiser and Utzinger, 2006). The WHO recommends various interventions for morbidity 
control (development of diagnostics and effective PZQ chemotherapy) after 1970s (Kloos, 1995). It 
further advocates a dual strategy (Engels et al., 2002), a strategy for morbidity control in high-
burden areas like SSA using preventive chemotherapy with PZQ, and an integrated control strategy 
in low-endemic areas where elimination is feasible. Most SSA countries are not at an elimination 
stage yet due to higher transmission potential and prevalence rates (Rollinson, 2013).  
There is also need to monitor impact of the control interventions which have been 
implemented, improve disease surveillance once the morbidity becomes very low (prevalence of less 
than 10%), improve diagnostic tests and build capacity of personnel involved in schistosomiasis 
control (Zhou et al., 2011; Solomon et al., 2012). These require strong political will, appropriate 
legislation and intersectoral collaboration. In addition, with the agenda of schistosomiasis control 
moving from morbidity to elimination, there are recommendations for intensive implementation of 
a combination of the successful control strategies, namely health education, preventive 
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chemotherapy, Intensified case management, provision of safe water supplies, improved sanitation 
and hygiene and vector (snail) control, which will go a long way to achieve with the available global 
resources (Rollinson et al., 2013; Colley, 2014). 
Despite availability of this safe and effective drug, much still needs to be done to reduce 
prevalence and intensity of schistosomiasis since the infection continue to persist and long-term 
sustainable control remains a challenge in many endemic areas of LMICs (Rollinson, 2009; Stothard, 
Bustinduy and Montresor, 2014). Schistosomiasis control in endemic areas is faced with numerous 
challenges, namely: mobilisation of required funding for successful interventions; coordination, 
monitoring and evaluation of control programmes at various levels; scale-up plans; sustainability; 
limited capacities; lack of country ownership, leadership and political will; poor stakeholder and 
intersectoral collaborations; operation research; and limited development of improved diagnostic 
tools Africa (Tchuente, 2012). Success stories in elimination of schistosomiasis in Japan, China and 
Morocco among others, resulted from setting clear goals for control and elimination, high 
government commitment, funding mobilisation, leadership and research which are lacking in most 
endemic countries, especially in sub-Saharan Africa (Tchuente, 2012). 
Preventive measures for schistosomiasis include adequate health awareness and education 
on schistosomiasis to reduce frequency of contact with infested water bodies as well as 
contamination with schistosome eggs in urine and faeces; improved access and availability of safe 
water to communities in endemic areas, and treatment of water sources; improved sanitation which 
includes use of toilets instead of water bodies; preventive chemotherapy through mass drug 
administration with PZQ in endemic areas (Knopp et al., 2013). Of the 78 endemic countries in the 
world, 52 countries require preventive chemotherapy with PZQ for at least 220 million children and 
adults, of which over 90% are in SSA (WHO, 2018c).  
Intersectoral snail control measures have been advocated in certain areas which include 
removal of vegetation around freshwater bodies, biological control using predator fishes, crayfish, 
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ducks and other snail species. These preventive measures tackle particular stages of the life-cycle of 
schistosomes, contributing towards elimination of the disease (Colley, 2014), as described below: 
a. Preventing specific intermediate snail hosts from getting infected by encouraging infected 
people from urinating or defecating in water bodies and using toilets. This is achieved 
through improved health education and awareness, improved sanitation and hygiene and 
behaviour change, while involving community participation at all levels (Kloos, 1995). 
b. Killing or replacing the snail hosts using biological control measures such as competitor snails 
and snail-eating fishes, chemical control like targeted, biological-friendly mollusciciding and 
environmental modification where removal of vegetation is done to get rid their habitats. 
c. Stopping people from getting infected by reducing contact with water bodies harbouring 
infected snails or cercariae through provision of safe water supplies for personal, household 
and recreational purposes, adequate health education and awareness on the disease. 
d. Killing adult schistosome worms in people laying eggs and causing disease through regular 
preventive chemotherapy with PZQ to all infected and at-risk populations in endemic areas 
as well as improved access and availability of diagnosis and treatment at health facilities in 
endemic areas. 
Currently, there’s no vaccine available and its progress of development has been slow due to 
inability to identify appropriate protective antigens eliciting host immune reactions to attack the 
parasite without cross-reacting with egg antigens which causes severe chronic disease (Rollinson, 
2009). 
2.10. Human immunodeficiency virus (HIV) infection in Africa 
HIV is a lentivirus, belonging to a large, diverse and complex group of retroviruses (Figure 10) 
which affect the human immune system (Fauci et al., 1996; Coffin, Hughes and Varmus, 1997). The 
virus slowly destroys the immune CD4 cells, resulting in an advanced and incurable disease, Acquired 
immunodeficiency syndrome (AIDS) (WHO, 2016b). HIV continues to be a major global public health 
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issue, with 37.9 million people infected by the virus globally in 2018, 770,000 dying from HIV-related 
diseases and 1.7 million new infections, especially among the young adults and women (UNAIDS, 
2019). Eastern and southern parts of the SSA is the most affected and the epicentre of HIV 
pandemic, with 20.6 million infected people and over half of the global total of new HIV infections.  
 
Sexual transmission account for over 85% of all HIV infections despite the lower probability 
of sexual infection than other routes like blood contact or transfusion (Royce  et al., 1997; Cohen, 
2004). This raises the idea of possibility of other factors and infections contributing to the epidemic. 
Evidence has shown that chronic parasitic diseases influence the natural history of HIV infection in a 
deleterious way (Harms and Feldmeier, 2002). In addition, sex workers and men who have sex with 
Figure 10: Schematic diagram of the HIV structure with key parts for human cell invasion. 




men (MSM) have more than 20 times increased risk of acquiring HIV infections (UNAIDS, 2019). 
Unfortunately, only 79% of people globally know their HIV status, with 8.1 million in need of access 
to HIV testing services.  
In order to control HIV infection, several interventions have been developed, implemented 
and evaluated by WHO, UNAIDS, Ministries of Health in SSA and globally together with other 
stakeholders. These interventions include provision of accurate HIV testing and counselling services 
to all people in SSA areas and other areas affected with the disease, treatment to all HIV infected 
people with standard antiretroviral therapy (ART) in accordance to approved WHO and national 
guidelines, regular monitoring of treatment and virological suppression, prevention and treatment 
of opportunistic and severe infections, nutrition support as well as health education and 
psychosocial support through peers, family and health personnel (Deeks, Lewin and Havlir, 2013; 
WHO, 2016a;b;2019). 
ART are highly active drugs acting at various levels in the HIV life cycle, which have 
significantly contributed to reduction of HIV transmission to uninfected sexual partners (new 
infections / incidence), severe diseases related to AIDS (morbidity) and AIDS-related deaths 
(mortality) of people infected with HIV through viral suppression when regularly taken (Fauci and 
Folkers, 2012). Although 23.3 million people were accessing ART globally in 2018 (62% of all people 
living with HIV), 13.8 million (67%) were from the Eastern and southern Africa. Interesting, 92% of all 
pregnant women with HIV in this African region were on ART to prevent transmission to their child, 
which is much higher than the global percentage of 82% (UNAIDS, 2019).  
The different classes of ART available to people, depending on their site of the action in the 
virus life cycle (Figure 11), include: 
a. Those targeting HIV protein reverse transcriptase (Nucleoside reverse transcriptase 
inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs)). 
b. Those targeting HIV protein protease (Protease inhibitors (PIs)) 
c. Those targeting HIV protein integrase (Integrase inhibitors (INSTIs)) 
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d. Those interfering with binding, fusion and entry of HIV into host cell by blocking one of 
several targets (Early or Fusion inhibitors (FIs)) 
e. Those that target particular receptor on human helper T-cell, CCR5 (Chemokine 
receptor antagonists (CCR5 antagonists)).  
 
ART is provided in a combination form of 2 or more classes with NRTI/NNRTI as a backbone 
drug to prevent resistance as much as possible through suppression of the HIV, examples listed in 
Table 2. Of those on ART in 2018, only 53% achieved virological suppression, posing a significant 
challenge in achieving the 90-90-90 strategy for HIV control and ending the global AIDS epidemic  
Figure 11: Schematic diagram of the areas in the life cycle of HIV where ART works. 
Image courtesy of Parfum BUKANGA Christian, African Institute of Mathematical Sciences, 
Cameroon, 14th August 2019 (https://www.researchgate.ne/publication/335170083_Community-
Based_HIV_Care) and Thomas Splettstoesser, Nov 2013 (https://www.scistyle.com) 
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(UNAIDS, 2019). The 90–90–90 targets comprise of ensuring that 90% of the people living with HIV 
know their HIV status, 90% of the people living with HIV who know their HIV status are accessing 
treatment; and 90% of people with HIV who are receiving treatment have suppressed viral load.  
Furthermore, a campaign was launched in 2016, known as U = U (Undetectable = 
Untransmittable), based on that a person with HIV having undetectable VL does not transmit HIV to 
their partners (PAC, 2016; The Lancet, 2017). This echoes the need to improve access to HIV testing 
and ART treatment to people especially in the SSA region, in addition to regular VL monitoring to 
undetectable levels and support to reach and maintain complete viral suppression. 
Table 2: Examples of different classes of antiretroviral drugs used in ART combinations 










Lamivudine Nevirapine Atazanavir Ritonavir Dolutegravir Maraviroc 
Abacavir Efavirenz Darunavir Cobicistat Raltegravir Enfuvirtide 
Zidovudine Etravirine Lopinavir  Elvitegravir  
Tenofovir disoproxil 
fumarate 




    
Emtricitabine      
 
As highlighted earlier, the advent of ART has resulted in a number of benefits at both 
individual and population level. At individual level, ART results in improved health and longer life and 
at a population level, there is reduction in HIV transmission and acquisition. These benefits accrue 
from ART’s impact on the HIV-1 viral load. An undetectable HIV-1 viral load results in reduced HIV 
transmission from the index case to the uninfected partner.  
This principle however is impacted by other health related issues in both the index case and 
the uninfected partner. Sexually transmitted illnesses (STIs) have been well known to increase the 
risk of both HIV transmission (in the index case by raising genital fluid viral load) and HIV-1 
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acquisition in the uninfected partner (by providing easy access to CD4 carrying cells within the 
genital tract as a result of inflammation).  
2.10.1. HIV in Malawi 
Since the first report of AIDS case in 1985, the prevalence of HIV among adults 15 – 64 years 
in Malawi has been considered to be high, recorded as 10.6% in recent national survey (Ministry of 
Health, 2017). The HIV prevalence varies from one area to another in the country, with higher rates 
observed in Mangochi district (11.8%) which bears the south shoreline of Lake Malawi and endemic 
for schistosomiasis where fishermen are among the high-risk occupational groups in Malawi with 
higher HIV prevalence, which was 11.5% in 2014 (NSO, 2014; NAC, 2015).  
Integrated efforts in HIV prevention and control involving government, communities and 
various stakeholders have contributed reducing the incidence and mortality, namely robust, 
abundant health awareness on HIV/AIDS infection, testing and counselling, provision of ART and 
preventive treatment for opportunistic infections, care and support for people living with HIV and 
family members.  
On ART provision in Malawi, the government through the Ministry of Health develops and 
disseminate national guidelines for comprehensive HIV treatment, care and support, accepted drugs, 
coordination, monitoring and supervision of all approved health facilities in the country. These 
guidelines are adopted from the WHO consolidated guidelines and updated policies for HIV 
treatment and prevention and ensures harmonisation of ART regimens across the country and 
relevance with the practice globally.  
The ART regimens available in the country comprised of standard and alternate first-line, 
second-line and third-line regimens of which lamivudine (3TC) is the backbone in all 1st and 2nd line 
regimens due to its extremely well tolerance and resilient activity even in presence of drug-resistant 
virus (Ministry of Health, 2016). Since July 2014 following the WHO recommendation for Test and 
Treat that all people living with HIV be provided with ART (WHO, 2016a), the standard 1st line was 
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also changed to a regimen of fixed dose combination comprising of tenofovir disoproxil fumarate, 
lamivudine and efavirenz (TNF/3TC/EFV) for adults (Table 3).  
Table 3: Standard ART regimens for Malawi from 1st July 2014 to 31st December 2018 
Line Regimen 








Standard for children and 
adults 35kg+ 
TDF 300 / 3TC 300 
/ EFV 600 
None 0, 2, 6, 8, 9, NS 
1st 2 
Standard for children and 
adults under 35kg 
AZT 300 / 3TC 150 
/ NVP 200 
AZT 60 / 3TC 30 / 
NVP 50 
0, 4, 5, 6, 7, 9, NS 
1st 0 No 
ABC 600 / 3TC 300 
+ NVP 200 
ABC 60 / 3TC 30 + 
NVP 50 
2, 4, 5, 6, 7, 8, NS, 
ABC/3TC+EFV 
1st 4 No 
AZT 300 / 3TC 150 
+ EFV 600 
AZT 60 / 3TC 30 + 
EFV 200 
0, 2, 5, 6, 7, 9 
1st 6 No 
TDF 300 / 3TC 300 
+ NVP 200 
None 0, 2, 5, 8, 9, NS 
2nd 7 No 
TDF 300 / 3TC 300 
+ ATV/r 300/100 
None 8, 10, 12, NS 
2nd 8 No 
AZT 300 / 3TC 150 
+ ATV/r 300/100 
None 7, 9, 11, 12 
2nd 9 No 
ABC 600 / 3TC 300 
+ LPV/r 200/50 
ABC 60 / 3TC 30 + 
LPV/r 100/25 
10, 11, 12 
2nd 10 No 
TDF 300 / 3TC 300 
+ LPV/r 200/50 
None 7, 8, 11, 12 
2nd 11 
Preferred start regimen 
for children under 3 years 
at sites with extra support 
AZT 300 / 3TC 150 
+ LPV/r 200/50 
AZT 60 / 3TC 30 + 
LPV/r 100/25 
7, 8, 10, 12 
3rd 12 No 
DRV 600 + r 100 + 
ETV 100 + RAL 400 
None NS 
All strengths are in mg. Alternate regimens are provided after possible adverse reaction(s). 3TC = Lamivudine, 
ABC = Abacavir, ATV = Atazanavir, AZT = Zidovudine, DRV = Darunavir, EFV = Efavirenz, ETV = Etravirine, LPV = 
Lopinavir, NVP = Nevirapine, r = Ritonavir, RAL = Raltegravir, TDF = Tenofovir. Fixed dose combinations (FDC) 
shown with a slash (e.g. TDF / 3TC / EFV), combinations made up of separate tablets shown with + (e.g. 
AZT/3TC + EFV). An “A” is added to the regimen number for adult formulations (e.g. Regimen 2A) and a “P” is 
added for paediatric formulations (e.g. Regimen 2P). 
As of now, since 1st January 2019, the standard 1st line regimen in Malawi has been changed 
to dolutegravir-based combination (Ministry of Health, 2018), following overwhelming evidence of 
its superior efficacy over previous TDF / 3TC / EFV regimen (Table 4). 
Table 4: Current Standard ART regimens for Malawi since 1st January 2019 
Line Regimen 








New standard for all patients 
30kg+ 
TDF 300 / 3TC 300 
/ DTG 50 
None 





Alternative for patients with 
(relative) DTG 
contraindications 
TDF 300 / 3TC 300 
/ EFV 600 
None 
, 4, 7, 8, 11, 13, 
14, 15, 17 
1st 4 No 
AZT 300 / 3TC 150 
+ EFV 600 
AZT 60 / 3TC 30 + 
EFV 200 
5, 7, 9, 10, 11, 13, 
15, 17 
1st or 2nd 9 
New standard for children 
under 20kg 
ABC 600 / 3TC 300 
+ LPV/r 200/50 
ABC 120 / 3TC 60 
+ LPV/r 100/25 
7, 8, 10, 11, 12, 
13, 14, 15 
1st or 2nd 14 No 
AZT 300 / 3TC 150 
+ DTG 50 
 AZT 60 / 3TC 30 + 
DTG 50 
4, 7, 8, 9, 10, 11, 
15, 17 
1st or 2nd 15 
Standard for children 20 – 
29.9kg 
ABC 600 / 3TC 300 
+ DTG 50 
None 
4, 7, 8, 9, 11, 13, 
14, 17 
1st  16  
ABC 600 / 3TC 300 
+ RAL 400 
ABC 120 / 3TC 60 
+ RAL 25 
7, 8, 11, 15, 
TDF/3TC+RAL 
1st 17  
ABC 600 / 3TC 300 
+ EFV 600 
ABC 120 / 3TC 60 
+ EFV 200 
4, 5, 7, 8, 9, 11, 
13, 14, 15, 16 
2nd 7 No 
TDF 300 / 3TC 300 
+ ATV/r 300/100 
None 
10, 11, 12, 13, 15, 
NS 
2nd 8 No 
AZT 300 / 3TC 150 
+ ATV/r 300/100 
None 
9, 11, 12, 13, 14, 
15, NS 
2nd 10 No 
TDF 300 / 3TC 300 
+ LPV/r 200/50 
None 
7, 8, 9, 12, 13, 14, 
15 
2nd 11 No 
AZT 300 / 3TC 150 
+ LPV/r 200/50 
AZT 60 / 3TC 30 + 
LPV/r 100/25 
8, 9, 12, 13, 14, 
15 
3rd 12 No 
DRV 600 + r 100 + 
DTG 50 (± NRTIs) 
None NS 
All strengths are in mg. Alternate regimens are provided after possible adverse reaction(s). 3TC = Lamivudine, 
ABC = Abacavir, ATV = Atazanavir, AZT = Zidovudine, DRV = Darunavir, DTG = Dolutegravir, EFV = Efavirenz, ETV 
= Etravirine, LPV = Lopinavir, NVP = Nevirapine, r = Ritonavir, RAL = Raltegravir, TDF = Tenofovir. Fixed dose 
combinations (FDC) are shown with a slash (e.g. TDF / 3TC / DTG), combinations made up of separate tablets 
are shown with + (e.g. AZT/3TC + EFV). An “A” is added to the regimen number for adult formulations (e.g. 
Regimen 2A) and a “P” is added for paediatric formulations (e.g. Regimen 2P). 
2.10.2. Schistosomiasis and HIV co-infections 
Observations in SSA indicate substantial geographical overlap of HIV and schistosomiasis in 
countries with high endemicity (Ndeffo Mbah et al., 2013; Bustinduy et al., 2014). As already stated, 
schistosomiasis is highly prevalent in fishing communities where opportunities for HIV transmission 
can be raised (Figure 12). Similar to the high relative risk of HIV infections associated with sexually 
transmitted diseases causing genital inflammation and elevated viral copies (Cohen et al., 1997; 
Royce  et al., 1997; Dyer et al., 1998; Mabey, 2000; Cohen, 2004), MGS can potentially raise the risk 
of HIV transmission in dually infected males to their sexual partners, as noted in an observational 
study among men on ART coinfected with UGS in Zimbabwe (Midzi et al., 2017). 
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As described earlier, mechanical breach of the genital mucosa caused by the schistosome 
eggs may render schistosomiasis-infected individuals more prone to contracting HIV during 
intercourse (Kjetland et al., 2005; Kjetland et al., 2006; Secor, 2006). In addition, local recruitment of 
CD4+ cells in the genital tissues during granuloma formation around the trapped eggs may also 
facilitate uptake of HIV viruses and establishment of infection (Leutscher et al., 2005).  
Previous studies observed increased levels of inflammatory cells and immunological 
mediators such as neutrophils, eosinophils, leukocytes, macrophages, CD4+ lymphocytes, eosinophil 
cationic protein among others in semen harbouring Schistosoma eggs, which also necessitate viral 
attachment and replication, highlighting the possibility of increased risk to HIV acquisition and 




The current control interventions of schistosomiasis and HIV which are running parallel in 
dual-epidemic regions, are also leaving out sexually-active men, women and girls who are also at 
high-risk of both conditions, thereby slowing down efforts of arresting the burden of both diseases 
(Hotez, Fenwick and Kjetland, 2009; Rollinson et al., 2013; Stothard, Bustinduy and Montresor, 2014; 
Stecher et al., 2015; Stothard et al., 2016). 
Figure 12: Global distribution of HIV and Schistosomiasis infections in 2015. 




2.11. Hypothesis of the MGS cohort studies 
Schistosome eggs cause UGS in local men inhabiting endemic areas on the shores of Lake 
Malawi who further suffer from genital consequences, described as MGS, however the burden 
remains unknown on the shoreline. Furthermore, MGS could potentially increase the HIV viral 
shedding in semen of those men with both HIV and MGS infections. 
Therefore, the multidisciplinary studies tested the hypotheses that PZQ treatment reduces 
the prevalence and morbidity of MGS as well as the potential risk of HIV transmission through 
reduced seminal viral shedding in dually infected fishermen living along south shoreline of Lake 
Malawi. 
2.12. Specific aims and objectives of the cohort studies 
The main aims of the cohort research studies were to determine the current prevalence and 
morbidity of MGS among fishermen in schistosomiasis-endemic areas along shores of Lake Malawi in 
the southern Malawian district of Mangochi and evaluate the extent of relationship between MGS 
and HIV-1 VL through potential increased viral shedding in their semen. 
Specific objectives are: 
1. To assess prevalence of MGS and its associated knowledge, attitudes and practices. 
2. To assess morbidity and genital pathology associated with MGS by ultrasonography. 
3. To determine efficacy of praziquantel in treating MGS and morbidity resolution.  













This chapter describes the systematic review conducted prior to the longitudinal cohort 
studies, aimed at providing an update on the epidemiology of MGS in endemic areas, detailing the 
currently available literature on the epidemiology, clinico-pathological features, co-infections, 
available diagnostic techniques, treatment, management and control of MGS, as well as the existing 
gaps for future research prospects. This was published as cited below:  
Kayuni, S., Lampiao, F., Makaula, P., Juziwelo, L., Lacourse, E.J., Reinhard-Rupp, J., Leutscher, 
P.D. and Stothard, J.R., 2018. A systematic review with epidemiological update of male genital 
schistosomiasis (MGS): a call for integrated case management across the health system in sub-
Saharan Africa. Parasite epidemiology and control, p.e00077, 
https://doi.org/10.1016/j.parepi.2018.e00077 (Received 13 May 2018, Revised 16 October 2018, 
Accepted 16 October 2018, Available online 23 November 2018). 
My contribution to this manuscript was that I conducted the entire systematic review on all 
databases and literature on MGS. Thereafter, I wrote the manuscript of the review, detailing the 







Male genital schistosomiasis (MGS) is a gender specific manifestation of urogenital 
schistosomiasis (UGS) first described in 1911 by Madden in Egypt. Today, while affecting millions of 
men and boys worldwide, MGS receives insufficient attention, especially in sub-Saharan Africa (SSA). 
To provide an epidemiological update and a systematic review of MGS, inspection of both online and 
hardcopy resources was undertaken. A total of 152 articles were eventually identified with only 32 
articles resulting from original research that exclusively focused on MGS.  
From these, we discuss pertinent clinico-pathological features, highlight the possible 
connection between MGS and HIV, and current diagnostic techniques alongside consideration of 
their use and application in SSA. To appreciate the burden of MGS more fully, in endemic areas there 
is a clear need for better surveillance and longitudinal population research to investigate the best 
point-of-care (POC) diagnostic, as well as, explore alternative praziquantel dosing regimens for 
individual case management in men with or without HIV infection. 
 






Schistosomiasis is a snail-borne disease of humans caused by parasitic helminths of the 
genus Schistosoma (Colley et al., 2014). It remains a major neglected tropical disease (NTD) and a 
significant public health challenge in low and middle-income countries (Chitsulo et al., 2000; Engels 
et al., 2002; Christinet et al., 2016). There it causes significant morbidity and in certain areas 
mortality (van der Werf et al., 2003), however, the burden of schistosomiasis is underestimated due 
to incomplete disease surveillance often by stretched national healthcare systems (King, Dickman 
and Tisch, 2005; Gryseels et al., 2006) and national control programmes. The latter is more focused 
on tracking the delivery and treatment coverage of mass treatment campaigns offering donated 
praziquantel (PZQ) typically to school-aged children (Savioli et al., 2017) rather than monitoring the 
disease in adults per se.  
The consequences and disability caused by gender specific manifestations of urogenital 
schistosomiasis (UGS) in adults often go unremarked at national and local levels. In contrast to 
female genital schistosomiasis (FGS), male genital schistosomiasis (MGS), as evidenced by 
schistosome eggs (usually those of S. haematobium) in male genital organs and tracts thereof, 
remains poorly reported and much understudied. This review was conducted to draw attention to 
the current evidence on MGS and assess its public health importance. 
3.3.1. A brief history of schistosomiasis 
Corroborated references to signs and symptoms ascribed to UGS can be traced back to 1,900 
BC since haematuria (i.e. frank blood in urine) was described as a common occurrence and linked to 
‘menstruation’ in Egyptian males (Davis and Ansari, 1973). Schistosomiasis is a proven disease of 
antiquity for S. haematobium ova which have been found in kidney tubules of two Egyptian 
mummies from 1,250 to 1,000 BC (Ruffer, 1910) and more recently S. japonicum ova retrieved within 
Chinese cadavers dated to 206 to 220 AD (Coon, 2005). Schistosomiasis itself was originally 
described in Egypt by the German pathologist Theodor Bilharz in 1851 who discovered male and 
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female schistosome worms at autopsy, naming them all Distomum haematobium. This led him to 
ascribe, incorrectly, that UGS and hepato-intestinal disease were linked to this species alone 
(Rollinson, 2009). Some sixty years later, and again in Egypt, this unfortunate mistake and 
subsequent confusion was fully resolved by Robert T. Leiper who demonstrated the independent 
lifecycles of S. haematobium and Schistosoma mansoni (Leiper, 1916) and their respectively 
aetiology in urinary and hepato-intestinal disease (Leiper, 1916; Stothard et al., 2016).  
Out of the 24 species of schistosomes recognised worldwide, only six cause human diseases, 
namely S. haematobium, S. mansoni, S. japonicum, S. mekongi, S. intercalatum and S. guineensis 
(Rollinson, 2009). The first three species are the most important from a public health perspective. 
Although there may be exceptions owing to ectopic egg laying sites, S. haematobium is exclusively 
associated with UGS which is widely distributed in Africa and adjacent regions, affecting more 
people (112 million) than all other species [(WHO) see 
http://www.who.int/schistosomiasis/epidemiology/table/en/]. Schistosoma mansoni, S. japonicum 
and the other species causes hepato-intestinal schistosomiasis, with S. mansoni prevalent in the 
Caribbean and South America, Africa and Asia, and S. japonicum in South East Asia (Colley et al., 
2014). Of note, S. mansoni, S. japonicum, S. intercalatum and S. guineensis have been reported to 
cause genital manifestations but even collectively they are minor as compared to S. haematobium 
alone. 
3.3.2. Focus on male schistosomiasis 
Male genital schistosomiasis is a specific manifestation of schistosomal disease, associated 
with presence of ova and pathologies thereof in various genital organs and fluids. The first original 
report of MGS was made by Professor Frank Cole Madden, Professor of Surgery at Kasr-el-Ainy 
Hospital in Cairo, Egypt.  In 1911, he described a 14-year Egyptian boy having enlarged scrotum 
showing epidydimal schistosomiasis and an English soldier complaining of haemospermia (blood in 
semen) concurrently with urinary schistosomiasis (Madden, 1911).  
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Other symptoms of MGS described in literature include pelvic pain appearing spontaneously, 
during coitus or on ejaculation, ejaculate changes, erection discomfort or dysfunction, infertility 
(Butterworth et al., 2013; Bustinduy and King, 2014; Squire and Stothard, 2014). Although 
observations indicate that genital organs are frequently infested with schistosome eggs along with 
the urinary bladder (S. haematobium) or intestines (S. mansoni), the current extent of morbidity 
associated with MGS in endemic areas remains under-researched, since most of the descriptions 
have been on post-mortem studies and case reports.  
On the other hand, FGS has been associated with a three-fold increased risk of human 
immunodeficiency virus (HIV) infection in women living in endemic areas of SSA (Kjetland et al., 
2006; Kjetland, Leutscher and Ndhlovu, 2012). There is a similar plausibility of additional risk of HIV 
transmission among dually-infected males in schistosomiasis-endemic areas due to observed 
increase in inflammatory cells and immunological mediators in semen of people with MGS which 
might increase the viral copies (Leutscher et al., 2005). Hence treatment of MGS with PZQ could 
support the control of HIV/AIDS in overlapping prevalent areas of both diseases, especially in SSA.  
This systematic review on MGS in endemic areas, has the following specific objectives: 
1. update the epidemiology of MGS in endemic areas,  
2. review the clinicopathological features of MGS including co-infections with other 
diseases,  
3. assess the available diagnostic techniques and treatment of MGS, and  
4. determine the existing gaps to develop future research agenda of MGS.  
3.4. Methods of literature review 
An online literature search was conducted systematically from 9th January 2017 to 30th April 
2018 for publications made from 1900 up to 2017, using the main search term ‘male genital 
schistosomiasis’ in PUBMED, EBSCOhost (CINAHL Complete, MEDLINE Complete, Global Health, 
eBook Collection), COCHRANE LIBRARY and WEB OF KNOWLEDGE databases, following the 
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stipulated guidelines of each database. The main search term was combined with terms for known 
symptoms of MGS retrieved from the main textbooks on Tropical Medicine (Butterworth et al., 
2013; Bustinduy and King, 2014; Squire and Stothard, 2014), which included ‘haemospermia’, 
‘haematospermia’, ‘ejaculate’, ‘erectile dysfunction’, ‘infertile’, ‘sterile’, ‘painful’, ‘discomfort’, 
‘spermaturia’, ‘semen’. In addition, the main term was combined with terms of male genital organs, 
listed as ‘prostate’, ‘seminal vesicle’, ‘spermatic cord’, ‘epididymis’, ‘vas deferens’, ‘testis’ and 
‘reproductive organ’.  
In the PUBMED database after inputting the main search term, it automatically searched the 
terms as Medical subject headings (MeSH) and all fields, to produce the total results which were 
narrowed to those of English language. The search of the main terms in the EBSCOhost database 
involved all possible forms of the terms, augmented using relevant syntax ‘OR’, ‘AND’; for example, 
‘male+ OR male* OR man* OR man+’ AND ‘genital+ OR genital*’ AND ‘schistosomiasis+ OR 
schistosomiasis* OR Schistosoma* OR Schistosoma+ OR bilharzia+ OR bilharzia* OR bilharziosis* OR 
bilharziosis+’. These terms were automatically expanded for equivalent subjects and related words, 
also narrowed by English language. The search in the COCHRANE LIBRARY followed a similar pattern 
to the EBSCOhost database. For the WEB OF KNOWLEDGE, the main terms were searched using both 
field tags ‘TOPIC’ and ‘TITLE’ and then combined with Booleans ‘OR’, and ‘AND’ appropriately.  
The results were compiled together to produce the final list of articles. Additional articles 
from other sources such as references from the textbooks and known parasitologists were added to 
the final lists from these four databases. The final articles in French and Portuguese languages were 
translated into English (Refer to Appendix 1 Supplementary Tables). All the articles were screened in 
the following five stages:  
• Stage 1: Lists of articles were checked for possible duplications, which were removed. 
• Stage 2: Thereafter, the titles of the remaining articles were screened for relevance to MGS 
and excluded accordingly. 
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• Stage 3: Then, the abstracts of those remaining were read and screened for relevance to 
MGS. Those articles not related to MGS were removed from the list. 
• Stage 4: The full text of the remaining articles was retrieved and read through to select 
those manuscripts on MGS to be included in the review.  
• Stage 5: The references and citations of the full-text articles included in the review were 
screened for additional articles not retrieved in the above database searches.  
Furthermore, leading articles on FGS and texts from prominent textbooks describing 
schistosomiasis (Gelfand, 1967; Jordan and Webbe, 1969; Jordan, Webbe and Sturrock, 1993; Kamel 
and Lumley, 2004; Weiss, 2004) were read to form background knowledge and comparison to MGS 
where necessary. Alerts were installed on all the databases searched for this review to capture new 
publications and additional articles relevant to MGS. 
3.5. Analysis of assembled literature 
The online database search produced a combined total of 3,329 publications using the main 
search term (Figure 13 & Table 5). Four articles were added from the alerts on the searched 
databases. After screening through the five stages described earlier, the final articles included in this 
MGS review are 152 (Supplementary Table 2), of which 32 were original research studies, 96 case 
reports, 1 article describing voluntary schistosome infection, 2 editorial papers, 3 systematic reviews 
and 18 literature reviews on schistosomiasis with aspect of male genital pathology. The period of 
publications was from 1911 to 2018.  
Thirty-two original research studies have been published from 1952, with half directly on 
genital schistosomiasis, while the other half focussed on schistosomiasis with brief descriptions on 
genital symptoms, pathologies or complications. Sixteen studies reported only on S. haematobium, 3 
on S. mansoni, 9 on mixed S. haematobium and S. mansoni infections, while 4 had no mention of 
species (Figure 13). In addition, 26 studies were conducted in Africa [Madagascar-6, Nigeria-6, Egypt-
5, Zimbabwe-5, Zambia-2, Ghana-1] and one each in other continents except Australasia. There were 
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11 necropsy studies, 5 histopathological studies, 6 longitudinal cohort studies, 2 qualitative studies, 
1 radiography study and 1 hormonal analysis study. Seven studies involved examination of all genital 

































   
Records identified through 
database searching (n = 3,329) 
Records after removing duplicates (n = 2,304) 
Records excluded = 1,029) 
Additional records identified 
through other sources (n = 4) 
Total records identified (n = 3,333) 
Articles included in the final review (n = 152) 
Records after title screening (n = 353) 
Records excluded (n = 1,951) 
Articles in references, citations (n = 
27) and those from Alerts (n = 4) 
Full-text articles assessed for eligibility (n = 227) 
Articles to be included in the final review (n = 121) 
Articles excluded (n = 106) 
Records excluded after abstract 
screening (n = 126) 
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Table 5:  Results of literature search on the online databases conducted from January 2017 to April 
2018 
Online database 






‘symptoms’ and ‘organs’ 
EBSCOhost 680 837 1,677 
PUBMED 181 339 812 
WEB OF KNOWLEDGE 140 275 570 
COCHRANE LIBRARY 17 96 270 
TOTAL 1,018 1,547 3,329 
 
Ninety-six case reports were made between 1911 and 2018, with only five reports published 
prior to 1952. Fifty-five case reports were from endemic areas mostly in Africa [n=35; 64%] while 40 
reports were on travellers or people emigrating from endemic areas to non-endemic countries, 
especially in Europe [n=30; 75%] (Figure 14). Some travellers diagnosed in non-endemic countries in 
Europe, Asia and Australia, were infected after swimming or walking in Lake Malawi in SSA, which is 
endemic mainly for S. haematobium. In France, ten of the 12 case reports were of travellers to or 
emigrants from North, West and Central African countries of Algeria, Cameroun, Central African 
Republic, Chad, Democratic Republic of Congo (DRC), Egypt, Gabon, Libya, Mali, Mauritania, Niger 






Figure 14: Global map showing distribution of the publications on MGS from 1911 to 2018.  
The two charts displaying number of publications in the first and second 50 years and per continent. (The original research studies comprise post-mortem studies 
conducted in Africa and South America; prospective studies mainly in Africa). 
80 
 
Sixty case reports (63%) were on S. haematobium, 22 (23%) on S. mansoni, and the rest (5%) 
on mixed S. haematobium and S. mansoni (n=2), on S. haematobium, S. mansoni and S. intercalatum 
(n=2), on S. japonicum (n=1), whereas 9 (10%) had no speciation. The pathological organs described 
in 74 case reports included scrotum (including testis and vas deferens) [n=39], prostate [n=17], 
seminal vesicles [n=17], spermatic cord [n=3], epididymis [n=7] and penis [n=1]. The main presenting 
symptoms or complaints were swelling of scrotum and other genital organs [n=58], pelvic pain 
[n=23], haemospermia [n=14], hydrocele [n=12], changes in semen / ejaculate [n=11], infertility 
[n=6] and urethral discharge [n=2].  
The 3 systematic reviews were published in 2011 and 2015, discussing the relationship 
between UGS and HIV (Mbabazi et al., 2011), prostate adenocarcinoma associated with prostatic S. 
haematobium infection (Figueiredo et al., 2015) and MGS treatment as a future HIV prevention tool 
(Stecher et al., 2015). 
3.5.1. Update on the epidemiology of MGS 
As described earlier, S. haematobium is endemic in Africa where most knowledge originates, 
and the first recognised description of MGS was made by Madden a century ago (Madden, 1911). 
However, earlier literature by Chaker, Lortet, Vialleton, Letulle and Madden [1885-1909] described 
lesions in genital organs like seminal vesicles and prostate which were infiltrated by schistosome ova 
and granuloma formation (Madden, 1909; Mensah et al., 1972; Guirassay et al., 2008). Other genital 
organs have been described in the subsequent reports and research studies. 
Post-mortem studies were among the earliest research in endemic areas especially in Africa, 
describing the epidemiology of genital schistosomiasis, four decades after the Madden report, giving 
the background knowledge to understanding MGS (Mohammed, 1952; Gelfand and Ross, 1953; 
Edington et al., 1970; Gelfand et al., 1970; Edington, Nwabuebo and Junaid, 1975). Digestive 
methods were performed using potassium hydroxide (KOH) to harvest the ova from the genital 
organs with pathologies caused by S. haematobium and S. mansoni. Seminal vesicles were infected 
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almost as much as the urinary bladders, ranging from 50% to 80% of vesicles with over 90% of 
bladders (Mohammed, 1952; Gelfand and Ross, 1953) with approximately 20,000 ova found in the 
vesicles [Table 6] (Edington et al., 1970; Gelfand et al., 1970; Edington, Nwabuebo and Junaid, 1975). 
Histopathological examinations were also conducted, in other studies to compare with the digestive 
methods which showed that more ova were observed with the latter technique (Gelfand et al., 
1970). 
Table 6:  Total number of Schistosoma ova in pelvic organs in necropsy studies 
Study participants 
Post-mortem studies 
Gelfand et al. 1970 Edington et al. 1975 
Total number 200 54 
 
Pelvic organs 
Intensity of Schistosoma egg distribution 
Mean egg count Range of egg distribution 
Bladder 105,011 13,260 - 87,100 
Seminal vesicles 19,801 4,312 – 12,027 
Vas deferens 2,913 - 
Prostate 34 169 – 9,828 
In endemic areas of S. haematobium and S. mansoni, the former predominates with more 
genital pathologies in literature than the latter, similarly to the case reports (Grace and Aidaros, 
1952; Alves, Woods and Gelfand, 1955). From these studies, it has been described that MGS affects 
between 1%  to 20% of those in endemic areas at risk and suffering from UGS (Ricosse, Emeric and 
Courbil, 1980; Fievet et al., 1984). This could be a gross underestimation, because several studies 
have reported that at least 50% of genital organs are infected by schistosome ova, emphasising that 
MGS is as common as urinary manifestations of schistosomiasis but with lower intensity of ova 
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[Table 7] (Edington et al., 1970; Edington, Nwabuebo and Junaid, 1975; Elem and Patil, 1987; Patil 
and Elem, 1988).   
The first identified prospective study on MGS was conducted in Madagascar in 1999-2000, 
where 19 of 44 participants (43%) had MGS by S. haematobium ova in semen (Leutscher et al., 
2000). Although the sample size of this study was small, subsequent longitudinal studies in the same 
country showed similar prevalence of MGS, ranging from 28% in 2005 to 53% in 2009 (Leutscher et 
al., 2005; Leutscher et al., 2008a; Leutscher et al., 2008b; Leutscher, Host and Reimert, 2009). 
Schistosoma ova were present in semen only in some cases, highlighting fact that the prevalence of 
MGS is quite significant, similarly to that of UGS in endemic areas, despite not having been studied 
as extensively. 
Table 7: Schistosoma ova in male genital organs seen in necropsy studies. 
Year Author(s) Country Autopsies Species Infected genital organs 
1955 Alves et al. Zimbabwe 50 Sh, Sm 
18% vas deferens; 18% prostate; 4% 
tunica vaginalis; 2% epididymis 
1956 Arban Brazil 3,233 Sm 
10/3,233 infected: 20% prostate; 
30% testes 
1970 Gelfand et al. Zimbabwe 200 Sh, Sm 
54% seminal vesicles; 39.9% 
spermatic duct; 20.5% prostate 
1975 Edington et al. Nigeria 54 Sh 
Severe infections: 100% prostate; 
100% seminal vesicles; 57% testes; 
57% epididymis 
1987 Elem & Patil Zambia 50 Sh 
62% bladder; 58% seminal vesicles; 
50% prostate 
1988 Patil & Elem Zambia 100 Sh 
62% bladder; 58% seminal vesicles; 
50% prostate 
Sh - S. haematobium; Sm - S. mansoni 
3.5.2. Clinico-pathological features of MGS including co-infections 
From our search, genital organs with schistosomal pathologies have been recorded in case 
reports from Africa, namely prostate, seminal vesicles, vas deferens, testis and scrotum which were 
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more associated with S. haematobium than S. mansoni (Cerqua, 1930; Mohammed, 1930; Makar, 
1937; Gelfand and Davis, 1940). An early report from South America  associated with S. mansoni, 
presented of enlarged scrotum, thickened seminal vesicles and hydrocele (Armbrust, 1951). 
Subsequent reports indicate that a higher burden of MGS is in S. haematobium - endemic areas of 
Africa than other schistosome - endemic areas in the world.  
Although most of the MGS pathologies have been reported on S. haematobium in 
inhabitants and travellers to endemic areas, similar reports have been made on S. mansoni, S. 
intercalatum and S. japonicum (Corachan et al., 1994; Vilana et al., 1997; Yu et al., 2013). Infestation 
of genital organs result in several early symptoms of MGS. One major symptom observed in early 
stages is haemospermia resulting from egg penetration and release into seminal vesicle lumen, 
causing ulceration of mucosal lining, and pain during coitus and ejaculation (Madden, 1911; Makar, 
1937; Mohammed, 1952; Kato-Hayashi et al., 2013; Lang, Minion and Wong, 2017).  Haemospermia 
can occur as the only symptom or first symptom preceding haematuria, occurring within three 
months of exposure to infection (Becquet, 1966; Pedro Rde, Barros Rde and Amato Neto, 1973; 
Corachan et al., 1994; Schwartz et al., 2002).   
Of interest, this symptom has been described more frequently among travellers than 
inhabitants of endemic areas, in 8 of the 12 case reports found in the search. This could be due to 
failure to recognise the symptoms, societal acceptance of condition as male menstruation and 
maturing from boyhood to adulthood, not knowing or making an association with MGS, being 
mistaken with sexually transmitted infections (STIs) or infidelity (Ukwandu and Nmorsi, 2004; 
Yirenya-Tawiah, Ackumey and Bosompem, 2016). In relation to haemospermia, other reported 
symptoms include alteration in semen quality and appearance with discolouration (McKenna, 
Schousboe and Paltridge, 1997; Torresi et al., 1997; Hawary et al., 2012), subjective change (Davies 
and Hamdy, 1998), lumpy semen (Lewis, al-Adnani and Murphy, 1996; Lang, Minion and Wong, 
2017), rice grains with increased volume (Pedro Rde, Barros Rde and Amato Neto, 1973) and 
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reduced viscosity or volume (Perignon, Pelicot and Consigny, 2007; van Delft et al., 2007; Knapper, 
Morrell and Lomax, 2012).  
The symptoms associated with mucosal thickening and enlargement of organs such as 
seminal vesicles cause irritation of the sympathetic nervous system leading to sexual 
hyperexcitability, night dreams and frequent painful erections (Mohammed, 1952). However, these 
symptoms have not been reported in the last four decades, raising the question of their reliability in 
the earlier studies or non-reporting in the recent studies, possibly due to the sensitive descriptive 
nature. The enlargement of genital organs has also been mistaken for other diseases such as 
tuberculosis or malignancy resulting in extraneous surgical interventions where PZQ treatment 
provided earlier might have prevented the surgery (Madden, 1911; Chippaux, Cornet and Datchary, 
1957; Eltayeb, 1969; Kazzaz and Salmo, 1974; Fievet et al., 1984; Githae, 1992; Ferreira et al., 2015). 
Untreated, the organs chronically become nodular, firmer, smaller and non-functional. 
More recently reported symptoms of MGS include spermaturia (sperm in urine) as a result 
of fibrosis and abnormal cystic dilatation of seminal vesicles (Etribi, Girgis and Saleh, 1967), 
hydrocele formation (Gelfand and Davis, 1940; Armbrust, 1951; Van Beukering and Vervoorn, 1956; 
Pawel et al., 2008; Ramarakoto et al., 2008; Rambau et al., 2011), epididymitis (Alves, Assis and 
Rezende, 2004), funiculitis (Durand et al., 2004), orchitis (Mikhail et al., 1988; Ihekwaba, 1992; Al-
Qahtani and Droupy, 2010), prostatitis (Cerqua, 1930; Alexis and Domingo, 1986; Patil and Elem, 
1988; Cohen, Edgar and Cooper, 1995; Fender, Hamdy and Neal, 1996; Basilio-de-Oliveira et al., 
2002; Al-Saeed et al., 2003; Lambertucci, Voieta and Barbosa, 2006; Bacelar et al., 2007; Sharma et 
al., 2015), infertility from oligospermia, azoospermia either obstructive from blockage of vas 
deferens, spermatic cord, epididymis, tunica vaginalis or non – obstructive through infarction (Kini et 
al., 2009; Abdel-Naser et al., 2018a; Abdel-Naser et al., 2018b), fibrotic lesions (Edington, Nwabuebo 
and Junaid, 1975) or functional lymphotic infiltration in testis (Adisa et al., 2012). While egg load in 
the bladder tissue has been found to correlate with pathological severity, few ova in seminal 
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vesicles, prostate and other genital organs have been associated with severe extensive pathological 
changes (Edington et al., 1970; Edington, Nwabuebo and Junaid, 1975).  
On malignancies of genital organs, our search showed that MGS has been reported among 
travellers and those emigrating from endemic areas, apart from testicular or scrotal schistosomiasis 
simulating neoplasia (Alexis and Domingo, 1986; Cohen, Edgar and Cooper, 1995; Ma and Srigley, 
1995; Basilio-de-Oliveira et al., 2002; Bacelar et al., 2007; Lopes, de Almeida and Jacobino, 2007; 
Figueiredo et al., 2015). Prostatic adenocarcinoma has been observed to occur together with 
Schistosoma ova, resulting in epithelial granulomata, marked fibrosis and organ enlargement, which 
have been described in reports of tissue histopathology and cancer spread to other genital organs 
affected by MGS. Despite an accepted link between chronic UGS and squamous cell carcinoma of the 
bladder (Honeycutt et al., 2014), the mechanism of association between prostatic cancer and 
schistosomiasis remains unknown.   
Our search produced recent systematic reviews addressing extensively the interactions of 
both MGS and HIV and were included in this review (Mbabazi et al., 2011; Stecher et al., 2015). As 
one of the leading causes of morbidity and mortality in the world, HIV has its epicentre in the SSA 
region (UNAIDS, 2016) where coincidentally schistosomiasis is endemic (Figure 15).  Female genital 
schistosomiasis (FGS) has been observed in 33-75% of women having UGS living in endemic areas in 
SSA (Kjetland, Leutscher and Ndhlovu, 2012). In addition, FGS has been associated with a 3-fold 
increased risk of HIV infection with characteristic sandy-grainy patches present in egg-infected 
genital organs, abnormal blood vessel formation and increased levels of inflammatory cells 
expressing CD4+ receptors triggered by Schistosoma granuloma (Kjetland et al., 2006; Christinet et 
al., 2016). More knowledge is needed on the risk of MGS on HIV infection. 
Various hypotheses have been proposed regarding the impact of MGS on HIV transmission. 
As described in Leutscher et al (2005) study and the systematic reviews by Mbabazi et al (2011) and 
Stecher et al (2015), men with MGS have elevated levels of eosinophils and lymphocytes among 
other inflammatory cells expressing CD4+ receptors together with cytokines IL-4, 6, 10, TNF-α. These 
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recruit more HIV-infected cells into semen, upregulating viral replication and increasing viral 
concentration (Leutscher et al., 2005; Mbabazi et al., 2011; Stecher et al., 2015). With the chronic 
inflammation and cell recruitment to the male genital tract, these may increase HIV viral load in 





Produced from (WHO, 2014; Kaiser-Family-Foundation, 2016) Figure 15: Map of Africa showing the correlation of the prevalence of HIV and schistosomiasis.  
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A recent observational pilot study in endemic SSA area demonstrated a reduction of viral 
load shedding in semen of HIV positive men coinfected with UGS 10 weeks after PZQ treatment 
(Midzi et al., 2017). Further case-cohort or randomized studies are needed to be conducted in 
endemic areas to explore these critical findings further. 
3.5.3. Techniques for detection of MGS 
Urine microscopy remains the definitive way for identifying schistosome ova (mainly of S. 
haematobium) to diagnose UGS. While it is the gold standard (Le and Hsieh, 2017) and also 
considered as a useful proxy for diagnosing MGS, our findings indicate challenges in its reliability due 
to presence of ova in semen or histological specimens in the absence of ova in urine (or stool), as 
well as other schistosome species that may on occasion cause MGS (Corachan et al., 1994; Torresi et 
al., 1997; Leutscher et al., 2000; Schwartz et al., 2002; Lang, Minion and Wong, 2017). As such, there 
is a direct need to conduct microscopy on semen and biopsy material from suspicious genital 
lesions/tissues to diagnose MGS.   
Also, semen should be analysed repeatedly with periods of abstinence to cater for the daily 
diurnal variations in excretion of ova from the genital organs and increase likelihood of maximum 
egg yield, similar to the recommended consecutive urine analyses (Leutscher et al., 2008b; Le and 
Hsieh, 2017). However, perceptions, beliefs and sensitivity of people in endemic communities with 
regards to semen samples can affect the collection or submission and analyses, therefore there will 
be need for more health education and counselling of those required to submit and the community 
to ensure acceptability and success in collection of the sample in the community (Price et al., 2005; 
Midzi et al., 2017).  
Leutscher and colleagues report on use of eosinophil cationic protein (ECP), circulating 
anodic antigen (CAA) and soluble egg antigen (SEA) as blood-based markers of MGS which showed 
positive correlation to urine egg count, with ECP significantly correlating with urine count and 
declining after PZQ treatment, highlighting its importance in diagnosis (Leutscher et al., 2000; 
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Leutscher et al., 2008b). However, other helminth, bacterial or viral infections and inflammatory 
conditions elevate ECP hence affecting the reliability in co-morbidities which are common in 
endemic areas. PCR and DNA-based tests on the other hand have shown to be highly sensitive and 
specific diagnostic tools, which can be used in urine, semen, and many other specimens (Le and 
Hsieh, 2017). These tests are still expensive for field use in endemic areas of Sub-Saharan Africa, 
hence the need to develop easier, accessible, low-cost tests. 
Our findings showed that ultrasonography is useful in diagnosing lesions caused by MGS and 
monitoring morbidity of the pathologies (Richter, 2000; Al-Saeed et al., 2003; Ramarakoto et al., 
2008). The pathological lesions seen in genital organs have been described as echogenic lesions and 
calcifications, with the former improving with treatment (Richter, 2000; Ramarakoto et al., 2008). 
Availability of portable sonography machines could be more cost-effective in endemic areas since 
other radiological techniques such as computerised tomography (CT) and magnetic resonance 
imaging (MRI) are very expensive, not feasible and almost non-existent in these regions. However, 
there has been limited radiological research on MGS in endemic areas, hence there is a need for 
more field studies to study the resolution of pathologies after treatment. 
3.5.4. Current treatment options for MGS 
Praziquantel has remained the mainstay treatment for most forms of schistosomiasis, 
including MGS (WHO, 2013a). It is effective with population cure rates of over 90% and targets adult 
worms thereby reducing egg excretion and averting morbidity, however, praziquantel does not 
successfully kill juvenile worms (Rollinson, 2009). Most identified case reports and studies used the 
recommended traditional dosage of 40mg/kg in treating MGS with some failure cases requiring 
further repeated doses or higher dose of 60mg/kg (Schwartz et al., 2002; Alonso et al., 2006; 
Perignon, Pelicot and Consigny, 2007). It has been suggested that higher doses are more efficacious 
in MGS treatment than the traditional dose (Lang, Minion and Wong, 2017).  
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Use of PZQ in most African programs are based on morbidity control through mass drug 
administration versus specific case management. The former is an attempt to keep prevalence and 
intensity down to an acceptable level, below 10% in the endemic population and obtain the greatest 
cost-benefit outcome at a populational level. There are well-known gaps in this approach, for 
example, school-aged children are targeted with donated stocks of PZQ ring-fenced (restricted) for 
this use in school-based programs. As an indirect consequence, many adolescents and adults rarely 
receive adequate treatment and PZQ is not always available in peripheral health clinics which further 
affects management of schistosomiasis in an individual case management setting (Christinet et al., 
2016; McManus et al., 2018).   
3.5.5. Existing gaps for further research of MGS 
This review conducted a systematic search to elucidate the burden of MGS in endemic areas, 
a century after the first recognised report in 1911. Despite the detailed epidemiology of 
schistosomiasis in the world highlighting the enormous impact of UGS, much remains unknown of 
the burden of genital manifestations of schistosomiasis either FGS or MGS, specifically. More 
description and research studies of UGS especially in endemic areas have concentrated on urinary 
system and associated pathologies, however, with the growing interest in cervical cancer screening 
there are opportunities to integrate surveillance of FGS (Christinet et al., 2016). On the other hand, 
for men, no such screening programmes exist and therefore the prevalence and morbidity of MGS in 
endemic areas will remain under-reported. 
In addition, the limited description of MGS is compounded by difficulties in diagnostic 
techniques and approaches, these include deficits in standardised protocols for analysis of semen. 
Indeed, future methods which involve molecular assays will be challenging to carry out in primary 
health facilities in SSA. Future research studies to explore the deployment of low-cost techniques 
and methods are urgently required. These would be particularly important regarding treatment and 
management of MGS, as currently there is a clear gap in our understanding of the optimal dose of 
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PZQ to treat MGS, whether single, repeated or higher dosages would be effect a parasitological cure 
(Schwartz et al., 2002; Alonso et al., 2006; Lang, Minion and Wong, 2017), notwithstanding tracking 
the dynamics of lesions in the genital tract. This highlights the need for further prospective 
longitudinal studies in endemic areas and more clinical research exploring an agenda of how best to 
integrate preventive treatment and management of MGS alongside ongoing interventions for HIV in 
SSA. 
3.6. Discussion  
This review has revealed that genital organs are infested with schistosome ova in the early 
stages of the infection, similar to other forms of the disease. These organs are infected with 
substantial numbers of ova as much as urinary bladder or intestines, further indicating the higher 
levels of MGS in endemic areas. Clinical manifestations associated with MGS in this review have 
been described previously by Barlow after self-infection with cercariae (Barlow and Meleney, 1949) 
and are regarded as major symptoms and diagnostic for MGS.  
As symptoms like haemospermia can also present in other diseases such as hypertension, 
prostatitis or STIs (Feldmeier et al., 1999), raising the need to exclude other conditions before 
concluding the diagnosis of MGS. Underreporting and misconceptions of these symptoms which may 
have negative perception in the community, contribute to misdiagnosis and underestimation of MGS 
in these endemic areas (Ukwandu and Nmorsi, 2004; Yirenya-Tawiah, Ackumey and Bosompem, 
2016). Furthermore, co-existence of MGS and prostatic metaplasia and malignancies require further 
research to understand the link and develop diagnostic and therapeutic interventions. 
Although urine microscopy has been considered as a proxy for diagnosing MGS, our findings 
observed challenges of ova found only in semen without any in urine or stool, hence the need to 
consider semen microscopy as a definitive way of diagnosing MGS. Accessible, low-cost molecular 
tests should be developed to address this diagnostic challenge. Similarly, radiological techniques like 
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field-based ultrasonography should be rolled out into endemic areas to monitor the morbidity and 
resolution of MGS pathologies. 
MGS appears to be prevalent in areas endemic for UGS, which coincidentally are high 
prevalent areas for HIV. Some people in these areas in SSA have higher HIV prevalence and also  at 
higher risk for schistosomiasis due to their lifestyles and daily activities, as reported about fishermen 
in Malawi (NSO, 2014; NAC, 2015). With some evidence of MGS potentially upregulating viral 
replication, increasing the concentration of HIV particles in the semen and exponentiating the 
infectiousness of dually infected males, treatment of MGS could be an importance tool in helping to 
avert new HIV infections in SSA (Stecher et al., 2015). Interestingly, one of the current effective 
intervention of HIV prevention, male circumcision, was considered by ancient Egyptians around 2300 
BC as an intervention to prevent schistosomal infection among men bathing in infested waters, 
though later disputed (Allen, 1909; Madden, 1919; Jordan, 2000; Weiss, 2004).  
Although this review followed general principles of a systematic review, it was not registered 
with PROSPERO and did not include 2 reviewers for the literature screening as recommended by the 
PRISMA guidelines. The recent systematic review on UGS and HIV, Zirimenya study 
(https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=116648), was registered 
with PROSPERO in 2018, however there are no obvious published outputs from it. 
3.7. Conclusion 
MGS is an under-appreciated manifestation of UGS and has been reported worldwide but its 
current distribution is most tightly linked with areas endemic for S. haematobium. In SSA, MGS likely 
blights the lives of millions of men who currently do not have adequate access to point-of-care 
diagnostics or access to optimal praziquantel treatment regimes. We propose that MGS should be 





3.8. Supplementary Tables 
Table 1:  Additional articles on MGS received from Parasitologists and Alerts from databases 
Articles added to those retrieved from online search before the screening stages 
No. Authors Year Key facts 
1. Barlow and Meleney  1949 Voluntary schistosomal infection with haemospermia in early 
stages 
2. Feldmeier et al.  1999 Male genital schistosomiasis and haemospermia 
3. Rollinson 2009 Review of history, life cycle and clinic-pathologies of 
schistosomiasis 
4. Le and Hsieh 2017 Review of current diagnostics, challenges and future advances 
 
Articles added from the Alerts on the online searched databases after the screening stages 
1. Midzi et al.  2017 Decreased in seminal HIV-1 viral load after PZQ treatment of 
UGS coinfection in HIV-positive men 
2. Aber-Naser et al.  2018 Testicular schistosomiasis in an obstructive azoospermic man 
3. McManus et al. 2018 Review of the epidemiology, pathophysiology, diagnosis, 
management and control of schistosomiasis, some facts on 
genital manifestations 
4. Aber-Naser et al. 2018 Review of schistosomiasis as an important cause of male 
infertility in endemic areas 
 
Table 2:  All articles included in the review 
Original research studies (* those focussed specifically on MGS; ǂ those from references) 
No. Authors Year Country Organs / Specimens Key findings 
1. Mohammed*  1952 Egypt Post-mortems:  
Seminal vesicles 
Prostate 
80% seminal vesicles and 
19% prostates infected 
with bladder; dense 
fibrosis and calcified eggs 
2. Grace and Aidaros*ǂ 1952 Egypt Autopsies: 
Seminal vesicles 
95% seminal vesicles 
involved in infected 
autopsies, bilateral, 94% 
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with S. haematobium 
calcified eggs 
3. Gelfand and Rossǂ 1953 Zimbabwe Post-mortems:  
all organs, males and 
females 
S. haematobium more 
common than S. mansoni n 
prostate despite rectum 
close proximity 
4. Alves et al.*  1955 Zimbabwe Autopsies: male 
genital organs 
76% of autopsies showed 
bilharzial eggs; prostate, 
vas deferens, seminal 
vesicles involved most. 
5. ArbÁN 1956 Puerto Rico Autopsies and surgical 
removed specimens 
10 genitourinary lesions 
due to S. mansoni; kidneys, 
bladder, testes, prostate 
and seminal vesicles 
6. King  1965 South Africa Urine microscopy 
Radiological exam 
More epididymo-orchitis in 
no urine eggs than with; 
prostatitis in 0.11% with 
eggs, 0.16% without 
7. Etribi et al.*  1967 Egypt Histopathological 
analyses of thick vas 
deferens 
62.7% of sub fertile men 
had Bilharziasis (eggs in 
semen, urine, 
calcifications), obstructive 
testicles   
8. Gelfand et al.*  1970 Zimbabwe 
(S. Rhodesia) 
Autopsies: prostate, 
seminal vesicles, vas 
deferens 
Seminal vesicles, spermatic 
cord, prostate infected 
more with S. haematobium 
than S. mansoni eggs 
9. Edington et al. 1970 Nigeria Autopsies: all organs Mean egg load more in 
males; eggs in seminal 





10. Edington et al.* 1975 Nigeria Autopsies; male and 
female genital organs, 
appendix, brain 
Seminal vesicles, prostate, 
testes, epididymis were 
most infected; atrophy, 
fibrosis with calcified eggs 
11. Aboul et al.* 1977 Egypt Seminal vesicles Seminal vesiculitis due to 
severe bilharzial infiltration 
showed no obstructive 
infertility. 
12. Cheever et al. ǂ  1978 Egypt Autopsies: pathology 
of extrahepatic organs 
Active lesions in seminal 
vesicles, prostate and 
ejaculatory ducts; eggs, 
fibrosis, muscle 
hypertrophy 
13. Ricosse et al. 1980 France Pathological 
specimens 
Testes: hard, irregular, 
hydrocele 
Epididymis: nodular mass, 
inflamed 
14. Bello and Idiong  1982 Nigeria - 42.2% of the urethral 
discharge students had S. 
haematobium eggs 
15. Gwavava et al. ǂ  1984 Zimbabwe Surgical biopsies from 
all organs 
Penile ulcer, swollen testis 
/ epididymis, hydrocele 
haematuria 
16. Elem and Patil*  1987 Zambia Autopsies: bladder, 
seminal vesicles, 
prostate; urine, semen 
11 haemospermia men - no 
eggs; 100 semen – no eggs 
but 2 in urine; 58% 
prostate, 50% seminal 
vesicles 
17. Patil and Elem* 1988 Zambia Post-mortems: 
bladder, seminal 
vesicles, prostate 
Digestion vs histology 
exams: s. vesicles – 50% vs 
25%, prostate- 50% vs 9%, 
bladder – 62% vs 20% 
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18. Ogunbanjo et al.  1989 Nigeria - 2/54 seminal fluids from 
infertile men had S. 
haematobium eggs 
19. Skelly et al.* 1994 Brazil - No significant differences 
in testosterone levels 
between infected and non-
infected males 
20. Leutscher et al.*  2000 Madagascar - 57% with urine eggs, 43% 
in semen ECP in urine and 
semen correlated with 
number of eggs excreted 
21. Al-Saeed et al.  2003 Kuwait Seminal vesicles Solid masses of seminal 




22. Ukwandu and Nmorsi  2004 Nigeria - 66% with eggs in urine; 
4.3% in semen; 22% had 
sexual pain.  
23. Leutscher et al.*  2005 Madagascar - 67% in urine, 28% semen; 
cytokines, leucocytes, 
lymphocytes increased; 
declined with PZQ 
24. Mohammed et al.  2007 Nigeria Endoscopic or surgical 
biopsies (GIT, GUT) 
10% male genital organs 
affected: prostate, testis, 
epididymis 
25. Leutscher et al.*  2008 Madagascar - 62% eggs in urine, 42% in 
semen; ECP, SEA, CAA 
correlated with egg count, 
with CAA performing well 
26. Leutscher et al.  2008 Madagascar - 55% eggs in urine; 17% had 




painful ejaculate.  
27. Ramarakoto et al.*  2008 Madagascar Urogenital organs with 
S. haematobium 
Hyperechogenic and 
calcified lesions in seminal 
vesicles and prostate; 
enlarged 
28. Leutscher et al.*  2009 Madagascar - 53% egg in semen, lower 
volume, leukocytospermia; 
apoptosis correlate with 
ECP, lower with PZQ 
29. Coltart et al.  2015 UK - 6/10 patients with 
haematospermia had eggs 
in urine 




scrotum; 12.3% UGS help 
HIV acquisition 
31. Lima et al. 2017 Brazil Histopathological 
diagnosis for ectopic 
forms of S. mansoni 
5 cases of male genital S. 
mansoni: testis (3, 2 had 
orchiectomy for prostatic 
adenocarcinoma; 1 with 
chronic orchitis); penis (1) 
with squamous cell 
carcinoma; epididymis (1) 
with epididymitis. 
32. Midzi et al.  2017 Zimbabwe Urine & stool for 
schistosomiasis 
diagnosis; blood for 
HIV-1 diagnosis & RNA 
viral load monitoring; 
semen for RNA viral 
load monitoring 
18 HIV-positive men (6 
ART-naïve & 12 ART-
experienced) with S. 
haematobium in urine 
recruited and treated at 
baseline; followed up for 
10 weeks. Mean HIV viral 
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load reduction on follow-
up after PZQ & no S. 
haematobium in urine 
 
Case reports (#Letters to the Journal Editors, ǂ those from references) 
No. Authors Year Country Organs / 
Specimens 
Key findings 




Hard, painless swelling; 
epididymis replaced by nodules 
full of eggs.  
Haemospermia, haematuria, 
pain, thick seminal vesicle, eggs 
in urine 
2. Cerquaǂ  1930 Egypt Prostate Frequency, scalding erection; 
painless elastic swelling with 
eggs  
3. Mohammedǂ 1930 Egypt Seminal vesicle 
Vasa deferentia 
S. haematobium in urine; both 
organs fused with calcified eggs 




prostate, seminal vesicles, 
calcifications, S. haematobium 
eggs in urine, semen 
5. Gelfand and Davisǂ 1940 Zimbabwe Left testis 
Epididymis  
Enlarged, knobby testis; 
hydrocele, obliterated 
epididymis; also, eggs  
6. Armbrustǂ 1951 Brazil Scrotum Enlarged scrotum, hydrocele 
with dark fluid, S. mansoni in 
testes 




Scrotum Infertility; thick funiculi; 




8. Chippaux et al.  1957 France Seminal vesicles Haematuria, mass near seminal 
vesicle, with S. haematobium 
eggs 
9. Piganiol et al. 1957 Senegal Seminal vesicles 2-3 times increase in volume 
and hypertrophy of seminal 
vesicles 
10. Joshiǂ  1962 Ghana Scrotum  Bilateral painless swelling; mass 
with testis, epididymis and cord 
fused, infarcted with calcified 
eggs 
11. Cayret et al. 1963 France Seminal vesicles 7 cases presenting with 
haematuria, pelvic pain, 
enlarged vesicles, orchitis 
12. Klerk  1964 South Africa Seminal vesicles Dysuria, groin pain, firm seminal 
vesicles felt; calcified, thickened 
13. Houston  1964 Zimbabwe 
(S. Rhodesia) 
Right testis Enlarged abnormal; with 
bladder; having bilharzial 
pseudo-tubercles 
14. Chaves and Figueiredo 1965 Brazil Scrotum Pruritic eruptions, ulcer and 
oedema; nodules, papules with 
eggs 
15. Becquet  1966 France - Haemospermia, viable S. 
haematobium eggs in seminal 
fluid 
16. Joshi  1967 Sierra Leone Right scrotum Painless hard swelling; calcified 
eggs and fibrosis 
17. Eltayeb 1969 Sudan Right testis 
Epididymis 
Painless swelling, non-tender 
irregular with hard nodules and 
hydrocele; many eggs in 
epididymis 
18. Chatelain et al. 1969 France Epididymis Haematuria, dysuria, urethral 
shrinkage; fistulae lesion left 
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epididymis, large seminal 
vesicle 
19. Rosenberg et al.  1971 France  Left testicle Painless testicular mass with 
dilated calcified urethra, urine 
eggs 
20. Mensah et al.  1972 Senegal Prostate 
Epididymis 
Perineal pain, haematuria, 
enlarged prostate, hydrocele, 
discharge 
21. Richaud et al.  1972 France Right scrotum Nodule of cord lower part with 
eggs and sclero-inflammation 
22. Monnet et al. 1972 France Left testicle Swelling of left testicle in a 12-
year-old boy from Tunisia 
23. Pedro Rde et al.  1973 Brazil  - Haemospermia, watery red-
brown semen with rice grains, 
many eggs 
24. Kazzaz and Salmoǂ 1974 Iraq Epididymis Enlarged nodular swelling, 
multiple granuloma, calcified 
eggs, fibrosis 
25. Nwokolo 1974 Zambia - Purulent urethral discharge 
26. Steinberger et al. 1975 U.S.A. Left scrotum Left groin pain and swelling; 
necrosis and granuloma with 
eggs 
27. Mampilly and 
Sunkwa-Mills ǂ 
1976 Zambia Scrotum Left inguino-scrotal swelling; 
thickened epididymis and 
spermatic cord 
28. Badejo et al. ǂ 1978 Nigeria Penis Ulceration of penis with eggs in 
dermis; almost autoamputation 
29. Elbadawi et al. ǂ 1978 U.S.A. Left testicle Firm enlarged testis and 
prostate; tubular hyaline with 
calcified eggs 
30. Adeyemi-Doro et al.  1979 Nigeria Perineum Numerous, discrete, firm, 
painless papular eruptions; 
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biopsy with viable and calcified 
S. haematobium eggs 
31. Lembeli and 
Venkataramaiah# 
1981 Tanzania - S. haematobium eggs in semen 
32. Peyer and Graber  1982 Switzerland Testis  Testicular pain, haematuria; 
budding lesions with eggs and 
inflammation 
33. Fievet et al. ǂ 1984 France Right testicle nodule inferior pole; 
hypoechoic, epididymal nodule 
with pus, eggs 
34. Alexis and Domingo 1986 U.S.A. Prostate Urinary obstruction; S. mansoni 
eggs with adenocarcinoma 
35. Bambirra et al.  1986 Brazil Right testicle Enlarged firm testis, nodule, 
granulomas, viable and dead 
eggs 
36. Bac et al.  1987 South Africa Left scrotum Haematuria, hydrocele, firm 
irregular enlarged testis, 
nodules with many viable and 
calcified eggs 
37. Hamida et al. 1987 Tunisia Seminal vesicles Back pain, dysuria, haematuria, 
hypogastric mass; no urine 
eggs; cyst in right vesicle and 
eggs in muscularis 
38. Mikhail et al.  1988 Egypt Right scrotum 
Seminal vesicles 
Spermatic cord 
Swelling, heaviness, sensation 
loss, hydrocele; S. haematobium 
and S. mansoni eggs in testis  
39. Elem et al.  1989 Zambia Right testis 
Epididymis  
Painless enlarged testis; nodules 
on fibrocellular mass with eggs 
40. Fataar et al. 1990 New Zealand Seminal vesicles Seminal vesicle calcifications 
and granuloma seen on CT scan 
41. Wedel and Jess 1991 Denmark Right testis Haematuria, granulomas with 




42. Ihekwaba 1992 Nigeria Left testes Enlarged left testes; hydrocele; 
granuloma with calcified eggs 
43. Githae 1992 South Africa Left testicle Left hydrocele, hard, irregular 
non-tender testis, granuloma 
formation 
44. Bornman et al. 1992 South Africa - Primary infertility; S. 
haematobium eggs in semen, 
low sperm motility 
45. Fall et al. 1992 Senegal Left testicle Pelvic pain, haematuria; 
painless, firm, multinodular 
testis; orchidectomy with S. 
haematobium eggs found. 
46. Godec et al. ǂ 1992 U.S.A. Prostate Lower back pain, diffuse 
indurated prostate; bone 
metastases and prostate 
adenocarcinoma with S. 
mansoni eggs 
47. Obel and Black 1994 Denmark - Left inguinal pain; thin clotting 
semen with numerous S. 
haematobium eggs, none found 
in urine 
48. Corachan et al. 1994 Spain Prostate 
Seminal vesicle 
Haematospermia, perineal and 
coital discomfort, calcifications 
in prostate and seminal vesicle  
49. Cohen et al. 1995 South Africa Prostate  Elevated PSA, adenocarcinoma, 
with S. haematobium viable and 
calcified eggs; also, adult worms 
50. Ma and Srigley 1995 Canada Prostate 
Seminal vesicles 
Both enlarged; adenocarcinoma 
of both with calcified S. 
haematobium eggs; no 
granuloma or fibrosis 
51. Fender et al.  1996 U.K. Prostate 
Seminal vesicle 




haemospermia, boggy prostate 
and seminal vesicle 
52. Ingram et al. 1996 U.K. Testicles 
Epididymis 
Testicular pain, haemospermia, 
S. haematobium eggs in semen 
53. Lewis et al.  1996 U.K. Testicles Testicular pain; 2mm white 
lumps in semen, S. 
haematobium eggs 
54. Torresi et al. 1997 Australia - Thin, brown discoloured semen, 
with many S. haematobium 
eggs 




enlargement on scan 
56 McKenna et al. 1997 U.K. - Subjective ejaculate change, 
low volume and viscosity 
(watery) 
57. Davies and Hamdy# 1998 U.K. - Subjective change in ejaculate 
58. Soans and Abel 1999 Australia Right testis 2cm mass, hypoechoic lesions; 
necrotizing granuloma with 
eggs 
59. Basilio-de-Oliveira et 
al. 
2002 Brazil Prostate  Small nodule; adenocarcinoma 
with scattered S. mansoni eggs 
60. Schwartz et al.  2002 Israel - Haematospermia, haematuria, 
pain after ejaculation, eggs in 
semen 
61. Durand et al.  2004 France Spermatic cord Pain at coitus, haematuria, 
many S. haematobium eggs in 
semen 
62. Alves et al. 2004 Brazil Left epididymis Chronic pain, hardening; 
chronic granulomatous process 
with eggs  
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63. Mortati Neto et al. 2004 Brazil Right testis 2cm solid nodule; 
granulomatous lesion with 
schistosome egg. 
64. Faucher et al.  2004 France Seminal vesicles 
Ejaculatory duct 
Haematuria, dysuria, 
ejaculatory pain; hyperechoic 
vesicles and ducts, bladder 
biopsies with eggs 
65. Alonso et al. ǂ 2006 Spain Testis Dysuria, discomfort; pain on 
coitus; brownish, watery 
semen; eggs in semen 
66. Lambertucci et al. 2006 Brazil Prostate Elevated PSA, characteristic 
granuloma around S. mansoni 
eggs 
67. Dauda and Rafindadi 2006 Nigeria Left testicle Painless swelling, S. 
haematobium eggs viable and 
dead, granulomata 
68. Perignon et al. 2007 France - Yellow coloured ejaculate, 
reduced in viscosity; semen S. 
haematobium eggs 
69. Lopes et al. 2007 Brazil Seminal vesicle Elevated PSA and 
adenocarcinoma of the 
prostatic; unviable eggs in s. 
vesicle 
70. van Delft et al. 2007 Netherlands - Cough, wheezing, scrotal pain, 
watery semen, 
haematospermia; eggs in semen 
71. Lopes et al. 2007 Brazil  Right testis 2cm nodule, hypoechoic; S. 
mansoni eggs with granuloma 
formation 
72. Bacelar et al. 2007 Brazil Prostate Prostatic adenocarcinoma; 




73. Pawel et al. 2008 U.S.A. Right scrotum Pain, swelling; hydrocele; 
intense egg infiltrate, 
eosinophils; granulomas 
74. Athanazio and 
Athanazio# 
2008 Brazil Testicles Massive calcified egg load in 
right testis; left testis only 
sparse calcified eggs 
75. Guirassay et al. ǂ 2008 Guinea Prostate Pollakiuria, dysuria, terminal 
haematuria; enlarged prostate, 
fibrous with eggs 
76. Kini et al. 2009 U.K. Testicles Primary infertility; azoospermia, 
reduced size, normal testes 
morphology 
77. Lambertucci and Lippi 2010 Brazil - Few matured eggs in semen 
after vasectomy; none in stool, 
rectal biopsy 
78. Stevens et al.  2010 U.K. Rectum  Haemospermia; rectal bleeding, 
chronic inflammation with eggs 
79. Al-Qahtani and 
Droupy 
2010 France Right testis Primary infertility; azoospermia, 
white cells; small mass with 
eggs, granuloma 
80. Rambau et al. 2011 Tanzania Left scrotum Pain, testicular mass; hydrocele, 
atrophic granulomas with 
schistosome eggs 
81. Periyasamy et al. 2011 Malaysia Left testicle Genital discomfort; firm nodular 
swelling; eggs surrounded by 
granulomatous tissue 
82. Hassan et al. 2011 Egypt Right testis Painless large tense swelling; 
pus drained out; many eggs 
with granuloma reactions 
83. Hawary et al. 2012 U.K. - Yellow watery semen, particles; 




84. Knapper et al.  2012 U.K. - Orange-coloured watery semen; 
no eggs in urine or semen; ELISA 
positive 
85. Adisa et al. 2012 Nigeria Left testicle  Erectile dysfunction, 
oligospermia; eggs of S. 
mansoni and lymphocytes, left 
testis 
86. Kato-Hayashi et al. 2013 Japan  - Haematuria, dysuria, 
haematospermia; eggs in urine 
and semen 
87. Yu et al. 2013 China Prostate Frequent micturition; firm, 
enlarged prostate; with 
hyperplasia and eggs  
88. Ehsani and Osunkoya 2013 U.S.A. Prostate Haemospermia, elevated PSA 
levels; prostate needle biopsy 
showed S. haematobium eggs, 
no cancer 
89. Ze Ondo et al. ǂ  2014 Senegal Testicles 2 cases in 5 years of testicular 
nodule; orchidectomy done, 
histological analysis showed S. 
haematobium eggs 
90. Sharma et al. ǂ 2015 India Prostate Unable to urinate, enlarged 
prostate with inflammatory 
infiltrate with eggs  
91. Wobser et al. 2015 Germany Right scrotum Indurated subcutaneous 
nodule; granulomas with 
central necrotic areas 
92. Ekenze et al. 2015 Nigeria Left testicle Irregular hard mass; non-
caseating granulomas on viable 
and calcified eggs 
93. Ferreira et al 2015 Brazil Right testicle Difficulties in urinating, 
hardened nodule, hypoechoic; 
chronic granuloma reaction  
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94. Alves et al.  2017 Brazil Right testicle Orchiepididymitis; extensive 
loss of testicular structure and 
Schistosoma egg-induced 
granulomas, plus Zika virus 
95. Lang et al.  2017 Canada Seminal vesicle Painful ejaculation, 
haematospermia; cystic dilated 
left s. vesicle; ova in semen 
96. Aber-Naser et al. 2018 Egypt Genital organs 
especially both 
testis 
Persistent azoospermia with 
low semen volume, absent 
fructose & seminal vesicles, 
intact spermatogenesis; S. 
haematobium & S. mansoni 
eggs in right testicular biopsy, 
none in the left  
 
Editorial articles 
No. Authors Year Key facts 
1. Feldmeier et al.  1999 Male genital schistosomiasis and haemospermia 




No. Authors Year Topics 
1. Mbabazi et al. 2011 Examining the relationship between urogenital schistosomiasis and 
HIV Infection. MGS and FGS implications in endemic areas. 
2. Figueiredo et al. 2015 Prostate adenocarcinoma associated with prostatic 
infection due to S. haematobium. Causal or incidental finding 
3. Stecher et al. 2015 Considering treatment of male genital schistosomiasis as a tool 
for future HIV prevention. More clinical studies to be conducted 
 
Literature reviews (ǂ those from references) 
No. Authors Year Organs / Specimens Key facts 
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1. Maddenǂ 1909 Penis  Bilharziosis of glans, prepuce, body, erectile and 
subcutaneous tissues 
2. Al-Ghorabǂ  1968 Prostate  
Seminal vesicles 
Radiological manifestations of Genito-urinary 
bilharziasis 
3. Nozais et al. 1983 All genital organs Bilharzia of seminal vesicles, prostate, testicles, 
epididymis 
4. Richter 2000 - Ultrasonographic changes on schistosomal 
pathologies after therapy and exposure 
5. Scrimengeour 
and Daar 
2000 - Schistosomiasis review with relevance to 
surgeons in Australasia, includes epididymitis, 
orchitis, prostatitis 
6. Bichler et al. ǂ 2001 - Critical review of diagnostics and treatment of 
schistosomiasis, with mention of MGS 
7. Corachanǂ 2002 - Manifestations of schistosomiasis acquired 
during international travel including MGS 
8. Ghoneim 2002 - Bilharzial manifestations of seminal vesiculitis 
and prostatitis 
9. Richens 2004 All genital organs Genital manifestations of schistosomiasis which 
include bleeding and egg deposition in semen, 
calcifications of prostate and vesicles 
10. de Cassio Saito et 
al. 
2004 Scrotum Ultrasound of scrotum with schistosomiasis 
show enlarged testes with hypoechoic solid 
masses (granuloma) of increased vascularity 
11. Vennervald and 
Dunne 
2004 - An update on the morbidity of schistosomiasis 
with description of genital manifestations 
12. Coon 2005 - Detailed history and life cycle of schistosomiasis 
including aspects of MGS 
13. Maranya et al. 2007 Prostate  
Seminal vesicles 
Bilharzial seminal vesiculitis and prostatitis 
associated with haemospermia, painful 
ejaculation, low back pain and calcifications 
14. Rollinson 2009 - Overview of the history, life cycle and clinic-
pathological manifestations of schistosomiasis 
including MGS and its health implications 
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15. Shebel et al. 2012 Prostate 
Seminal vesicles 
Pathological radiographic findings in 
Genitourinary schistosomiasis 
16. Le and Hsieh  2017 - Review of current diagnostics and their 
challenges, with future advances in progress  
17. Aber-Naser et al. 2018 Genital system, 
especially testis 
Review of schistosomiasis as an important, but 
rarely reported cause of male infertility in 
endemic areas 
18. McManus et al. 2018 - Review of the current epidemiology, 
pathophysiology, diagnosis, management and 












This chapter provides the detailed description of our cohort for the longitudinal study 
assessing the current prevalence of MGS among local fishermen on the south shoreline of Lake 
Malawi in Mangochi District in Malawi. Further details of the methods of diagnosing UGS and MGS, 
used in this research are highlighted, which have been published as cited below:  
Kayuni S.A., Corstjens P.L., LaCourse E.J., Bartlett K.E., Fawcett J., Shaw A., Makaula P., 
Lampiao F., Juziwelo L., de Dood C.J., Hoekstra P.T., Verweij J.J., Leutscher P.D.C., van Dam G.J., van 
Lieshout L. and Stothard J.R. (2009). How can schistosome circulating antigen assays be best 
applied for diagnosing male genital schistosomiasis (MGS): an appraisal using exemplar MGS cases 
from a longitudinal cohort study among fishermen on the south shoreline of Lake Malawi. 
Parasitology, Volume 146, Issue 14, pages 1785-95, https://doi.org/10.1017/S0031182019000969. 
(Received: 20 February 2019, revised: 30 June 2019, accepted: 3 July 2019, published online: 27 
August 2019). 
My contribution to this manuscript was that I conducted the literature review on MGS and 
the research fieldwork along south shoreline of Lake Malawi. Thereafter, I wrote the manuscript and 





4.2. Introduction to the longitudinal MGS cohort study 
As a way of understanding the burden of MGS in local inhabitants of schistosomiasis-
endemic areas in SSA, the focus was placed on local fishermen along the south shoreline of Lake 
Malawi in Mangochi District in Malawi.   
Malawi is one of the South Eastern African countries where both S. haematobium and S. 
mansoni are prevalent and highly focal around most water bodies (Teesdale and Chitsulo, 1985; 
Makaula et al., 2014). The shoreline of Lake Malawi, the third largest lake in Africa, is endemic for 
urogenital schistosomiasis (UGS), with a high prevalence of egg-patent urine S. haematobium 
infections (Madsen et al., 2011; Stauffer, Madsen and Rollinson, 2014). More recently,  with the 
discovery of Biomphalaria pfeifferi there is also emergence of autochthonous transmission of 
intestinal schistosomiasis by S. mansoni (Alharbi et al., 2019). More broadly, due to frequent contact 
with cercariae-infested waters, children, women, farmers and fishermen are at greater risk of UGS as 
well as growing threat of intestinal schistosomiasis.  
The prevalence of HIV  in Malawi is considered high (10.6%), especially in this lakeshore 
region (11.8%), despite the control efforts contributing to reducing the incidence and mortality 
(NAC, 2015; Ministry of Health, 2017). Despite the wide awareness for the significant burden of UGS 
in the area, MGS typically remains undiagnosed and underreported among men. With no 
information about the burden of MGS on the south shoreline of Lake Malawi in Mangochi District, 
the research study was set out to determine the current prevalence and morbidity of MGS among 
local fishermen on the shoreline and the potential risk of raised HIV transmission through viral load 
shedding in semen. 
4.3. Study methodology 
4.3.1. Study area and population 
The research study was conducted among fishermen living in fishing communities (villages) 
identified and selected along the south shoreline of Lake Malawi in Mangochi district from October 
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2017 to December 2018 (Figure 16). Mangochi is the largest district in the southern region of 
Malawi, covering 6,729 km2 of land with at least 1.1 million people and population density of 171 
people per km2 (NSO, 2019). The district has a tropical continental climate with a longer dry season 
of cold weather from May to August and hot weather from September to November, and a relatively 
shorter wet season from December to April (NSO and ICF, 2011).  
The Ministry of Health through the District Health Office (D.H.O.) is responsible for provision 
and management of all health services delivery in the district. The services are provided through 
government health centres, faith-based and private facilities which are monitored by the D.H.O. 
Each health centre has a catchment area comprised of villages / communities that it serves. Fishing 
communities in the study area where most fishermen live and carry out their routine fishing related 
activities, were selected from the information provided by the D.H.O. of Mangochi District, together 




4.3.2. Study sampling 
This was a longitudinal cohort study, comprising of baseline surveys of MGS among 
fishermen and follow-up studies after praziquantel (PZQ) treatment, conducted in villages and 
nearby health centres. All fishermen aged at least 18 years willing to provide written informed 
consent were eligible and invited to participate in the study. Using the estimated 20% prevalence of 
S. haematobium UGS in adults from previous studies and assuming 10% having MGS, plus the 
formula, (Z2 x p x [1 - p]) ÷ e2, where Z is the value from normal distribution curve (at a desired 
confidence interval of 95% = 1.96), p is the expected prevalence (0.2), and e is the acceptable level 
Figure 16: Schematic map of Study area showing health facilities along Lake Malawi  
(The study map was produced by Dr Sekeleghe Kayuni (4th August 2019), while the maps of Africa and 
Malawi were reproduced from the maps at the Central Intelligence Agency (CIA) website, public domain: 
https://www.cia.gov/library/publications/the-world-factbook/attachments/locator-maps/MI-locator-
map.gif and https://www.cia.gov/library/publications/the-world-factbook/attachments/maps/MI-map.gif)   
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of precision (0.05), a minimum sample size of 275 fishermen (adjusted for assumed 10% loss to 
follow-up), was planned to be recruited for the study to measure the current prevalence of MGS and 
subsequent follow-up studies (Kirkwood and Sterne, 2006; CDC, 2014).  
In order to assess impact of MGS on the risk of HIV transmission, a pilot HIV study was 
conducted alongside this cohort study, recruiting a minimum sample size of 20 HIV positive 
participants co-infected with MGS (as study cases) and 20 HIV positive participants without MGS 
(study controls). This was due to no similar previous studies conducted in endemic areas. 
Ethical clearance for the study was granted by both the Liverpool School of Tropical 
Medicine Research Ethics Committee (LSTM REC, Approval number: 17-018, Appendices 1 and 2) 
and the National Health Sciences Research Committee of Malawi (NHSRC, Approval number: 1805, 
Appendices 3 - 5). 
 
4.3.3. Data collection and analysis 
Data were collected by the Principal Investigator (PI) and study team members, comprising 
of Health Surveillance Assistants (HSAs) from the health centre(s) in study area, Laboratory and 
Figure 17: Sensitisation meeting with some fishermen during the MGS 
cohort study.  Photo credit: Dr Sekeleghe Kayuni, Malawi, June 2018. 
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Radiology technicians, who were trained prior to the onset of the study. The D.H.O. and personnel at 
the health centre(s) in the study area were briefed followed by the community leaders. The HSAs 
were orientated during the training on the research objectives, sensitization of community leaders, 
mobilization of potential participants and the process of questionnaire interviews., Thereafter, the 
HSAs visited villages in the study areas, briefed the community leaders on the study and afterwards 
approached the potential study participants for recruitment into the study (Figure 17). Adequate 
research information was given to the potential study participants together with information leaflets 
(Appendices 6 and 7) describing the study objectives and methods. The following were the data 
collection methods and analyses used in the study: 
4.3.3.1. Individual questionnaires 
After briefing about the study and obtaining written informed consent (Appendices 8 and 9), 
fishermen were recruited in their communities (Appendices 10 and 11) and interviewed with 
individual questionnaires (Figure 18), collecting information on demographic, health, hygiene, 
sanitation and socio-economic characteristics (Appendices 12 - 15). This information assessed their 
knowledge, perceptions, attitudes and practices on MGS and HIV.  
The questionnaires were developed from standardised questions administered elsewhere in 
a similar study (Ukwandu and Nmorsi, 2004). The questionnaires were piloted on the first 10 
participants to assess the reliability of the questions. After the questionnaire interviews, the 





4.3.3.2. Parasitological analyses 
At the health facility, they were provided with a clean sample container to submit urine, 
between 10am and 2pm for filtration to examine for schistosome eggs (confirming UGS). Semen was 
submitted in a clear, transparent, self-sealing plastic bag, see Figure 21, after abstaining from coitus 
for two days to examine for MGS, defined in the study as the presence of schistosome eggs in 
semen.  
4.3.3.3. Urine analysis including filtration 
Urine was analysed (Appendix 16) immediately for macrohematuria by visual inspection 
using a urine colour card (scores 0, 1, 2 or 3), and then for microhaematuria, leukocytes and 
proteinuria using reagent strips (Siemens multistix 10G) and scores were recorded in the following 
categories: negative, trace, +, ++ and +++ (Figure 19). Point-of-care circulating cathodic antigen 
(POC-CCA) test was conducted on the urine to assess for possible intestinal infection by S. mansoni, 
following manufacturer’s instructions (Rapid Medical Diagnostics, South Africa; batch no. 
171103130) and as described previously (van Dam et al., 2004) (Figure 20). Urine was measured and 
Figure 18: Individual questionnaires interviews with participants during the MGS study 
A. Interviewing a fishermen during the study. B. Screening and reviewing the questionnaires.  




recorded accordingly, before conducting filtration following approved standard guidelines (WHO, 
1991; Cheesbrough, 2009). 
 
The entire volume of urine was filtered through a disinfected filter containing a clean 
polycarbonate membrane with 20 µm pores to trap all S. haematobium eggs in the sample. The 
membrane was removed, placed on a standard glass slide and examined under the microscope. A 
drop of Lugol’s iodine was added to visualise the eggs distinctly. The number of eggs was calculated 
by first, dividing the total eggs observed by the total volume filtered and then multiplying by 10, to 
express the resultant egg count per 10 ml of urine. Highest infection intensity for UGS was defined as 
egg count of ≥ 50 eggs per 10 ml urine as widely described (Cheesbrough, 2009).  
Figure 19: Urine analyses for macrohaematuria and microhaematuria. 
A and B. Analysing urine using Siemens multistix 10 SG reagent strips 
(microhaematuria); C and D. using visual colour card (scores:  0  = normal; 1 – 3 









4.3.3.4. Seminal microscopic analysis 
After submission, the bag with semen was placed under room temperature on a clean bench 
surface to allow the semen to liquefy (Appendix 17). Thereafter, the semen was pushed gently to 
one corner of the clear plastic bag. Then the bag was heat-sealed to evenly concentrate the semen 
for easy visualization during microscopy (Figure 21). Direct examination of the semen bag was 
conducted under a microscope using x40 and x100 magnification to check for schistosome eggs and 
the presence of leukocytes (WHO, 2010), thereafter the results were recorded as per ml of ejaculate.  
Afterwards, the semen was measured and centrifuged at 5, 000 rpm for 5 minutes to collect 
the seminal plasma. The sediment was re-dissolved in 0.5 ml normal saline for wet mount inspection 
using 2-3 drops and placed on a slide with a coverslip for microscopy, followed by recording of the 
results. Thereafter, 0.5 ml of ethanol was added to the remaining sediment for preservation and 
stored together with the seminal plasma at -80c in preparation for shipment to the United Kingdom 
for real-time polymerase chain (PCR) analysis of Schistosoma DNA and HIV viral load for those 
Figure 20: Analysing urine using POC-CCA test and filtration during the cohort study 
A and B. Urine testing using POC-CCA test cassettes. C. Intepretation of POC-CCA test results. D. Conducting urine 
filtration using filter holder containing polycarbonate filter membrane. E. S. haematobium eggs observed on a filter 
membrane placed on a microscope slide after adding Lugol’s iodine, or F. without addition of iodine.  
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participants on ART. After semen submission, the participants were interviewed on any problems or 
challenges experienced during submission of semen sample using the plastic bag (Appendices 18 and 
19). 
 
4.3.3.5. UCP-LF CAA seminal analysis 
A trichloroacetic acid (TCA) extraction was performed on the seminal plasma following 
standard methods used for serum with an equal volume of 4% w/v TCA (Corstjens et al., 2008) 
(Figure 22). Small volume extraction (50 µl seminal plasma with 50 µL TCA) in microfuge tubes 
resulted in a clear supernatant after centrifugation (5 min, 13,000 rpm). The up-converting 
phosphor-lateral flow (UCP-LF) CAA analysis was performed according to standard methods with 20 
µl of the clear supernatant, with a cut-off threshold of 10 pg/ml. High volume extraction (0.5 ml 
seminal plasma with 0.5 ml TCA and a cut-off threshold of 1 pg/ml) required extended centrifugation 
time (30 min) before a clear supernatant was obtained; the resulting pellet was not rigid. Amicon 10 
kDa centrifugal filtration devices (Merck Millipore) were used to concentrate 0.5 ml of the clear 
supernatant targeting concentration to 20 µl following standard methods used for serum undergoing 
centrifugation for 30 min at 13,000 rpm (Corstjens et al., 2014).  
Figure 21: Description of the seminal analysis for schistosome ova.  
A pictorial methodology of visualisation of schistosome ova in semen with a clean, non-sterile 
transparent plastic bag. A. Semen is concentrated to one corner; B. the bag is heat sealed to trap the 
liquid; C. the bag is placed on microscope stage and inspected at x40 or x100 magnification; D. an egg 




4.3.3.6. Schistosoma DNA real-time PCR analysis 
The ethanol preserved semen sediment was defrosted and centrifuged for 1 minute at 
10,000 rpm. The ethanol layer was removed, and the pellet washed twice with 1 ml of phosphate 
buffered saline (PBS) (Figure 23). The pellet was suspended in 0.4 ml of PBS containing 2% 
polyvinylpolypyrrolidone (PVPP) (Sigma, Steinheim, Germany). The suspension was heated for 10 
min at 95°c and stored frozen overnight at -20°C. DNA was extracted using the QIA symphony DSP 
virus / pathogen midi kit and pathogen complex 400 protocol of the QIA symphony Sample 
Processing (SP) system (Qiagen, Hilden, Germany). In each sample, a fixed amount of Phocine Herpes 
Virus 1 (PhHV-1) was added within the isolation lysis buffer, to serve as an internal control for the 
isolation procedure and to monitor inhibition of the real-time PCR.  Schistosoma genus-specific real-
Figure 22: Preparing urine and semen samples for UCP-LF CAA analyses. 
A. Extracting of sample supernatants in preparation for centrifugation. B. Making oral presentation on the 
MGS study fieldwork in Malawi to the team at Leids Universitair Medish Centrum (LUMC), indicated on C. 





time PCR was performed using primers and probes as described previously (Obeng et al., 2008; 
Kenguele et al., 2014). 
 
4.3.3.7. Blood collected for further analysis 
Participants were requested for their consent to have their venous blood collected following 
the standard aseptic and infection prevention guidelines using approved personal protective 
equipment into 4ml EDTA-coated tubes (Cheesbrough, 2005). All safety precautions were observed 
to minimize the risks associated with blood collection. Thereafter, the blood was centrifuged at 5, 
000 rpm for 5 minutes to harvest plasma.  
After the preparation, the blood plasma together with seminal plasma were shipped under 
dry ice at - 80°c to LSTM in United Kingdom for comparative HIV viral load analyses and Schistosoma 
soluble egg antigen (SEA) enzyme-linked immunosorbent assay (ELISA). 
4.3.3.8. Schistosoma serology SEA ELISA 
Schistosoma serology SEA ELISA microwell kits (SCHISTO-96 IVD IgG/M, New Life Diagnostics 
LLC, Lot. 1729) manufactured by IVD Research Inc. (Carlsbad, CA 92010 USA. www.ivdresearch.com) 
were used to run ELISA on the participants’ plasma to detect schistosome antibodies. The kits were 
Figure 23: Preparing semen pellets for real-time PCR using automated QIA symphony. 
Photo credit: Dr Sekeleghe Kayuni, LSTM, U.K. September 2018. 
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placed on bench at room temperature for half an hour after removal from 2-8˚C cold room before 
opening and use. The plasma was defrosted and then spun at 13,000 rpm for seven minutes. 
Using the microwells, 100 µl of prediluted negative control was first added into designated 
well, followed by 100 µl of prediluted positive control from the kit, and finishing 100 µl of diluted 
(1:40 and 1:80) plasma from participants to the remaining wells. The negative and positive controls, 
designed by the manufacturer for easy validation and quality control of the kit, were also added to 
the last two wells.  
The microwells was then incubated at room temperature for 10 minutes before shaking out 
the contents and washing three times with diluted wash buffer. Two drops of enzyme conjugate was 
added to each well and incubated at room temperature got another 10 minutes, before shaking out 
contents and washing three times. Two drops of chromogen (substrate) was added to each well and 
incuabted for 5 minutes, beofre two drops of Stop solution were added to each well.  
Thereafter the well were read visually and then using Fluostar Omega BMA-LABTECH 
spectrophotometer with filters at 450 nm (Figure 24). Absorbance reading equal or greater than 0.2 
OD units were recorded as positive while those less than 0.2 were negative. Further quality control 
of this ELISA was conducted on 33 participants’ plasma, using DRG IgG test kits (Lot. G062, IQA 
reference: 2462/19) at an accreditated clinical laboratory at LSTM whose results are described in 




4.3.3.9. Point-of-care Prostate specific antigen (POC-PSA) 
A rapid test for the semi-quantitative detection of Prostate specific antigen (PSA) in whole 
blood, serum or plasma (ALL TEST PSA Rapid Test Cassette, MedNet GmbH, Ref. TPS-402, Lot.: 
PSA18110014), manufactured by Hangzhou All Test Biotech Company Limited. (Hangzhou - 310018, 
P.R. China, www.alltests.com.cn) was conducted on some participants with abnormal 
ultrasonograophy results on their prostates for possible malignancy. The frozen plasma sample was 
used in this test, after completely thawing, mixing well.  
A drop of plasma (approximately 40 µl) was transferred using the dropper provided with the 
kit, to the specimen well, labelled S on the cassette, and then a drop of the buffer also provided was 
added  to the specimen well (Figure 25). Thereafter a timer was started to run for 5 minutes before 
reading the results. The results area was expcted to display coloured lines, namely control (C), 
reference (R) and test (T) lines, for reading the test results. Positive results were interpreted with 
presence of all the 3 coloured lines while negative results only showed the control and reference lines, 
without the test line (Figure 26). 
Figure 24: FluoSTAR Omega Spectrophotometer used for reading ELISA kit microwells 






Figure 25: ALL TEST PSA Rapid Test showing the test kit, buffer and used cassettes. 
Photo credit: Dr Sekeleghe Kayuni, LSTM, U.K. July 2019. 
Figure 26: Outline of the procedure for ALL TEST PSA rapid test, in accordance to 
the manufacturer’s instructions showing the expected results. 
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4.3.3.10. HIV-1 RNA detection 
HIV-1 RNA detection on the collected blood and semen plasma samples were conducted using 
a commercially available Cepheid Xpert® assay for qualitative and quantitative plasma detection of 
HIV-1 (Cepheid, 2019). The Xpert system is a semi-automated quantitative real-time polymerase chain 
reaction (RT-PCR) amplification test system. The system is designed to combine automated and 
integrated sample preparation, nucleic acid extraction, amplification and detection of HIV-1 target 
sequence using real-time reverse transcription PCR within 90 minutes of test initiation. The system is 
a fully closed system that includes an internal control and utilises a single disposable cartridge (Figure 
27) for each run minimising the risk of contamination and biological hazard (WHO, 2017). The assay 
quantifies HIV-1 Group M, N and O with a range of 40 to 107 copies/ml. 
 
Firstly, validation experiments were carried out using semen samples from two HIV-negative 
and schistosome-negative men from the study area. These semen samples were spiked with the third 
WHO reference standard for HIV-1 RNA (NIBSC 10/152) reconstituted to 1 millilitre with a final 
concentration of 10,000,000 viral copies per millilitre. In the first set of experiment, the detection 
Figure 27: Cepheid Xpert cartridge 
Image courtesy of https://www.cepheid.com/en/. 
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threshold of the Xpert HIV QUAL assay was confirmed in the absence of semen inhibition by 
performing the experiments using a 10-fold dilution factor.  
In these experiments, semen sample was spiked with the HIV standard to different 
concentration ranging from 105 to 102 copies/ml (105, 104 ,103 and 102) including an unspiked plasma 
sample from a HIV-1 negative patient for quality control. In the second experiments, the HIV-1 RNA 
concentration was kept fixed at 500 IU/ml (equivalent to 291 copies/ml) whereas the proportion of 
semen sample to diluent was varied to different proportions each totalling 1 ml. In this experiment, 
semen (200, 300, 400, 500 and 900 µl) was diluted to an input totalling 1 ml prior to testing. Samples 
were then tested with the Cepheid Xpert HIV QUAL assay, which has a reported lower limit of 
detection of 278 copies/ml (equivalent to 478 IU/ml).  
The second set of experiments was performed in duplicate, with or without a prior spin step 
following dilution. The spin step involved wash step and low-speed centrifugation at 500 rpm to 
separate possible sediments without precipitation of the virus. Analysis of data from these 
experiments subsequently determined the approach for testing the patients’ semen samples. Upon 
successful completion of the validation, quantification of the HIV-1 VL was conducted on participants 
in the study. 
Plasma were separated in the field study area from collected whole blood samples in 4ml plain 
vacutainer tubes by centrifugation at 5,000 rpm for 5 minutes. The semen collected was put in sterile 
2ml microtubes following liquefaction and then centrifugation at 5,000 rpm for 5 minutes to harvest 
seminal plasma. The seminal pellets were mixed with equal volumes of saline and ethanol to preserve 
the samples for schistosome real-time PCR, described above. The plasma samples were shipped frozen 
and monitored at -80oc to Liverpool School of Tropical Medicine (LSTM) and Institute of Infection and 
Global Health in University of Liverpool (IGH) in United Kingdom.  
Samples were prepared and diluted in the IGH extraction laboratory, packed in Saf-T-Pak and 
taken for HIV-1 RNA viral load testing to the virology department of the Royal Liverpool and 
Broadgreen University NHS Hospital where the Xpert infinity platform was located. For plasma, one 
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millilitre of sample input was transferred into the cartridge and processed on the platform. For seminal 
plasma testing, samples were diluted based on sample availability ranging from 2.5-fold dilution (400 
µl of semen sample to 600 µl of diluent) to 10-fold dilution (100 µl of semen sample to 900 µl of 
diluent) using molecular grade water as diluent and loaded into the cartridge for testing on the Infinity 
test platform. 
4.3.3.11. Ultrasonography examination of genital organs 
a. Preparations for the procedure 
Safety precautions including use of appropriate protective wear and gloves were ensured 
during the ultrasonography examinations to prevent exposure to hazards (Appendix 20). Participants 
were briefed on the transabdominal and scrotal ultrasonography procedures to be conducted on 
them using a portable Chison Q5 ultrasound scanner (Figure 28) with 3.5MHz probe (Mount 
International United Services Ltd, Gloucester, United Kingdom). The scanner was put on the right 
side of the participants and set on the appropriate urology mode for the procedure. Participants 
were asked to present with a full bladder, before the procedure to increase the visualisation and 
validity of the images. Whenever possible, room lightning was turned off to maximise screen 
visibility. 
b. Outline of the ultrasonographic procedure 
The participant’s study number was registered in the ultrasound machine and report form 
prior to commencing the procedure. The participant was positioned supine on the examination 
couch and a reasonable amount of ultrasound gel was put on the probe. The scanning procedure 
investigated the appearance, size and abnormalities of the following key pelvic and genital organs, 
namely urinary bladder, seminal vesicles and scrotum (tests, epididymis). Visualization conditions 





i. Urinary bladder  
Probe position: The probe was placed transverse (TS) above the pubic symphysis with probe 
orientation projecting the right side of the patient on the left side of the screen.  Transverse sweeps 
through the bladder were performed to assess the shape (distension) and wall thickness of the 
bladder, as well as the distal ureters where possible. Care was taken to adjust depth and gain 
settings appropriately for anterior and then posterior bladder wall/ureters to avoid artefacts and 
reduced visibility of bladder wall. Longitudinal (LS) sweeps were also be performed in similar way.  
Description of results: Normal finding was the bladder being fully distended and having a 
regular, rectangular shape; the bladder wall was of regular thickness and not thicker than 5 mm. 
Normal distal ureters not being visible. Pathological findings of schistosomiasis-related urinary 
pathologies included a rounded or irregular shape of the bladder, wall thickening with diffuse or 
focal thickening of > 5 mm (mild: 6 - 10 mm; severe: ≥11 mm), bladder wall calcifications and masses 
Figure 28: The portable Chison Q5 ultrasound scanner in an examination room 
Photo credit: Dr Sekeleghe Kayuni, June 2018. 
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or pseudopolyps protruding in the bladder lumen; the distal ureters were considered pathological 
when dilated.  
Storage of images and clips: Bladder wall thickness were measured in mm and stored as a 
separate still image. After performing several sweeps through the bladder, the best representative 
sweep was stored under the label “bladder”. In case of any pathologic findings additional still images 
with relevant measurements were stored. Once the bladder wall thickness was abnormal, the 
kidneys were scanned for evidence of hydronephrosis.   
ii. Prostate  
Probe position: The prostate was visualised with the probe directed deep into the pelvis, 
after scanning the bladder. Care was also taken to adjust depth and gain settings appropriately to 
clearly and fully visualise the prostate.  
Description of results: Normal finding was the prostate being normal when volume is 30 
mm3 or less with smooth outline. Pathological findings of schistosomiasis-related pathologies 
included nodules or masses above 1 cm, and calcifications of the prostate.  
Storage of images and clips: The prostate was measured in mm3 or ml and stored as a 
separate still image. After performing several sweeps through the prostate, the best representative 
sweep was stored under the label “prostate”. In case of any pathologic findings, additional still 
images with relevant measurements were stored.  
iii. Seminal vesicles 
The seminal vesicles were visualised adequately with several sweeps, just after scanning the 
prostate. Description of results: Normal finding was the seminal vesicles being symmetrical, 
measuring 15 mm or less in antero-posterior (AP) plane with smooth outline. Pathological findings 
for schistosomiasis-related pathologies included enlarged and or asymmetrical vesicles with nodular, 
echogenic appearance. 
Storage of images and clips: if the vesicles measured larger than 15 mm in AP plane, their 
measurement were stored as a separate still image. Following performing several sweeps through 
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the vesicles, the best representative sweep was stored under the label “SV”. In case of any 
pathologic findings, additional still images with relevant measurements were stored.  
iv. Scrotum 
Probe position: The probe was placed transverse on the scrotum with probe orientation 
projecting the right side of the patient on the left side of the screen.  Axial sweeps on the scrotum 
were performed to assess both testes. Care was taken to adjust depth and gain settings 
appropriately.  
Testis: if found abnormal, a description on absence or presence of nodules, masses, atrophy 
or calcifications; Epididymis whether normal or enlarged; and other abnormalities like hydrocele.  
c. Disinfection at the completion of the procedure 
At the end of the procedure of each participant, the probe was cleaned with tissue paper to 
remove the gel, and with methylated spirit. Similarly, the gel on the procedure was wiped off with 
tissue paper and disposed together with used gloves, disposable protective wear and other waste in 
accordance with the approved standard infection prevention protocols for the Ministry of Health in 
Malawi. All participants were notified of pathological findings that day, and further appropriate 
investigations and management were organised in accordance with standard clinical practice. 
Thereafter, praziquantel treatment at 40 mg/kg as a single dose was offered along with an invitation 
to follow-up studies after 1-, 3-, 6- and 12-months. 
4.3.4. Statistical analyses 
All the information collected during the study was screened and quality-controlled before 
entry into Microsoft Excel and SSPS computer packages (Appendices 21 and 22). No double data 
entry was conducted. Screening for errors using descriptive analyses and cleaning were conducted, 
before commencing statistical analyses to present the results of the study. All video clips and digital 
images were coded for data protection and were then stored onto the device before transferring to 
a password-protected external hard drive for further analyses. A sample of 15% of the scan images 
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were randomly selected and re-read by specialist radiologist for quality control, who conducted 
training on ultrasonography of genital organs related to schistosomiasis. 
All video clips and digital images collected from ultrasonography were stored onto the 
device before transferring to the external hard drive for further analyses. The data collected from 
clips, images and report forms comprising from symmetry, thickness, echogenicity, calcifications, 
nodules, polyps, masses and hydroceles, were screened to clear all errors before entry into IBM SSPS 
programmes in accordance to evidence-based recommendations and guidelines on specific 
ultrasonography  (Vilana et al., 1997; WHO, 2000; Martino et al., 2014). Summary statistics were 
calculated to explore the data and thereafter correlations and significant tests were conducted to 
describe and interpret the results further, mainly using nonparametric tests. 
4.3.5. Ethical considerations 
Utmost privacy and confidentiality were maintained in the study and where necessary, the 
information was anonymised to protect the identity of the participant. Participants were informed of 
their right to opt-out at any stage of the study if they wish to do so. No disruption was caused to 
their normal daily activities or seeking other services at any health facility. Since this was a test-to-
treat study, participants were offered praziquantel treatment at the end of the visit before inviting 
them to the next follow-up study. 
4.4. Description of the study cohort 
A total of 384 fishermen were approached on the shorelines and fishing communities along 
of Lake Malawi and briefed of the MGS study, of which 376 accepted and were recruited into the 
study (Figure 29). These participants included 56 who were HIV infected and taking ART for at least 6 
months prior to the study. All were interviewed with questionnaires and thereafter invited to the 
nearby health facilities for parasitological and ultrasonography examinations. 
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The participants came from 39 villages located in two Traditional Authorities (T/A) of 
Mponda and Nankumba, along the shoreline within the study area. Further description of the cohort 
and subsequent results have been outlined and discussed in the subsequent chapters. 
The cohort was not randomly selected as any eligible fishermen found in the study area 
were approached and recruited into the study which introduces possible recruitment bias and may 
affect the generalisability to the whole population of Malawian fishermen. In addition, the absence 
of HIV testing and reliance on participants’ self-declared results from past testing pose a challenge 
on interpreting the participants’ HIV status since people’s recall of their test results can be limited 
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KAP, all urine and semen microscopy results at Baseline are presented in Chapter 5;  Semen real-time PCR and blood Schisto ELISA at all time-
points and all urine results at F1, F3, F6 and F12 are in Chapter 6; Ultrasonography at all time-points are in Chapter 7; and Semen and Blood HIV 
viral load results are in Chapter 8. 
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This chapter described the results of the longitudinal cohort study on male genital 
schistosomiasis (MGS) conducted at baseline, from the individual questionnaires administered to 
local fishermen aged 18+ years (study participants) along the south shoreline of Lake Malawi, 
regarding their knowledge, attitudes and practices related to schistosomiasis especially MGS and HIV 
infection.  
In addition, results of the field parasitological tests on the urine and semen samples 
submitted from participants are described in this chapter. Prevalence of urogenital schistosomiasis 
(UGS) in the cohort was 17.1% among those participants who submitted urine samples (n = 210, 
median = 0.9 eggs / 10 ml, range = 0.1 – 186.0) and for MGS was 10.4% of those who gave semen 
samples (n = 114, median = 5.9 eggs / ml ejaculate, range: 0.4 – 30.0).  
Furthermore, more participants with MGS reported during questionnaire interviews to have 
experienced dysuria, frequency, haematuria and blood in stool, compared to those without MGS. In 
contrast, only one of 12 MGS-positive participants reported having experienced classical symptoms 
of MGS, namely pain in their genital organs, compared to 22 MGS-negative participants who had 
haemospermia, pain in their genital organs, during coitus and on ejaculation. This elaborates that 







Although schistosomiasis is a prevalent parasitic, neglected tropical disease (NTD) affecting 
over 200 million people globally, especially in SSA (McManus et al., 2018; WHO, 2018b), its chronic 
genital consequences have been overlooked.  Male genital schistosomiasis (MGS) is a specific gender 
manifestation of schistosomiasis especially urogenital schistosomiasis (UGS), associated with snail-
borne schistosome eggs and related pathologies in genitalia of men inhabiting or visiting endemic 
areas in SSA (Feldmeier et al., 1999; Leutscher et al., 2000). Despite the first recognised MGS patient 
report described by Madden in 1911 (Madden, 1911), the epidemiology, diagnostic testing and case 
management of MGS are not well described owing to limited research and diminishing focus over 
several decades.  
Schistosome eggs evoke immunological responses causing granuloma formation and 
pathological consequences in genital organs (Poggensee and Feldmeier, 2001; Leutscher et al., 
2008b). Men suffering from MGS in endemic areas experience pelvic, coital or ejaculatory pain, 
abnormal ejaculates, haemospermia, abnormal swelling of genital organs and infertility, which is 
generally underreported (Butterworth et al., 2013; Bustinduy and King, 2014). Schistosome eggs and 
pathologies have also been observed in seminal fluids and tissues of seminal vesicles, spermatic 
cord, vas deferens and prostrate during parasitological, histopathological and radiological tests (Al-
Ghorab, 1968; Gelfand et al., 1970; Fataar et al., 1990; Vilana et al., 1997).  
Furthermore, observations from female genital schistosomiasis (FGS) studies has shown 
increased risk of HIV infection in women having schistosomiasis due to characteristic genital mucosal 
breach, increased abnormal vasculature, inflammatory cells and mediators which could facilitate 
Human immunodeficiency virus (HIV) acquisition and replication (Kjetland et al., 2006; Downs et al., 
2017b). This has also been observed in males with MGS, highlighting the plausible risk for 
acquisition, intensive shedding and increased transmission of HIV (Leutscher et al., 2005; Leutscher 
et al., 2008b), which can be reduced after PZQ treatment, the mainstay antihelminth for 
schistosomiasis (Midzi et al., 2017).  
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Malawi is one of the SSA countries where both S. haematobium and S. mansoni are 
prevalent and highly focal around most water bodies, especially Lake Malawi (Teesdale and Chitsulo, 
1985; Makaula et al., 2014). In addition, HIV prevalence among adult population (15 – 49 years) is 
considered high at 10.6% in SSA region, despite the control efforts including provision of 
antiretroviral treatment (ART) (NAC, 2015; Ministry of Health, 2017; UNAIDS, 2019). Fishermen are 
one of the high-risk occupational groups in Malawi with higher HIV prevalence, also with a plausible 
risk of increased HIV transmission to their sexual partners, if dually infected MGS. 
With no information about the burden of MGS on southern shoreline of Lake Malawi, this 
longitudinal cohort study was set out to assess prevalence of MGS among local fishermen dwelling 
along the southern shoreline of Lake Malawi in Mangochi district and their knowledge, attitudes and 
practices related to MGS. 
5.3. Specific objectives of the study 
The specific objectives of the study were: 
a. to determine the prevalence of MGS among local fishermen at the baseline of the 
longitudinal cohort study. 






5.4.1. Study area, population and sampling 
The research study was conducted among fishermen living in fishing communities (villages) 
identified and selected along southern shoreline of Lake Malawi in Mangochi district, the largest 
district in southern region of Malawi, from October 2017 to December 2018.  Most of fishermen in 
the area live in specific fishing villages, closer to the lake to carry out their routine activities. 
 Fishermen aged ≥ 18 years willing to provide written informed consent were eligible to 
participate in the study. They were asked about results of their recent HIV test, with the last 12 
months and reported accordingly. A minimum sample size of 275 fishermen was planned to be 
recruited for the study to measure the current prevalence of MGS and subsequent follow-up studies 
(Kirkwood and Sterne, 2006; CDC, 2014), as described in Chapter 4. 
5.4.2. Study data collection and analysis 
5.4.2.1 Individual questionnaires 
As described in Chapter 4, briefing about the study were conducted before obtaining written 
informed consent from the fishermen and recruiting them into the study. Individual questionnaires 
developed from previous similar study (Ukwandu and Nmorsi, 2004) and piloted in the study area, 
were administered to the participants, collecting information on demographic, health, hygiene, 
sanitation and socio-economic characteristics.  
5.4.2.2 Parasitological analyses 
After the questionnaire interviews, the participants were invited to the nearby health facility 
where they submitted urine, semen and underwent ultrasonography examination. They were 
provided with a clean 120 ml sample container to submit midmorning urine for visual inspection for 
macrohaematuria, reagent multistix dipstick for microhaematuria, point-of-care circulating cathodic 
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antigen (POC-CCA) test for possible intestinal S. mansoni schistosomiasis and finally for filtration to 
detect and confirm UGS (WHO, 1991; Cheesbrough, 2009).  
Semen was submitted into a transparent, sealable plastic bag to examine for MGS in the 
field, defined in the study as presence of schistosome eggs in semen. Participants were advised to 
abstain from coitus for at least two days before submitting semen sample. After the field tests, the 
seminal plasma and pellet were harvested after centrifugation and preserved in preparation for 
shipment to the United Kingdom for real-time polymerase chain reaction of Schistosoma genus DNA 
and HIV viral load accordingly. Detailed description of the methodology has been described in 
Chapter 4. 
5.4.3. Statistical analyses 
All the data collected during the study was screened and quality-controlled before entry into 
Microsoft Excel and SSPS computer packages. Screening for errors and cleaning were done, before 
conducting descriptive statistics to describe the data, producing frequencies, proportions, medians 
and ranges of the variables of interest, defining the prevalences of UGS and MGS. Thereafter, the 
data was explored to further assess the association of different variables related to MGS as well as 
explore any differences existing between the groups of participants in the study. Non-parametric 
statistics were used to analyse the data due to its lack of normal distribution, resulting from low 
numbers of participants especially those with MGS.    
5.4.4. Ethical considerations 
Ethical clearance to conduct the study was provided by the National Health Sciences 
Research Committee (NHSRC) of Malawi and Liverpool School of Tropical Medicine (LSTM) Research 
Ethics Committee (LSTM REC), as outlined earlier. Utmost privacy and confidentiality were 
maintained in the study and where necessary, the information was anonymised to protect the 
identity of the participant. Since this was a test-to-treat study, participants were offered PZQ 




After the briefing and sensitisation about the study, 384 fishermen expressed interest in the 
study, with 376 recruited and interviewed with questionnaires (Figure 30). Fifty-six participants were 
HIV positive and taking anti-retroviral therapy (ART) for at least 6 months. The participants came 
from 39 villages located in two Traditional Authorities (T/A) of Mponda and Nankumba, along the 
shoreline within study area.  
5.5.1 Demographic information of the study participants 
The median age of the participants was 30.0 years with a range of 18.0 to 70.0 years 
(Interquartile range [IQR]: 13) and their duration of stay in the fishing village ranged from 1 month to 
70 years (median: 20.0 years, IQR: 24.3, range: 0.1 – 70.0 years; Table 8). There was a strong, 
positive correlation between the age and duration of stay (Spearman’s coefficient rho = 0.44, n = 
318, p < 0.001). The median weight of the participants was 58.3 kg (IQR: 8.7, range: 43.0 – 85.0 kg).  
For the HIV-positive participants, the median age was 39.5 years (IQR: 17.0, range: 21.0 – 
65.0 years), the duration of stay was 24.0 years (IQR: 24, range: 1.0 – 59.0 years) and weight of 56.4 
kg (IQR: 8.8, range: 43.0 – 74.0 kg). There was a significant difference in the median age between 
HIV-positive participants and those who were negative (independent samples Mann-Whitney test U 
= 10,917.5, z = 5.80, p < 0.001).  
Regarding their education status, 11.4% never went to school, 48.4% did not finish primary 
school while only 7.7% finished secondary school (Table 9). Of the total participants, 65.7% were 
married and 67.3% had children regardless of their marital status (range: 1 – 16 children). There was 
a positive correlation between participant’s age and number of his children (rho = 0.70, n = 260, p < 
0.001), but negative correlation with education status (rho = -0.24, n = 370, p < 0.001). Apart from 
fishing, 20% of participants were involved in other activities including farming, business, studies and 





Figure 30: Consort diagram showing the outline of the study 
Participants submitted urine for parasitological tests 
(n = 210) 
Inclusion criteria:  
• Fishermen (5 excluded)  
• Age ≥ 18 years (3 excluded) 
Participants who submitted semen and received PZQ 
(n = 114) 
Follow-up studies post-PZQ at 1, 3, 6 and 12 months 
Participants invited to be recruited into the Study  
(n = 384) 
Participants recruited & had questionnaire interviews 
(n = 376) 
Invited to clinic for urine and blood 
• 166 didn’t submit 
Invited to submit semen at the clinic 
• 96 didn’t submit 
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Table 8: Demographic information of the study participants at baseline 
  






30.0 18 – 70 13.0 
Duration in the area (years) 20.0 0.1 – 70.0 24.3 





28.0 18 - 70 13.0 
Duration in the area (years) 19.0 1 – 70 21.5 




39.5 21 – 65 17.0 
Duration in the area (years) 24.0 1 – 59 24.0 
Weight (kg) 56.4 43 – 74 8.8 
Samples submitted 
Urine 210 30.0 18 – 70 15.0 
Semen 114 29.0 18 – 67 15.0 
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Table 9: Additional demographic information of the study participants at baseline 
5.5.2 Prevalence of UGS and MGS in the study cohort 
Out of the total recruited participants, only 210 submitted urine after questionnaires 
(55.9%) and 114 submitted semen (30.3%). Forty-three participants on ART submitted urine while 26 
Variable N Percent (%) 
Level of education 
Never went to school 43 11.4 
Didn’t complete Primary school 182 48.4 
Completed Primary school 41 10.9 
Didn’t complete Secondary school 70 18.6 
Completed Secondary school 29 7.7 
Didn’t complete Tertiary school 4 1.1 
Completed Tertiary school 1 0.3 
Marital status 
Single 83 22.1 
Married 247 65.7 
Co-habiting / engaged 2 0.5 
Divorced 21 5.6 
Other (widowed) 2 0.5 
Children 
No 64 17.0 
Yes 253 67.3 
Other occupation 
Farming 2 0.5 
Business 2 0.5 
Household work 69 18.4 
Student 4 1.1 
Unemployed 1 0.3 
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submitted semen samples. The median age of participants who submitted urine was 30.0 years (IQR: 
15, range: 18.0 – 70.0) and for semen was 29.0 years (IQR: 15, range: 18.0 – 67.0; Table 8 and Figure 
31). Urine examination for macrohaematuria using colour-score card revealed that most of the urine 
was clear in appearance (97.1%) while few samples were cloudy (2.9%).  
 
 
Figure 31: Histograms showing age distribution of participants who submitted samples 
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Further examination of the urine using reagent Siemens multistix strips showed most of the 
urine was negative for leukocytes (82.4%), blood (72.9%) and protein (63.8%; Table 10). None of the 
urine was positive for glucose, suggestive of no glycosuria associated by other diseases.  
Table 10: Proportion of 210 participants who submitted urine according to results of reagent strip 
 
After urine filtration, 36 participants (17.1%) had S. haematobium eggs in urine (UGS), their 
median egg count was 0.9 eggs per 10 ml (IQR: 5.4, range: 0.1 - 186.0 eggs; Table 11). Only three 
participants had the highest infection intensity, defined as 50+ eggs per 10 ml of urine (92, 137.8 and 
186 eggs). The urine submitted by participants ranged from 10 ml to 240 ml.  
Eight (22.2%) of those 36 participants with UGS were on ART, representing 14.3% of HIV-
positive participants who submitted urine in the study cohort. There was no significant difference in 
the urine egg count according to the participants’ HIV infection status (median: 1.0 egg, n = 21 
[Negative]; median: 0.1 egg, n = 8 [Positive]; Mann-Whitney test U = 85.0, z = 0.05, p = 0.96). In 
addition, the age of participants did not correlate with UGS infection (rho = -0.16, n = 36, p = 0.35). 
Eight participants of those who submitted urine (3.8%, n = 210) had a positive POC-CCA test, 
suggestive of possible S. mansoni intestinal schistosomiasis infection. There was a positive 
correlation between reagent strip scores for leukocytes, blood and proteins with urine egg count 
Reagent strip score Leucocytes Blood Protein 
Negative 173 (82.4%) 153 (72.9%) 134 (63.8%) 
Trace 14 (6.7%) 28 (13.3%) 29 (13.8%) 
+ 11 (5.2%) 10 (4.8%) 34 (16.2%) 
++ 11 (5.2%) 8 (3.8%) 9 (4.3%) 
+++ 1 (0.5%) 11 (5.2%) 3 (1.4%) 
++++ 0 (0.0%) 0 (0.0%) 1 (0.5%) 
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(rho = 0.23, p = 0.001; rho = 0.36, p < 0.001; and rho = 0.25, p = 0.001 respectively), while there was 
no correlation between urine colour card with egg count (rho = 0.01, n = 210, p = 0.89). 
For those who submitted semen, 12 (10.4%) had S. haematobium eggs in semen (MGS), with 
median egg count of 2.9 per ml of ejaculate (IQR: 6.3, range: 0.4 - 30.0 eggs) and seminal volume 
ranged from 0.1 to 4.5 mL (mean: 1.4 ml). None of the semen had blood in it or of abnormal colour. 
The semen bag method identified 8 participants (66.7%) whose mean egg count was 1.7, while the 
centrifugation method identified 9 participants (75%) with mean of 5.3 eggs, and only 5 participants 
(41.7%) were observed to have MGS by both methods simultaneously (Figure 32). There was no 
statistical difference in the egg count between the methods. Eight participants (66.7%) with MGS 
had no eggs in urine. 
 
 
Figure 32: Venn diagram showing positive results of the urine filtration, semen microscopy using 


















The median age of those with MGS was 46.0 years (IQR: 23.0, range: 18 – 54) while those 
who were MGS negative, it was 29.0 years (IQR: 14, range: 18 – 67), with statistically significant 
differences (Mann-Whitney test U = 833.0, z = 2.04, p = 0.04).  The ages of participants with MGS 
correlated significantly with their egg count (rho = 0.19, n = 114, p = 0.001). Furthermore, there was 
no correlation between semen egg count with urine card score, POC-CCA test results or urine egg 
count.  
Twenty of those participants (17.5%) who submitted semen had leukocytes in their semen, 
with 13.2% (n = 15) had less than 50 leukocytes, 1.8% (n = 2) had 51 - 100 leukocytes and 2.6% over 
100 leukocytes. None of the participants with leukocytes had schistosome eggs in their semen while 
only 5 participants with S. haematobium eggs in urine (UGS), with no correlation and statistical 
difference (urine: rho = 0.035, n = 98, p = 0.73, Mann-Whitney test U = 801.5, z = 0.27, p = 0.79; 
semen: rho = 0.09, n = 98, p = 0.37, Mann-Whitney test U = 581.5, z = 1.01, p = 0.31). 
Table 11: Parasitological analyses on urine and semen of the study participants at baseline 





Eggs in urine (per 10 ml) 36/210 0.9 0.1 – 186.0 5.4 
Eggs in semen (per ml) 12/114 2.9 0.4 – 30.0 4.3 
Eggs in semen bag (per ml) 12/114 0.8 0.0 - 9.3 2.5 
Eggs by centrifugation (per ml) 12/114 2.9 0.0 - 30.0 6.25 
HIV-negative 
participants 
Eggs in urine (per 10 ml) 28/166 1.0 0.1 – 137.8 5.1 
Eggs in semen (per ml) 7/88 3.0 0.8 – 9.3 4.0 
Eggs in semen bag (per ml) 7/88 2.5 0.5 – 9.3 3.3 
Eggs by centrifugation (per ml) 7/88 4.7 0.8 – 6.7 4.3 
HIV-positive 
participants 
Eggs in urine (per 10 ml) 8/44 1.4 0.1 – 186.0 28.9 
Eggs in semen (per ml) 5/26 2.7 0.4 – 30.0 16.3 
Eggs in semen bag (per ml) 5/26 1.2 0.4 – 2.0 - 
Eggs by centrifugation (per ml) 5/26 5.0 2.7 – 30.0 - 
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Table 12: Proportion of all 376 participants who reported experiencing symptoms of 
schistosomiasis including MGS 
 
5.5.3 Symptoms and diseases reported by study participants and their spouses 
Regarding symptoms related to schistosomiasis, participants reported in their questionnaire 
interviews among others, change in urine colour (47.1%), dysuria (27.6%), frequency (24.9%), 
haematuria (19.6%) and blood in stool (7.3%) (Table 12). Specifically, for MGS, fewer participants 
reported to have experienced pain in their genital organs (7.6%), during coitus (4.8%) and on 
ejaculation (3.2%), haemospermia (1%), with none of those with MGS reporting any of these classical 
symptoms. On the diseases reported, 28.6% had schistosomiasis, malaria (32.1%), diarrhoea (31.7%), 
worm infestation (7.2%) and sexually transmitted infections (STI, 6.4%) (Tables 13 and 14). On their 
genital symptoms, two participants thought they were related to STIs (11.2%) and majority were not 
Symptoms n Percent (%) 
General 
Fever 110 30.9 
Weakness 85 22.6 
Abdominal pain 130 34.5 
Schistosomiasis 
Dysuria 104 27.6 
Urinary frequency 94 24.9 
Urine colour change 177 47.1 
Haematuria 74 19.6 
Blood in stool 27 7.3 
MGS 
Haemospermia 4 1.0 
Pain on sex 18 4.8 
Pain on ejaculation 12 3.2 
Pain in genital organs 22 5.9 
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sure of the cause (66.7%). The participants said that their spouses thought they had STIs (15.4%) and 
schistosomiasis (7.7%) among others. 
Table 13: Proportion of all 376 participants who reported the diseases and treatment received in 
the preceding months before the study 
 
Table 14: Comparison of 114 participants who reported experiencing symptoms of schistosomiasis 
according to the MGS infection status 
Variable n Percent (%) 
Disease 
Malaria 120 32.1 
Diarrhoea 119 31.7 
Dysentery 24 6.4 
Worm infestation 27 7.2 
Skin disease 49 13.1 
Sexually transmitted infections (STI) 24 6.4 
Schistosomiasis 107 28.6 
Treatment in last 12 months 
Antimalarials 134 39.0 
Albendazole 77 22.4 
Praziquantel (PZQ) 123 34.8 
Easily accessible to PZQ 
No 232 61.7 
Yes 129 34.3 
Symptoms 
MGS-positive (N = 12) MGS-negative (N = 102) 
n Percent (%) n Percent (%) 
General 
Fever 2 16.7 34 33.3 
Weakness 3 25.0 20 19.6 
Abdominal pain 3 25.0 38 37.3 
Schistosomiasis 
Dysuria 4 33.3 27 26.5 
Urinary frequency 3 25.0 27 26.5 
Urine colour change 6 50.0 41 40.2 
Haematuria 13 11.4 13 12.7 




With regards to symptoms reported by the participants’ spouses to them, 5.9% had a 
miscarriage, primary infertility (1.9%) and secondary infertility (2.7%), which have been previously 
described to be consequences of female genital schistosomiasis (FGS) (Table 15). Furthermore, 2.7% 
and 0.8% reported to experiencing pain during coitus and bleeding afterwards respectively which are 
also thought to be associated with FGS.  
Regarding the spouses’ symptoms, majority of participants thought they were due to either 
normal body functioning (22.4%) or contraceptives from health facility (20.4%), while some thought 
it was unknown disease (14.3%), pregnancy (8.2%), schistosomiasis (2.0%) and other conditions, with 
one surprisingly saying, “I think her blood is bad, doesn’t relate well with mine”. The spouses 
themselves had similar thoughts of normal body functioning (19.4%), contraceptives (19.4%), 
pregnancy (8.1%), unknown diseases (6.5%) among others, with one saying, “I think this is as a result 
of witchcraft”. Most of participants expressed their need for assistance with their symptoms and 
diseases (39.1%), diagnostic testing (13.0%) and treatment (8.7%) of schistosomiasis, and further 
information on the common diseases in the area (30.4%), namely schistosomiasis, malaria, HIV/AIDS, 
contraceptives use. Of particular interest, one participant commented that, “do not use modern 
contraceptives from health facility, rather use traditional methods from the village”. 
Table 15: Proportion of all 376 participants who reported the symptoms and conditions 
experienced by  their spouses in the preceding months before the study 
MGS 
Haemospermia 0 0.0 1 1.0 
Pain on sex 0 0.0 8 7.8 
Pain on ejaculation 0 0.0 5 4.9 
Pain in genital organs 1 8.3 8 7.8 
Variable n Percent (%) 
Symptoms 
Abdominal pains 68 18.1 
Pain on sex 10 2.7 




Praziquantel was accessed by 34.8% of participants in the last 12 months, 22.4% received 
albendazole, and 61.7% reported that they had difficulties to access treatment for schistosomiasis 
(PZQ), however no significant correlation with MGS in this study. 
5.5.4 Water contact, fishing and sanitation information of the study participants 
The participants admitted to swimming or walking (92.5%), bathing and washing their bodies 
and clothes (94.1%) in the lake, at least four times in a week. The main reasons for using the lake 
were because of its convenience to their daily routine since they spend vast time in the lake (44.9%), 
and its clear, fresh and free water (41.9%) which encourages them to be clean (6.4%), while a small 
proportion reported that the borehole water was salty (1.0%) or located at a far distance (3.7%).  
With regards to their fishing, the median duration of fishing was 7.0 years (IQR: 9.3, range: 
0.2 - 60 years) and participants spending an average of 4 days per week on fishing in the lake (IQR: 5, 
range: 1 – 7 days; Table 16). There was a strong, positive correlation between participant’s age and 
number of years he has been fishing (rho = 0.51, n = 298, p < 0.001) as well as frequency of fishing in 
a week (rho = 0.14, n = 352, p = 0.008), highlighting the potential increased risk of exposure to 
schistosomiasis. 
Table 16: Proportion of participants who reported on their water contact and fishing history in the 
Lake in the preceding months before the study 
Menstrual pains 36 9.6 
Menstrual change 36 9.6 
Conditions 
Miscarriage 22 5.9 
No children in marriage 10 2.7 
Infertility 7 1.9 
Variable N Median Range 
Interquartile 
Range (IQR) 
Swim / walk in the Lake 
(times per week) 




Close to two-thirds (66.2%) admitted to fish in other areas, more than 3 times in a year (IQR: 
2, range: 1 - 20), mainly following larger fish catches at a particular time (91.6%), as well as increased 
availability of fishing boats in specific area (3.8%), following friends migrating to other areas (peer 
pressure, 3.4%) and better fish prices (1.3%).  
Since the lake closes to fishing from December to January every year, in accordance to 
Malawi government regulations for fish breeding season, most of the participants do other activities 
including farming (50.4%), casual work, other skilled works (hair-cutting, tailoring, carpentry, 
building, welding: 7.7%), while some do nothing (22.2%). The duration of fishing was negatively 
correlated with education status of the participants, which was statistically significant (rho = - 0.16, n 
= 295, p = 0.005). 
Only 12.7% use protective wear during their water contact. The reasons for not using 
protective wear include lack of special wear (17.3%), inconveniencing as they have difficulties work 
with them (19.7%), fear of drowning due to heavy weight once soaked (26.5%), while some find 
them not necessary (7.1%) and 10% stated that there are rules against use of protective wear or any 
heavier clothing when fishing in the lake.   
Half of study participants used their home toilet for urination (56.9%), followed by those 
using the lake (32.3%), both lake and home toilet (9.7%) and only 3 use the bush (0.8%). Similarly, 
Bath / wash in the Lake 
(times per week) 
373 4 1 – 7 5 
Protective wear in the Lake 
(times per week) 
372 5 1 – 7 4 
Fishing in the Lake  
(number of years) 
298 7.0 0.2 – 60 9.3 
Frequency of fishing  
(days per week) 
352 3 1 – 7 5 
Fish migration to other 
areas (times per year) 
354 3 1 – 20 2 
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more participants used their home toilet (60.8%) for defecation, some still use the lake (30.8%), both 
places (9.7%) and the same number used the bush. Thus, indicating the participants do increase the 
risk of being infected during frequent water contact and transmitting the disease due to their poor 
sanitary behaviour. 
Most have home toilet (92.4%), which they used on average 6.3 days in a week (95% C.I.: 6.2 
– 6.5 days), contradicting to their earlier response. For those participants without, use toilet of their 
parents (50%), neighbour (30%) or drinking bar (10%).  
5.5.5 Multivariate analysis of reported symptoms, diseases, water contact and tests results 
Further statistical analyses were conducted to explore the relationship between the MGS 
infection status and reported symptoms, diseases, water contact and fishing history. There was a 
significant correlation between MGS infection and the frequency of fishing in a week (rho = - 0.25, n 
= 100, p = 0.01) and fishing in other areas (rho = 0.23, n = 73, p = 0.05), while only the duration of 
stay in the study site was slightly significant correlated with UGS infection (rho = 0.16, n = 178, p = 
0.03).  
There was no correlation between infection status and number of days involved in 
swimming, walk, work, bath or wash in the lake per week, use of protective wear in the lake or use 
of home toilet. However, there was statistical difference in MGS infection status with regards to 
their use of the lake for bathing or washing (p = 0.01), explanation for their use of the lake (p = 
0.008) and their village of stay (p = 0.001). 
Furthermore, there was a significant statistical difference in the fishing duration in a week 
according their MGS infection using the Mann-Whitney U test (median: 3 days, n = 93; median: 1 
day, n = 7; U = 142, z = -2.54, p = 0.01, r = 0.03; respectively), suggesting that those with less number 
of fishing days were likely to have MGS. There was no difference in the frequency of water contact 
during swimming, bathing, washing, number of years fishing and frequency of fishing in other areas. 
All the variables were not statistically difference with their UGS infection status.  
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There was no statistical difference in the infection status with the response to the symptoms 
and diseases experienced by the participants, during and in the months preceding the study. On the 
participants’ response to PZQ access for schistosomiasis treatment, there was no significant 
difference in MGS and UGS infection status. Similarly, on the easy access to PZQ treatment for 
schistosomiasis was not significantly different between those participants with and without MGS, 
similarly to those who either or not received treatment in the last 12 months preceding the study. 
One-way between groups analysis of variance (ANOVA) was conducted to explore the 
impact of participants’ education status on the MGS and UGS infection, which were divided into 4 
groups according to their responses: never went to school, primary education, secondary education 
and college education. With no violation of homogeneity of variances, there was no statistically 
significant difference in UGS and MGS infection among the education status groups of the 
participants: F (2, 204) = 0.20, p = 0.82 (UGS), and F (2, 108) = 0.07, p = 0.92 (MGS). Of the MGS 
participants in the study, 9 (75%) attended primary education while the remaining 3 (25%) attended 
secondary education. 
5.5.6 Multivariate analyses of the different diagnostic tests for schistosomiasis 
On the relationship between the tests conducted in the study, there was no statistical 
difference between the urine colour-card scores and the urine egg counts using Kruskal-Wallis tests 
(n = 210, p = 0.89), while there was significant difference in the reagent strip scores and urine 
schistosome egg counts (n = 210, p = 0.012 (leukocytes), p < 0.001 (blood, protein)). The reagent 
strip scores correlated with the semen egg count (rho = 0.23, p = 0.001 [leukocytes]; rho = 0.36, p < 
0.001 [blood]; and rho = 0.25, p = 0.001 [protein]), while the colour card scores were not correlated 
with semen egg counts. 
Comparing the urine tests with semen egg results, there was statistical difference between 
the reagent strip scores for protein and semen egg counts (n = 114, p = 0.01), with no difference in 
reagent strip scores for leukocytes, blood and colour card scores. When compared, the semen bag 
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and centrifugation methods had a Kappa measure of agreement value was 0.56, with statistical 
significance (p < 0.001). Using semen centrifugation method as a reference test, the sensitivity of 







Looking at the literature, this is the first original research study investigating MGS among 
local inhabitants along the shoreline of Lake Malawi in a schistosomiasis-endemic area. Previous 
reports have been case descriptions of travellers or non-dwellers visiting the lake for recreation or 
business (Schwartz et al., 2002; van Delft et al., 2007; Kayuni et al., 2019a). 
Despite its first description over a century ago by Madden (Madden, 1911), MGS remains 
unknown, unrecognised, misdiagnosed and underreported among men in endemic areas like as Lake 
Malawi shoreline, thereby suffering from its consequences ranging from persistent genital, coital 
and ejaculatory pain, abnormal ejaculates, haemospermia, swollen organs and infertility. Coupled 
with the long known poor health-seeking behaviour of men, certainly MGS impacts the male 
reproductive health negatively, making it an ignored aspect of an NTD and a public health concern in 
such endemic areas.   
5.6.1. On detection of MGS among local fishermen along Lake Malawi 
Our study population comprised young and middle-aged fishermen who had spent most of 
their life on the lake shoreline in the fishing communities, as observed from their median age of 30.0 
years. This is similar to the national trend of the country population, pegged at 17.6 million in 2018 
with over 230,000 men aged ≥ 18 years in the district and over 70,000 in the two T/A of the study 
area. In such endemic areas, people get infected as earlier in life as in infancy (Poole et al., 2014) and 
as they grow, repeated exposure through contact with infested lake water, results in re-infections 
and progressive development of chronic manifestations of schistosomiasis, including MGS (Madsen 
et al., 2011; Colley et al., 2014). Despite some case reports on MGS being in young children (Rambau 
et al., 2011; Ekenze et al., 2015), most reports on MGS has been in adults beyond adolescence, 
similar to our observation for the mean age of those with MGS being higher and significantly 
different to those without disease (Kayuni et al., 2019a). 
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The prevalence of MGS observed in our study was similar to the assumed prevalence 
(10.4%), but lower from previous studies in other endemic countries (Leutscher et al., 2000; 
Leutscher et al., 2008b). As observed in this study, majority of MGS participants (66.7%) had no eggs 
in urine (UGS) which also explains the non-correlation of both tests. Urine filtration has been used as 
a proxy to diagnosing MGS, due to challenges encountered in semen submission with individual 
perceptions around the sample (Price et al., 2005). However, filtration is known to have low 
sensitivity and specificity especially when the prevalence starts declining (Le and Hsieh, 2017), 
especially with the mass drug administration (MDA) campaigns with PZQ, which the national control 
programme in Malawi conducts annually. Interestingly, in the study, the scores of the urine reagent 
multistix strips correlated significantly with MGS, hence the need to develop more accessible, 
affordable, point-of-care sensitive and specific diagnostic tests for MGS (Stecher et al., 2015).  
The novel semen bag method described and used in the study showed reasonable sensitivity 
and specificity when compared to the standard semen examination technique (centrifugation 
method) which has been routinely used (WHO, 2010). This could serve as the first-line examination 
tool for semen in diagnosing MGS in endemic areas, owing to the readily availability of the tool, 
compared to most sample collection tools like non-spermicidal condoms or disposable containers.  
In addition, the use of POC-CCA urine tests could assist in determination of intestinal 
schistosomiasis (van Dam et al., 2004; Colley, Andros and Campbell, 2017; Le and Hsieh, 2017), 
which happen to be an emerging infections having autochthonous transmission on the shoreline 
(Alharbi et al., 2019). Further investigation of positive men on POC-CCA can elucidate this infection 
and explain the absence of S. mansoni eggs in semen unlike previous reports from other areas 
(Pedro Rde, Barros Rde and Amato Neto, 1973; Lambertucci, Voieta and Barbosa, 2006; Lambertucci 
and Lippi, 2010). 
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5.6.2. Clinical symptomatology, attitudes and practices related to MGS 
With regards to the symptoms, fewer participants reported having the classical symptoms of 
UGS and specifically MGS, certainly none of the symptoms had a significant relationship with MGS 
infection status. This was similar to their perceptions of the symptoms not related to schistosomiasis 
but rather other diseases including STI, similarly observed in other studies (Ukwandu and Nmorsi, 
2004; Yirenya-Tawiah, Ackumey and Bosompem, 2016). In previous reports, such classical symptoms 
were like haemospermia, abnormal ejaculates were observed in naïve individuals visiting endemic 
areas and displaying early stages of schistosomiasis preceding diagnosis of MGS (Ross et al., 2002; 
van Delft et al., 2007; Knapper, Morrell and Lomax, 2012).  
On their water contact during bathing, washing or swimming in the lake, there was no 
correlation observed with MGS infection status which was surprising. However, their frequency of 
fishing in the lake per week was noted to correlate with the infection, supporting the known fact 
that repeated exposure to infested water increases the risk of schistosome infection, its intensity 
and afterward development of MGS, coupled with their low usage of protective wear (Gryseels et 
al., 2006; Colley et al., 2014). The mean frequency of fishing was significantly different between the 
infection statuses which suggest more days of fishing contribute to more exposure which 
subsequently result in MGS infection. 
Furthermore, practices of some participants in using the lake for urination and defecation 
instead of toilets contribute to continuation of the life cycle because the intermediate snail hosts will 
be infected with miracidia from their hatched eggs. This does not appear surprising observing that 
the level of education had no impact on the infection status, since all the MGS participants attended 
primary and secondary education, although education is supposed to contribute towards 
modification and transformation of behaviour with regards to schistosomiasis (Kloos, 1995). There is 
need for comprehensive health education through diverse available channels like beach committee 
meetings which involves all fishermen, community radio programs, health meetings among others in 
order to engage the men on schistosomiasis and MGS in particular. Certainly, there is need to 
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develop local tailor-made water, sanitation and health (WASH) interventions together with the men 
to address issues of poor hygiene and sanitation observed in the study. 
5.6.3. Limitations of the MGS research study 
The drop-out of participants in submitting samples especially semen limit the generalisation 
of the study results to male population in the country and endemic region. This could be explained 
by negative perceptions and myths associated with semen in rural communities, however previous 
study examining semen in the district did not encounter such challenges (Kipandula and Lampiao, 
2015). In addition, the rumours of blood suckers (vampires) visiting and terrorising the local 
communities negatively affected the trust and confidence local men had on the study team, thus 
additional sensitisation and discussions were conducted with local traditional and opinion leaders, 
health workers and police officers. Also, some participants could be reluctant to submit samples at 
the health centres, due to poor health-seeking behaviour. However, previous studies describing MGS 
had similar or even lower number of participants submitting semen, hence our results contribute to 
the current knowledge of MGS in local inhabitants of a schistosomiasis endemic area.  
5.7. Conclusion 
In conclusion, male genital schistosomiasis remains a prevalent, unrecognised manifestation 
of schistosomiasis, especially UGS, commonly in men with frequent exposure to infested waters in 
endemic areas like Lake Malawi shoreline. This study illustrate the need for more education on 
schistosomiasis, specifically MGS among men, to timely seek medical assistance to access PZQ which 













This chapter described the diagnostic outcomes for male genital schistosomiasis (MGS) using 
molecular real-time polymerase chain reaction (PCR) on semen samples. At baseline, real-time PCR 
detected a higher MGS prevalence of 26.6% among the study participants (n = 64, Ct-vale range: 
18.9 – 37.4), compared to 10.4% prevalence using semen microscopy. In total, 25 of those 
participants who submitted semen at baseline (21.9%, n = 114) were detected with MGS using either 
semen microscopy or real-time PCR. 
Furthermore, the results of parasitological and molecular tests conducted at 1-, 3-, 6- and 
12-months follow-up time-points are being described in this chapter, indicating varying prevalences 
despite receiving standard single-dose PZQ treatment. 
Application of more sensitive and specific diagnostic tests on semen such as real-time PCR 
technique improves diagnosis of MGS in men living in schistosomiasis-endemic areas. Despite PZQ 
treatment being able to acutely clear schistosome eggs in semen, re-exposure and re-infection 
significantly contributes to recurrence of MGS, hence the need for research study on the impact of 







Male genital schistosomiasis (MGS) is a severe chronic consequence of urogenital 
schistosomiasis (UGS), which was first reported in 1911 (Madden, 1911), and is generally 
unrecognised in most endemic areas (Leutscher et al., 2000; Bustinduy and King, 2014; Squire and 
Stothard, 2014). Currently, semen microscopy to visualise schistosome eggs is considered as a 
standard technique for diagnosing active MGS infection, with urine filtration being a diagnostic proxy 
marker in the presence of MGS symptoms (Kayuni et al., 2019b).  
However, there have been reports of seminal schistosome eggs in negative urine filtrations, 
raising serious diagnostic challenges in MGS, as opposed to substantial progress in defining female 
genital schistosomiasis (FGS) diagnosis gold-standard (WHO, 2015a). Similarly, sensitivity and 
specificity of semen microscopy is affected by the diurnal variation of schistosome egg excretions 
observed in the ejaculate (Ramarakoto et al., 2008). In addition, pathologies in genital tissues have 
been observed during histopathological examinations and ultrasonography, in absence of other 
genital diseases, which can also be applied as additional diagnostic tools for MGS (Leutscher et al., 
2008b). Molecular techniques like PCR can been applied to MGS, which could improve the diagnosis, 
treatment and monitor the progress of the disease.  
In addition, schistosomiasis has been associated with increased risk of Human 
immunodeficiency virus (HIV) infection due to the possible alterations of genital mucosa, chronic 
immunomodulation of the host susceptibility to the virus, thereby facilitating increased risk in HIV 
acquisition in women and transmission in co-infected men (Leutscher et al., 2005; Kjetland et al., 
2006; Stecher et al., 2015). Praziquantel (PZQ) treatment for schistosomiasis could be one of the 
preventive strategies in controlling the possible transmission of HIV among dually infected men in 
addition to Antiretroviral therapy (ART) (Ndeffo Mbah et al., 2013; Midzi et al., 2017). Malawi being 
one of the SSA countries endemic to schistosomiasis along most water bodies (Teesdale and 
Chitsulo, 1985; Makaula et al., 2014) as well as HIV infection (NSO, 2014), which put most high-risk 
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populations like fishermen at vulnerable position to MGS and transmitting HIV to their sexual 
partners.  
As described in Chapter 5, our longitudinal cohort study among fishermen along the south 
shoreline of Lake Malawi in Mangochi district observed a prevalence of 17.1% for UGS and 10.4% for 
MGS on semen microscopy at baseline. In order to describe further diagnosis of MGS among high-
risk men in an endemic area, this research study was set out to assess the application of seminal 
real-time PCR to determine the prevalence of MGS among local fishermen living along the southern 
shoreline of Lake Malawi in Mangochi district and monitor the progress of infection after PZQ 
treatment. 
6.3. Objectives of the Study 
The specific objectives of the study were: 
a. to determine the performance of seminal real-time PCR in diagnosing MGS.  
b. to describe the efficacy of PZQ in treating MGS by clearing seminal schistosome eggs and 






6.4.1. Study area, population and sampling 
As described in Chapter 4, this research study recruited fishermen living in fishing villages 
along the south shoreline of Lake Malawi in Mangochi district  (NSO and ICF, 2017) from October 
2017 to December 2018. This longitudinal cohort study comprised of baseline and follow-up studies 
after PZQ treatment in fishing villages and nearby health centres, with a minimum sample size of 275 
recruited fishermen aged ≥ 18 years, eligible to participate in the study (Kirkwood and Sterne, 2006; 
CDC, 2014). 
6.4.2. Data collection 
The methods of this study data collection as described earlier in Chapter 4, comprised of 
individual questionnaires administered to recruited fishermen on the shoreline and communities 
and parasitological analyses of the collected urine and semen samples and transabdominal 
ultrasonography in the nearby health facilities located in the study area. (WHO, 1991; Ukwandu and 
Nmorsi, 2004; van Dam et al., 2004; Cheesbrough, 2009). Blood was also collected where plasma 
was harvested and shipped together with preserved semen at -80C for further analyses including 
SEA ELISA using SCHISTO-96 IVD IgG/M microwell kits (New Life Diagnostics LLC, Lot. 1729, IVD 
Research Inc., USA) and DRG IgG kits (Lot. G062, IQA ref.: 2462/19), point-of-care Prostate Specific 
Antigen (PSA) using ALL TEST PSA rapid test cassettes (Ref. TPS-402, Lot.: PSA18110014, Hangzhou 
All Test Biotech Company Ltd, P.R. China) and comparative HIV virological load analyses in the UK. 
Semen was collected in a clear, transparent, self-sealing plastic bag for direct microscopy 
after liquefication and later centrifugation (WHO, 2010), and the results were recorded as per ml of 
ejaculate. Afterwards, 0.5 ml of ethanol was added to the semen sediment for preservation before 
shipment to the United Kingdom and Netherlands for real-time polymerase chain reaction (real-time 
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PCR) of Schistosoma genus DNA. Due to the little volume of some semen samples, not all 
participants who submitted semen underwent real-time PCR.  
6.4.3. Real-time PCR for Schistosoma DNA 
Ethanol was removed from the preserved semen sediments after centrifugation, as 
described in Chapter 4. The pellet was washed twice with phosphate buffered saline (PBS) before 
suspending in PBS containing 2% polyvinylpolypyrrolidone (PVPP) (Sigma, Steinheim, Germany). The 
suspension was then heated and frozen overnight, before DNA extraction using the QIA symphony 
Sample Processing (SP) system (Qiagen, Hilden, Germany). Phocine Herpes Virus 1 (PhHV-1) was 
added as an internal control and monitor for inhibition of the real-time PCR, which was performed 
using primers and probes described previously (Obeng et al., 2008; Kenguele et al., 2014). 
6.4.4. Statistical analyses 
The data collected from diagnostic, serological and molecular tests during the study was 
screened and quality-controlled before entry into Microsoft Excel and SSPS programmes. Summary 
statistics were calculated to explore the data and thereafter correlations and significant tests were 
conducted to describe and interpret the results further, mainly using nonparametric tests.   
6.4.5. Ethical considerations 
Ethical clearance to conduct the study was provided by the National Health Sciences 
Research Committee (NHSRC) of Malawi and Liverpool School of Tropical Medicine (LSTM) Research 
Ethics Committee (LSTM REC). Utmost privacy and confidentiality were maintained in the study and 
where necessary, the information was anonymised to protect the identity of the participant. Since 
this was a test-to-treat study, participants were offered PZQ treatment at the end of the visit before 




6.5.1. Study population 
A total of 376 fishermen were recruited into the study, from 39 villages located in two 
Traditional Authorities (T/A) of Mponda and Nankumba along the shoreline and had questionnaire 
interviews. Fifty-six participants had HIV infection and were on anti-retroviral therapy (ART). Out of 
the total recruited participants, only 210 submitted urine (55.9%) and 114 submitted semen (30.3%). 
The median age of participants who submitted urine was 30.0 years (Interquartile range [IQR]: 15, 
range: 18.0 – 70.0) and for semen was 29.0 years (IQR: 15, range: 18.0 – 67.0) (Table 17). 
Table 17: Age distribution of the study participants who submitted samples for diagnostic tests 
6.5.2. Urine filtration and semen microscopy of the study cohort 
Examination of the urine using reagent Siemens multistix® 10 G strips showed most of the 
urine was observed to be negative for leukocytes (82.4%), blood (72.9%), protein (63.8%) or glucose 
(Table 18).  
Table 18: Proportion of 210 participants who submitted urine according to results of reagent strip 
Sample submitted N Median Range 
Interquartile 
Range (IQR) 
Urine 210 30.0 18 – 70 15.0 
Semen 114 29.0 18 – 67 15.0 
Reagent strip score Leucocytes Blood Protein Glucose 
Negative 173 (82.4%) 153 (72.9%) 134 (63.8%) 210 (100.0%) 
Trace 14 (6.7%) 28 (13.3%) 29 (13.8%) 0 (0.0%) 
+ 11 (5.2%) 10 (4.8%) 34 (16.2%) 0 (0.0%) 
++ 11 (5.2%) 8 (3.8%) 9 (4.3%) 0 (0.0%) 




Urine filtration showed that 36 participants (17.1%) had S. haematobium eggs in urine (UGS) 
(median egg count: 0.9 per 10 ml; range: 0.1-186.0; IQR: 5.4; volume range: 10-240 ml (Table 11). 
Eight (3.8%) were positive for POC-CCA, possibly intestinal S. mansoni schistosomiasis. Twelve 
participants (10.4%, n=114) had S. haematobium eggs in semen (MGS) (median: 2.9 eggs per ml of 
ejaculate; range: 0.4-30.0; volume range: 0.1-4.5 ml. Eight participants (66.7%) with MGS had no 
schistosome eggs in urine. 
6.5.3. Schistosoma serology SEA ELISA 
A total of 106 blood plasma samples from all time points were retrospectively analysed with 
SCHISTO-96 IVD IgG/M kits. Using absorbance cut-off value of 0.20 OD units, 74 participants were 
positive on ELISA, giving a cohort Schistosoma seroprevalence of 69.8%. Further ELISA results are 
described alongside with real-time PCR results at the specific time-points. Comparing the IVD ELISA 
results with that of an accreditated clinical laboratory (DRG IgG ELISA) conducting the external 
quality control, 54.5% of 33 semen samples were positive using IVD ELISA while 48.5% were positive 
on the DRG ELISA. Using the DRG ELISA as a reference test, the sensitivity of the IVD ELISA was 
observed to be 81.3% and specificity was 70.6%, witha significant Kappa measurement of agreement 
(value = 0.516, p = 0.003) and correlation (rho = 0.52, p = 0.002). 
6.5.4. Real-time PCR for Schistosoma DNA 
The real-time PCR was conducted on semen samples collected from all the time-points, as 
well as on urine samples collected at 6- and 12-months’ time-points (Figure 33). Threshold cycle (Ct-
value) of less than 45 was considered positive result for schistosomiasis. 
 





Figure 33: Diagram showing the number of study participants at each time-point, the semen samples submitted and tested using real-time PCR 
1-month 6-months 3-months 12-months Baseline 
Real-time PCR conducted on semen samples 
Number of Participants 
(n = 60) 
Number of Participants 
(n = 63) 
Number of Participants 
(n = 64) 
Number of Participants 
(n = 45) 
Number of Participants 
(n = 210) 
Semen samples 
submitted (n = 41) 
Semen samples 
submitted (n = 53) 
Semen samples 
submitted (n = 48) 
Semen samples 
submitted (n = 44) 
Semen samples 
submitted (n = 114) 
Semen samples tested  
(n = 34) 
Semen samples tested  
(n = 49) 
Semen samples tested  
(n = 46) 
Semen samples tested  
(n = 41) 
Semen samples tested  
(n = 64) 
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6.5.4.1 Baseline time-point 
Real-time PCR was conducted on only 64 semen samples submitted at baseline, due to 
limited volume of the samples from some participants. The median age of the participants was 32.5 
years (IQR: 22.0, range: 18.0 – 67.0 years), duration of stay was 22.0 years (IQR: 23.8, range: 0.5 – 
54.0 years) while their bodyweight was 57.4 kg (IQR: 7.5, range: 43.0 - 75.4 kg). Seventeen 
participants (26.6%) were positive for real-time PCR, with median Ct-value of 26.5 (IQR: 8.5, range: 
18.9 – 37.4). Of those MGS participants, eight had no eggs in semen or urine, six had eggs in semen 
only, while 27 had eggs in urine only (Figure 34). For the cohort, 25 participants were detected with 
MGS using semen microscopy and real-time PCR, raising the prevalence of MGS from 10.4% to 
21.9% (n = 114).  
 
Figure 34: Venn diagram showing positive results of the different diagnostic tests at baseline of 
the study (n = 52) 
Comparing results of all diagnostic tests with age, the proportion of positive semen 
















6.5.4.2 1-month time-point 
Of all the 114 participants who submitted semen at baseline and invited for follow-up, only 
sixty participants returned and were examined at 1-month follow-up time-point. Real-time PCR 
conducted was conducted on 34 out of 41 semen samples submitted at this time-point. The median 
age of the participants was 34.5 years (IQR: 18.0, range: 19.0 – 49.0 years). While none of the 41 
participants who submitted semen had schistosome eggs, nine were positive for real-time PCR, 
showing MGS prevalence of 26.5%, with median Ct-value of 28.7 (IQR: 9.1, range: 23.7 – 37.0). Of 
the positive real-time PCR participants, only three had eggs in urine only.  
Six participants (10.5%) had S. haematobium eggs in urine (median: 12.8, IQR: 22.9, range: 
0.1 - 29.6) while nine (69.2%) were SEA ELISA seropositive (median: 0.31, IQR: 0.22, range: 0.24 – 
0.65) with all except one had no urinary schistosome eggs and negative semen real-time PCR. None 
Figure 35: Baseline clustered bar graph of proportion of positive participants on urine 
filtration, semen microscopy, ELISA and real-time PCR per age group. 
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of the participants were positive for POC-CCA test. Looking at all diagnostic tests with age at this 
time-point, only the proportion of positive real-time PCR increased with age (Figure 36). 
 
6.5.4.3 3-months’ time-point 
The real-time PCR was conducted on 46 semen samples submitted from 48 participants, and 
their median age was 33.0 years (IQR: 21.0, range: 19.0 – 67.0 years). Sixty-four participants were 
followed at this timepoint. Thirteen participants (28.3%) were positive for real-time PCR, with 
median Ct-value of 28.3 (IQR: 8.5, range: 22.5 – 36.9). Seven of the positive real-time PCR 
participants had no schistosome eggs in semen or urine, one had eggs in urine only, two in semen 
only while four had eggs in both urine and semen (Figure 37). In total, 14 participants were detected 
with MGS using semen microscopy and real-time PCR, showing the MGS prevalence of 29.2% (n = 
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Figure 36: 1-month follow-up clustered bar graph of proportion of positive participants on 
urine filtration, semen microscopy, ELISA and real-time PCR per age group. 




Seven participants (14.6%) had S. haematobium eggs in urine (median: 9.0, IQR: 19.2, range: 
0.3 - 69.0), 5 (10.4%) in semen (median: 2.5, IQR: 7.3, range: 0.8 – 10.0), while 8 (88.9%) were ELISA 
seropositive (median: 0.3, IQR: 0.42, range: 0.20 – 1.05). 
 
Figure 37: Venn diagram showing positive results of the different diagnostic tests at 3-months 
follow-up time-point of the study (n = 14) 
 
Comparing the diagnostic tests with age, only proportion of positive participants on urine filtration, 

















6.5.4.4 6-months’ time-point 
Semen samples submitted from 49 of the 53 participants at 6-months follow-up timepoint 
underwent real-time PCR analyses, and the participants’ median age was 31.0 years (IQR: 18.0, 
range: 18.0 – 54.0 years). A total of 63 participants took part in the study at this time-point. Eight 
participants were positive for real-time PCR (16.3%), with median Ct-value of 31.3 (IQR: 5.0, range: 
23.4 – 36.1), and had no schistosome eggs in urine or semen. Ten participants were detected with 
MGS using semen microscopy and real-time PCR, showing MGS prevalence of 18.9% (n = 53).  
Two participants (3.3%) had S. haematobium eggs in urine (mean: 1.95, SD: 2.62), 2 (3.8%) in 
semen (mean: 0.85, SD: 0.78), while 22 (71.0%) were ELISA seropositive (median: 0.37, IQR: 0.46, 
range: 0.20 – 1.51). Looking at the diagnostics tests used at this time-point, the proportion of 
positive participants of all the tests increased with age, as opposed to previous time-points, 
presented earlier (Figure 39). 
Figure 38: 3-months follow-up clustered bar graph of proportion of positive participants on 
urine filtration, semen microscopy, ELISA and real-time PCR per age group. 
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6.5.4.5 12-months’ time-point 
The real-time PCR was conducted on 41 out of 44 semen samples submitted at 12-month 
follow-up timepoint, and the median age was 35.0 years (IQR: 21.0, range: 18.0 – 67.0 years). Forty-
five participants were examined at this time-point. Twelve participants were positive for real-time 
PCR, showing MGS prevalence of 29.3%, with median Ct-value of 28.4 (IQR: 14.6, range: 17.6 – 36.6). 
Of the positive real-time PCR participants, 8 had no schistosome eggs, 2 had eggs in urine only, 1 in 
stool and another one in semen. In addition, real-time PCR was also conducted on 48 urine and 3 
stool samples at this time point, with only 3 (6.3%) urine samples being positive (mean Ct-value: 
31.0, SD: 5.43, range: 25.1 – 35.8). 
Four participants (8.3%) had S. haematobium eggs in urine (median: 3.05, IQR: 2.8, range: 
0.8 – 4.1), one (2.3%) in semen (mean: 0.85, SD: 0.78), one (33.3%) in stool (mean: 0.85, SD: 0.78) 
and 23 (69.7%) were ELISA seropositive (median: 0.41, IQR: 0.20, range: 0.20 – 2.18). Comparing the 
Figure 39: 6-months follow-up clustered bar graph of proportion of positive participants on 
urine filtration, semen microscopy, ELISA and real-time PCR per age group. 
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results of all diagnostic tests with age, a similar trend to that of 6-months’ follow-up was observed 
with all the proportions of positive participants decreasing with age (Figure 40).  
 
6.5.5. Comparison of the different diagnostic tests 
Using semen real-time PCR as reference test, the sensitivities of the other diagnostic tests 
ranged from 14.3% (semen microscopy) to 76.2% (ELISA) while the specificities ranged from 30.5% 
(ELISA) to 93.2% (urine filtration) (Table 19). Only urine filtration correlated significantly with real-
time PCR, with higher Kappa measure of agreement value and stronger statistical significance than 
other tests. The sensitivity increased while specificity decreased when any positive results from 
parasitological and antigen tests were compared with real-time PCR results, demonstrating 
correlated and statistically significant differences. When results of the diagnostic tests are combined 
to describe the prevalence of MGS, it shows that prevalence goes up from 10.4% (using semen 
microscopy only) to 30%, as shown in Figures 41 and 42, using results from the Study baseline. 
  
Figure 40: 12-months follow-up clustered bar graph of proportion of positive participants 
on urine filtration, semen microscopy, ELISA and real-time PCR per age group. 
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p-value value p-value 
Urine filtration 210 33.3 93.2 0.31 0.002 0.34 0.002 9.21 0.002 
Semen microscopy 114 14.3 91.5 0.07 0.45 0.09 0.45 0.58 0.45 
POC-CCA (antigen) 210 52.4 67.9 0.18 0.10 0.19 0.11 2.64 0.10 
ELISA (antibody) 106 76.2 30.5 0.04 0.56 0.07 0.57 0.34 0.56 
Positive by any 
parasitological test 
210 33.3 84.7 0.20 0.08 0.20 0.08 3.16 0.08 
Positive by any 
parasitological or 
antigen test 
210 71.4 59.3 0.24 0.02 0.27 0.02 5.86 0.02 
Positive by any of the 
four tests 






Figure 41: Bar graph of number of positive participants on diagnostic tests at the study baseline 
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Since its first description over a century ago by Madden (Madden, 1911), MGS remains 
unknown, unrecognised, misdiagnosed and underreported among men in endemic areas such as 
shores of Lake Malawi. Coupled with the long known poor health-seeking behaviour of men, MGS 
certainly impacts the male reproductive health negatively, making it an ignored aspect of an NTD 
and a public health concern in such endemic areas. This longitudinal cohort study among local 
fishermen along the south shoreline of Lake Malawi was the first original research to investigate the 
prevalence of MGS in a schistosomiasis-endemic area, following several previous case descriptive 
reports of travellers or non-dwellers visiting the lake for recreation or business (Schwartz et al., 
2002; van Delft et al., 2007; Kayuni et al., 2019a). 
6.6.1. Diagnostics for UGS with special focus on MGS among local inhabitants 
The diagnosis of UGS includes inexpensive, urine filtration which suffer low sensitivity and 
specificity and can be lacking in most endemic areas due to the limited resources and inadequate 
laboratory capacity, overburdened with other important prevalent diseases like malaria, diarrhoea, 
pneumonia, HIV. Although semen microscopy is considered as a standard diagnostic method for 
MGS, perceptions and challenges encountered in semen submission and analysis (Price et al., 2005) 
have resulted in urine filtration being used as a proxy to diagnosing MGS. Both methods suffer from 
the day-to-day diurnal variations in excretion of eggs into urine and semen, affecting their sensitivity 
and specificity which requires repeated sample submission and examination on consecutive days in 
order to improve detection of infected people (Le and Hsieh, 2017).  
This MGS study, comprising of fishermen aged between 18 and 70 years old, who spent 
most of their life on lake shoreline, observed a 17.1% prevalence for UGS and 10.4% for MGS using 
semen microscopy at baseline (Kayuni et al., 2019b). Also, most MGS participants in the study at 
baseline (66.7%) did not have schistosome eggs in urine, highlighting the need for more sensitivity 
and specificity diagnostic tests such as molecular techniques.  
180 
 
6.6.2. Novel findings with real-time PCR diagnostics for MGS 
Development of PCR has revolutionised the field of medicine, improving diagnosis of 
prevalent diseases especially NTDs. Detection of parasitic DNA in specimens from people exposed to 
infective parasites in endemic areas highly indicate presence of the infection, which demonstrates 
the high sensitivity and specificity of this diagnostic technique and contribute to control, treatment 
and prevention. Real-time PCR of schistosomiasis has also demonstrated better diagnostic 
performance in areas of low transmissions and non-endemic populations (Le and Hsieh, 2017).  
This technique has been applied to various active or preserved samples including urine, stool 
and vaginal secretions to detect Schistosoma DNA in comparison traditional standard tests and 
producing significant results in schistosomiasis diagnosis (Obeng et al., 2008; Aryeetey et al., 2013; 
Kenguele et al., 2014). However, this molecular technique is quite expensive and not readily 
available in endemic areas, just like in Malawi. It is worthy to note that our study is the first original 
research in an endemic area to apply semen real-time PCR to diagnose MGS, detecting 26.6% of 
participants at baseline, with median Ct-value of 26.5 and increasing the overall prevalence of MGS 
by 2-fold.  
Conducting other diagnostic tests in addition to urine filtration, such as like urine reagent 
multistix strips (which correlated with MGS in our cohort prevalence study), POC-CCA and ELISA can 
help in improving the diagnosis of schistosomiasis, identifying other infected people with other 
Schistosoma species (van Dam et al., 2004; Colley, Andros and Campbell, 2017; Le and Hsieh, 2017) 
and subsequently MGS. Our study demonstrated a significant Kappa agreement of measurement 
between any positive parasitological or antigen test with semen real-time PCR as a reference test (p 
= 0.015), correlation (p = 0.015) and statistical difference (p = 0.015). Also, urine filtration showed 
low sensitivity of 33.3%, high specificity of 93.4%, a significant Kappa agreement of measurement (p 
= 0.002), correlation (p = 0.002) and statistical difference (p = 0.002). In all, the number of people 
with schistosomiasis was seen to increase with multiple diagnostic methods, showing a higher 
prevalence of schistosomiasis than individual method. 
181 
 
At the baseline of the study, eight of the 17 participants who were positive on semen real-
time PCR had no eggs in urine or semen which highlights the need for multiple diagnostic platform 
as well as testing and use of more sensitive tests to detect more cases of MGS. Also, real-time PCR 
did not pick up all MGS cases as observed in participants with semen eggs but negative on PCR, 
which could explain an old infection with dead eggs migrating in the genital tissues and then 
released into ejaculatory ducts and seminal fluid.  
Furthermore, looking at the trend of the tests with age, the proportion of MGS participants 
diagnosed by semen microscopy and real-time PCR increased with age, compared to urine filtration 
and SEA ELISA. This could be due to MGS developing later in life as a result of repeated exposure to 
infested water bodies, having re-infections (Madsen et al., 2011; Colley et al., 2014) and presenting 
as a chronic consequences of schistosomiasis, especially UGS (Kayuni et al., 2019a).  
However, there have been reports of MGS at younger age (Rambau et al., 2011; Ekenze et 
al., 2015), showing since schistosomiasis starts as early as infancy (Poole et al., 2014), MGS can 
develop even before adolescence, as the children have frequent exposure to infested waters, 
experience high re-infection rates despite at times being provided PZQ treatment which has good 
cure rates and reverses early pathologies (Knopp et al., 2013). Of note, children especially in schools 
are targeted either with individual treatments or through annual mass drug administration (MDA) 
campaigns by national control programmes including Malawi, which leaves adults out. As part of this 
study, PZQ was provided during the study and assessed the clearance of MGS among the 
participants.  
6.6.3. Efficacy of standard single-dose PZQ treatment on progression of MGS 
Following the MGS participants after PZQ treatment, the study showed that schistosome 
eggs were cleared in semen 1-month later, despite 26.5% of 34 participants tested with real-time 
PCR being positive. This indicates presence of Schistosoma DNA in infected participants who were 
not excreting eggs in semen and limiting semen microscopy in MGS at this time-point, supporting 
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the low sensitivity of microscopy in diagnosing schistosomiasis. Also, comparison of the trend of 
diagnostics tests with age was similar as a baseline. At 3-months’ time-point, schistosome eggs were 
detected in 10.4% of participants’ semen with 28.3% being positive for real-time PCR, increasing the 
MGS prevalence to 29.2%.  
Similarly, at 6- and 12-months’ time-points, the prevalence of MGS was 16.7% and 29.3% 
respectively, demonstrating the possible treatment failure and re-infection of the study participants 
due their repeated exposure to the infested lake waters where they continued to conduct the 
income-generating fishing activities. This highlights the need for comprehensive control strategies 
for schistosomiasis like adequate health education on modify and transform behaviour 
schistosomiasis (Kloos, 1995), engaging men in water, sanitation and health (WASH) interventions, 
intermediate snail- host control in addition improving access to treatment in local health facilities 
and to inclusion and participation in PZQ MDA campaigns (WHO, 2013b), to reduce the prevalence 
and complications of MGS.  
6.6.4. Limitations and recommendations from the MGS cohort study 
The low number of participants in submitting semen samples limit the generalisation of the 
study results to male population in the country and endemic region. This could be explained by 
negative perceptions and myths associated with semen in rural communities, however previous 
study examining semen in the district did not encounter such challenges (Kipandula and Lampiao, 
2015). In addition, the rumours of blood suckers (vampires) visiting and terrorising the local 
communities negatively affected the trust and confidence local men had on the study team, thus 
additional sensitisation and discussions were conducted with local traditional and opinion leaders, 
health workers and police officers.  
Also, some participants could be reluctant to submit samples at the health centres, due to 
poor health-seeking behaviour. However, previous studies describing MGS had similar or even lower 
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number of participants submitting semen, hence our results contribute to the current knowledge of 
MGS in local inhabitants of a schistosomiasis endemic area.  
With the study findings, development of more accessible, affordable, point-of-care sensitive 
and specific diagnostic tests for MGS (Stecher et al., 2015) is strongly recommended since this 
molecular test remains unavailable and not feasible in endemic areas where currently can 
immediately benefit from a combination of tests to diagnose MGS among at-risk men. Also, timely 
provision of individual PZQ treatment and consideration to increase the frequency of PZQ preventive 
treatments given through MDA campaigns from annually to bi-annually, to prevent re-infections and 
monitoring of the disease regression.  
Furthermore, with the possibility of co-morbidities among local inhabitants of these endemic 
areas arising from other prevalent NTDs and infectious diseases including HIV, further diagnostics 
such as HIV viral load analyses are critical in integrated, holistic management of those affected men 
with dual or multiple infections, as described in chapter 8.    
6.7. Conclusion 
In conclusion, applying more sensitive and specific semen real-time PCR technique improves 
diagnosis of MGS, a prevalent, unrecognised gender manifestation of schistosomiasis in men in 
endemic areas like Lake Malawi shoreline, whose prevalence rose by 2-fold. It was also observed 
that PZQ treatment was able to acutely clear schistosome eggs in semen, although possible re-












This chapter described the genital abnormalities observed on transabdominal and scrotal 
ultrasonography conducted on study participants, describing morbidity associated with male genital 
schistosomiasis (MGS), in reference to the different parasitological and molecular tests.  
This study observed that nine (6.9%) of those 130 participants (out of 376 participants) had 
abnormalities in prostate, seminal vesicles, testis and testis at baseline. Four of these participants 
were negative on all parasitological and molecular schistosome tests. Over the follow-up time 
points, some of the abnormalities resolved, other persistent while new abnormalities appeared. In 
total, 146 participants were scanned during the entire cohort study, and abnormalities were 
observed in 16 participants at various time-points. 
Some of the results from the ultrasonography have been published as case reports in two 
journals, as cited below: 
Kayuni S.A., Corstjens P.L., LaCourse E.J., Bartlett K.E., Fawcett J., Shaw A., Makaula P., 
Lampiao F., Juziwelo L., de Dood C.J., Hoekstra P.T., Verweij J.J., Leutscher P.D.C., van Dam G.J., van 
Lieshout L. and Stothard J.R. (2009). How can schistosome circulating antigen assays be best 
applied for diagnosing male genital schistosomiasis (MGS): an appraisal using exemplar MGS cases 
from a longitudinal cohort study among fishermen on the south shoreline of Lake Malawi. 
Parasitology, Volume 146, Issue 14, pages 1785-95, https://doi.org/10.1017/S0031182019000969.  
Kayuni, S. A., LaCourse, E. J., Makaula, P., Lampiao, F., Juziwelo, L., Fawcett, J., Shaw, A., 
Alharbi, M., Verweij, J. J. and Stothard, J. R. (2019). Case Report: Highlighting Male Genital 
Schistosomiasis (MGS) in Fishermen from the Southwestern Shoreline of Lake Malawi, Mangochi 
District. The American Journal of Tropical Medicine and Hygiene, 101(6), pages 1331 – 1335, doi: 
https://doi.org/10.4269/ajtmh.19-0562. 
My contribution to these manuscripts were that I conducted the literature review on MGS, 
research fieldwork along south shoreline of Lake Malawi, wrote first drafts of the manuscript and 




Schistosomiasis is prevalent in SSA where more than 90% of infected people live, causing 
considerable morbidity and some deaths (McManus et al., 2018; WHO, 2018b). The pathological 
lesions of schistosomiasis give characteristic manifestations which can be detected by non-invasive 
radiological techniques such as ultrasonography which are becoming widely available and 
successfully utilised in endemic areas (WHO, 2011).  
These techniques are important, safe, effective and valuable diagnostic methods in tropical 
diseases, which are useful specially the control of NTDs (WHO, 2000; Ramarakoto et al., 2008). 
Ultrasonography is acceptable method which has undergone improvements producing affordable, 
portable instruments. Such equipment can be easily moved from one health facility to another in 
endemic areas, thereby supporting the semen microscopy and other available point-of-care 
diagnostics tests for schistosomiasis.  
Transrectal ultrasonography (TRUS), computed tomography (CT) and magnetic resonance 
imaging (MRI) have been noted to be very important and useful in schistosomiasis (Shebel et al., 
2012). These methods detect hypoechogenic and hyperechogenic lesions concomitant with 
granulomas and calcifications, determine the sizes of enlarged organs, as well as demonstrating 
calcified schistosome ova in the tissues (Fender, Hamdy and Neal, 1996; Vilana et al., 1997; Al-Saeed 
et al., 2003; de Cassio Saito et al., 2004).  
Such pathologies have been observed to be correlated with clinical features specific to MGS 
and subsequently they are noted to resolve more especially in earlier stages compared to 
irreversible, late presentation. With the abundant evidence of ultrasound validity of renal tract and 
liver, Niamey ultrasonography guidelines have been developed by radiologists which clearly defined 
the pathological lesions associated with urogenital schistosomiasis (UGS) as well as intestinal 
schistosomiasis (WHO, 2000). Although ultrasonography can be used as a surveillance method in 
MGS, currently there’s limited evidence in literature from few case reports of scrotal/lower 
abdominal studies in travellers describing MGS and impact of PZQ in an endemic setting, which 
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necessitate for further prospective studies to validate the use of ultrasonography in MGS and 
understand the evolution and resolution of the associated genital pathologies.  
As part of our novel longitudinal cohort study on MGS among fishermen in south-western 
shoreline of Lake Malawi, known to harbour both urogenital and intestinal schistosome species 
(Makaula et al., 2014; Alharbi et al., 2019), a ultrasonographical study was conducted to determine 
the morbidity associated with MGS.  
7.3. Objectives of the research 
The specific objectives of the study were: 
a. to document the morbidity associated with MGS using ultrasonography making specific 
reference to genital organ abnormalities.  
b. to determine by ultrasonography if, after PZQ treatment(s), there was morbidity 







7.4.1. Study area, population and sampling 
The research aspect of this investigation by ultrasonography was embedded within the 
larger longitudinal cohort study (see Chapter 4) as conducted among fishermen living in fishing 
villages identified and selected along the south shoreline of Lake Malawi in Mangochi District (NSO 
and ICF, 2017), from October 2017 to December 2018. The study comprised of baseline and follow-
up studies after PZQ treatment in fishing villages and nearby health centres. 
7.4.2. Data collection 
The study methods utilised for the data collection comprising individual questionnaires, 
parasitological analyses of urine and semen samples collected in health facilities, and blood 
collection. Further serological and molecular analyses for diagnosing schistosomiasis were 
conducted in the United Kingdom. In addition, all participants were invited to undergo 
transabdominal pelvic and scrotal ultrasonography examination (Figure 43) to assess morbidity 
features of MGS in the prostate, seminal vesicles, testes and epididymis. More description of the 




7.4.3. Statistical analyses 
The data collected from video clips, digital images and report forms comprising from 
symmetry, thickness, echogenicity, calcifications, nodules, polyps, masses and hydroceles, were 
entered into IBM SSPS programmes in accordance to evidence-based recommendations and 
guidelines on specific ultrasonography after quality control by a specialist radiologist (Vilana et al., 
1997; WHO, 2000; Martino et al., 2014). Summary statistics were calculated to explore the data and 
thereafter correlations and significant tests were conducted to describe and interpret the results 
further, mainly using nonparametric tests. 
7.4.4. Ethical considerations 
Ethical clearance to conduct the study was provided by the National Health Sciences 
Research Committee (NHSRC) of Malawi and Liverpool School of Tropical Medicine (LSTM) Research 
Ethics Committee (LSTM REC). Utmost privacy and confidentiality were maintained in the study and 
Figure 43: Conducting transabdominal ultrasonography on a participant at a health facility.   
Photo credit: Dr Sekeleghe Kayuni, June 2018. 
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where necessary, the information was anonymised to protect the identity of the participant. Since 
this was a test-and-treat study, participants were notified of the ultrasonography results including 
pathological findings at the end of the procedure and where necessary, further appropriate 
investigations and management were organised in accordance with standard clinical practice. 
Treatment with PZQ at 40 mg/kg as a single dose was offered before inviting them to the next 
follow-up studies at 1-month, 3-, 6- and 12-months’ time-points. Details of observed treatment were 
recorded when subsequent follow-ups were performed. 
7.5. Results 
Out of 376 fishermen recruited into the study, only 130 participants returned to the health 
facility and for the ultrasonography examinations at baseline of the study. 
7.5.1. Demographic information and diagnostic results 
The median age of the 130 scanned participants was 32.0 years with a range of 19.0 to 70.0 
years (Interquartile range [IQR]: 18) and their duration of stay in the fishing village ranged from 2 
months to 70 years (median: 22.0; IQR: 24.5; Table 20). The median weight of the participants was 
59.0 kg (IQR: 9.0, range: 43.0 – 75.4 kg).  
All participants except one submitted urine and 81 submitted semen (62.3%). Examination 
of urine visually for macrohaematuria using colour-score card revealed that most of the urine was 
clear in appearance (97.7%) while few samples were cloudy (2.3%). Further examination of the urine 
using reagent Siemens strips showed that more participants were negative for leukocytes (80.6%), 
blood (67.4%) and protein (65.1%; Table 21). None of the urine was positive for glucose (no 
glycosuria), suggestive of no possibility of diabetes mellitus, metabolic and renal diseases. 
After urine filtration, 27 participants (20.9%) had S. haematobium eggs in urine (UGS), their 
mean egg count was 19.1 eggs per 10 ml and ranging from 0.1 to 186.0 eggs (median: 1.0, IQR: 5.8). 
Six participants (4.9%) had a positive POC-CCA test, suggestive of possible intestinal S. mansoni 
infection. For the 81 participants who submitted semen, 10 (12.3%) had S. haematobium eggs in 
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semen (MGS), mean egg count was 3.9 per ml of ejaculate (median: 2.9 eggs), ranging from 0.4 to 
9.3 eggs and volume of semen ranged from 0.1 to 4.5 mL (mean: 1.6 ml). The real-time PCR 
conducted on 57 semen samples revealed that 16 participants (28.1%) were positive. Four 
participants were positive on both semen microscopy and real-time PCR. 
Table 20: Demographical information, diagnostic analyses on urine and semen with 
ultrasonography results of the 130 study participants 
Variable N Median Range 
Interquartile 
Range (IQR) 
Age 130 32.0 19.0 – 70.0 18.0 
Duration of stay in village (years) 120 22.0 0.2 – 70.0 24.5 
Weight (kgs) 115 59.0 43.0 – 75.4 9.0 
Eggs in urine (filtration, 10 ml) * 129 1.0 0.1 – 186.0 5.8 
Eggs in semen (ml)* 80 2.9 0.4 – 9.3 4.6 
Seminal real-time PCR (Ct-value) 57 26.4 18.9 – 36.6 10.5 
Prostate size (ml) 122 13.4 5.4 – 61.3 5.4 
 
Table 21: Proportion of 130 participants who submitted urine according to results of reagent strip 
 Reagent strip score Leucocytes Blood Protein 
Negative 104 (80.6%) 87 (67.4%) 84 (65.1%) 
Trace 7 (5.4%) 18 (14.0%) 21 (16.3%) 
+ 6 (4.7%) 8 (6.2%) 16 (12.4%) 
++ 11 (8.5%) 7 (5.4%) 8 (6.2%) 
+++ 1 (0.8%) 9 (7.0%) 0 (0.0%) 
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7.5.2. Baseline results of the ultrasonography exanimations 
Of the participants who had ultrasonography, 10 (7.7%) had one or more abnormalities in 
genitourinary (GU) organs, with 9 (6.9%) having abnormalities in prostate, seminal vesicles and/or 
scrotum (testis and epididymis) (Table 22).  
Table 22: Proportion of abnormal findings in particular organs at baseline 




Urinary Bladder 106 2 1.9% 
Kidneys* 4 1 25.0% 
Prostate 126 3 2.4% 
Seminal vesicles 117 1 0.9% 
Testis# 129 1 0.8% 
Epididymisǂ 129 1 0.8% 
Scrotumα 129 6 4.7% 
*Kidneys scanned for those who had severe bladder abnormalities; #Left testis; ǂRight epididymis; αHydroceles 
were observed in scrotums of five participants  
 
Three participants (3.1%) were observed to have abnormalities in at least two GU organs, 
and two had MGS, confirmed by parasitological and/or molecular tests, as shown in Table 23 below. 
















1 19 0 0 N/D# 
Irregular bladder wall and severe polypoid thickness, 
with bilateral hydronephrosis 
2 22 0 0 25.4 
Irregular bladder wall with severe flattened thickness, 
irregular prostate with hyperechoic nodule (Figure 44) 
3 69 0 N/Aǂ N/Aǂ 
Severely enlarged prostate (volume = 61.3 ml) and 
right epididymis, with bilateral hydrocele 
# Test not done, inadequate sample; ǂ Sample not submitted, test not done 
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Eighteen of all the scanned participants had UGS only, confirmed by S. haematobium eggs 
observed in urine, 15 had MGS only (six had semen eggs only while 9 were positive for real-time 
PCR) and only two participants were positive for all three diagnostic tests (Figure 45). Only 4 
participants of the 10 with abnormalities had MGS by semen microscopy and real-time PCR, two 
participants had schistosome eggs in urine and semen and positive real-time PCR, while none was 
positive for POC-CCA. In all, 18 (13.8%) of the scanned participants could be considered to have MGS 
at baseline, by being positive on semen microscopy, real-time PCR or pathological abnormality on 








Figure 44: Ultrasonographic images of an MGS positive study participant with abnormalities in the bladder and prostate at Baseline 
A and B. Irregular urinary bladder wall and severe flat thickness, measuring up to 13.6 mm. C. Normal symmetrical seminal vesicles. D. Prostate with abnormal irregular outline, but 




Figure 45: Venn diagram showing positive diagnostic tests on all scanned participants at baseline 
7.5.2.1. Urinary bladder and Kidneys 
Two participants had irregular outline of their urinary bladder with severe wall thickness of 
at least 11 mm (20% of total abnormal scans (AS); 1.9% of scanned bladders (SC)). One participant 
(number 1, Table 23) was negative for urine filtration and semen microscopy, whose 
ultrasonography of the kidneys revealed bilateral hydronephrosis. The other participant (number 2, 
Table 23) had MGS, by real-time PCR. 
7.5.2.2. Prostate 
Three participants (2.3%) had abnormal prostate appearance, two aged 51 and 69 years old, 
had enlarged prostates with volumes of 39.1 ml and 61.3 ml, while one, aged 22 years, had irregular 
prostate outline and hyperechoic nodule, (Figure 44), among other severe bladder abnormalities and 
positive real-time PCR. None had schistosome eggs in semen and point-of-care prostate specific 



















7.5.2.3. Seminal vesicles 
Although three participants (8.5%) had enlarged seminal vesicles, measuring at least 15 mm, 
only one had asymmetrical, hyperechoic vesicles, aged 24 years with S. haematobium eggs in urine 
and semen, as well as positive real-time PCR. The measurements for the scanned participants’ right 
vesicles ranged from 4.8 mm to 18.5 mm and the left vesicles from 3.7 mm to 17.5 mm. 
7.5.2.4. Scrotum 
Abnormalities observed on scrotal ultrasonography were particularly in testis, epididymis 
and coverings. One participant (0.8%) had left testicular nodule, with S. haematobium eggs detected 
in urine and semen (Figure 47). Only one participant was observed to have an abnormal enlarged 
right epididymis, among other abnormalities described above and had no had S. haematobium eggs 
in urine (participant 3, Table 23). 
A C D B E 
Figure 46: Images of the POC-PSA test conducted on participants with Prostate abnormalities 
A and E. Strong positive POC-PSA with no urine or semen eggs and no abnormalities. B. Negative POC-PSA with semen 
real-time PCR (Ct-value: 25.4), irregular prostate outline and hyperechoic nodule. C. Negative POC-PSA with no urine 
eggs, but had grossly irregular, enlarged prostate (61.3 ml), abnormal epididymis and bilateral hydrocele. D. Negative 





Figure 47: Ultrasonographic image of study participant 
with left testicular nodule at baseline. 
Figure 48: Ultrasonographic images of participants with hydroceles at baseline in Table 23. 
A and B Bilateral hydroceles of participant C showing larger amount of scrotal fluid, compared to moderate left 







Six participants (4.7%) were observed to have hydroceles of which three had bilateral 
hydroceles (Figure 48). Only one participant with left hydrocele was positive for all the diagnostic 
tests (participant B, Table 24). 
Table 24: Study participants with Hydroceles on Transscrotal ultrasonography at Baseline 
Participant Age (years) 
Location of 
Hydrocele 
Eggs in urine 
(per 10 ml) 
Eggs in semen 
(per ml) 
Real-time PCR  
(Ct-value) 
A 29 Left 0.0 N/Aǂ N/Aǂ 
B 30 Left 37.3 2.0 25.7 
C 49 Bilateral 0.1 0.0 45.0* 
D 49 Bilateral 1.0 0.8 N/D# 
E 54 Bilateral 0.0 0.0 45.0* 
F 69 Bilateral 0.0 N/Aǂ N/Aǂ 
* Ct-value of 45.0 is Negative; ǂ Sample not submitted; # Test not done, inadequate sample 
In context with all the abnormalities described above, there was no correlation between 
age, duration of stay, diagnostic tests’ results and abnormalities. 
7.5.3. Follow-up ultrasonography exanimations 
At the end of the ultrasonography examinations at baseline, PZQ treatment was provided to 
the participants on exit of the study after submitting semen sample for resolution of the 
abnormalities. The participants were invited to follow-up ultrasonography examinations at 1-, 3-, 6- 
and 12 months’ time-points. 
7.5.3.1. 1-month follow-up 
Only 29 participants were scanned out of the 60 participants who returned at 1-month 
follow-up, with 4 participants scanned for the first time and no abnormalities observed. Two of the 
repeat participants had S. haematobium eggs in urine, three were positive on semen real-time PCR 
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while none had S. haematobium eggs in semen. One of the repeat participants had abnormalities at 
this time point, who had no abnormalities at baseline.  
Three participants had hydroceles, with two being bilateral and were also present at 
baseline, namely participant II in Table 25 (participant C in Table 24) and participant III (participant D 
in Table 24), showing persistent abnormalities despite PZQ treatment (Table 26). Two of the 
participants had MGS, by semen real-time PCR. 
Table 25: Study participants with hydroceles on ultrasonography at 1-month follow-up 
Participant Age (years) 
Eggs in urine 
(per 10 ml) 






I 44 23.1 0.0 23.7 Left 
II 49 0.0 0.0 25.0 Bilateral 
III 49 0.0 0.0 45.0* Bilateral 
* Ct-value of 45.0 is Negative 
Table 26: Observations on ultrasonography of 2 participants at baseline and 1-month follow-up 
Age (years) 
Baseline 1-month Follow-up 
Test results Abnormalities observed Test results Abnormalities observed 
49 
Eggs in urine, 
none in semen; 
negative PCR 
Bilateral hydrocele 





Eggs in urine, 
semen; no real-
time PCR done 
Left testicular nodule, mild 
bilateral hydroceles 





7.5.3.2. 3-months follow-up 
Sixty-four participants were followed up at 3-months’ time-point of which 32 had 
ultrasonography examinations, and 4 were scanned for the first time. On diagnostic examinations, 5 
had S. haematobium eggs in urine (17.2%), 4 in semen (13.8%), 4 had trace POC-CCA test while 5 had 
positive semen real-time PCR. Pathological abnormalities were observed in three participants 
(28.1%). One participant had abnormalities for the first time in the study, while 2 participants 
remained with abnormalities from the previous 1-month time point (Table 27).  
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Table 27: Abnormalities observed at 3 time points in 2 scanned participants 
Participant Age (years) Baseline 1-month follow-up 3-month follow-up 
G 44 No abnormality Left hydrocele Left hydroceles 
Hβ 49 Bilateral hydroceles Bilateral hydroceles Bilateral hydroceles 
β This is participant C in Table 24 and II in Table 25 
Of the 3 participants with abnormalities at this time point, two had left hydroceles while one 
had bilateral hydroceles. One of the participants with left hydroceles was positive on the all 
diagnostic tests (participant G in Table 27, same as K in Table 28) and previously had the same 
abnormality at preceding time point, while the other one presented with abnormality for first time 
in the study (participant J in Table 28). 
Table 28: Study participants with hydroceles on ultrasonography at 3-months follow up time point 
Participant Age (years) 
Eggs in urine 
(per 10 ml) 
Eggs in semen 
(per ml) 




J 33 0.0 0.0 45.0* Left 
K 44 15.2 7.5 26.7 Left 
L 49 0 0 45.0* Bilateral 
* Ct-value of 45.0 is Negative 
7.5.3.3. 6-months follow-up 
Sixty-three participants were followed up at 6-months’ time-point of which 38 had 
ultrasonography examinations, and 4 were scanned for the first time. On diagnostic examinations, 2 
had S. haematobium eggs in urine (5.3%), 1 in semen (2.6%), 4 (10.5%) positive and 2 (5.3%) trace 
POC-CCA test results, while 3 had positive semen real-time PCR (7.6%).  
Pathological abnormalities were observed in 4 participants (13.2%), with 3 reported for the 
first time while one had the abnormalities reported at all previous time points (bilateral hydroceles) 
(Table 29). Two participants had left hydroceles, while two participants had no abnormalities at the 
time point which were observed previously.  
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M 25 0.0 0.0 N/D# Left hydroceles 
N 33 0 0 N/D# 
Enlarged, asymmetrical seminal 
vesicles (Figure 49) 
O 39 0.0 0.0 45.0* Left hydrocele 
P 49 0.0 0.0 45.0* Bilateral hydroceles 
* Ct-value of 45.0 is Negative; # Test not done, inadequate sample 
 
7.5.3.4. 12-months follow-up 
Forty-five participants were reviewed at 12-months’ time-point of which 17 had 
ultrasonography examinations, and 4 were scanned for the first time. One participant had abnormal 
bladder wall thickness and left kidney mass. On diagnostic examinations, the participants were 
negative for POC-CCA, urine filtration and semen microscopy, with 2 participants being positive on 
semen real-time PCR (11.8%). 
Figure 49: Ultrasonographic image of enlarged, asymmetrical seminal 
vesicles in participant N, Table 28 at 6-months follow-up time point. 
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Table 30 illustrates the progress of abnormalities detected at baseline, over the course of 
the study and Table 31 shows those with no abnormality at baseline but detected during the follow-
up. In total, 146 participants were scanned in the study and abnormalities were noted in 16 
participants at various time points. Table 32 shows the proportion of participants with abnormalities 




Table 30: Ten participants with abnormalities in GU organs on ultrasonography at baseline and progression over the time points in the study 








Didn’t show up No abnormality 
Inadequate bladder filling, not 
reported for repeat scan 




Inadequate bladder filling, not 
reported for repeat scan 
Lost to follow-up   
29 Left hydrocele Lost to follow-up    
30 Left hydrocele Didn’t show up Didn’t show up Didn’t show up No abnormality 
49 Bilateral hydroceles Bilateral hydroceles Bilateral hydroceles Bilateral hydroceles Lost to follow-up 
49 
Testicular nodule, mild 
bilateral hydroceles 
Bilateral hydroceles Lost to follow-up   
51 Enlarged prostate Didn’t show up Didn’t show up No abnormality Lost to follow-up 








Table 31: Six participants with abnormalities in GU organs on ultrasonography during follow-up time-points but none at baseline in the study 
Age (years) Baseline 1-month 3-months 6-months 12-months 
25 No abnormality No abnormality Didn’t show up Left hydrocele Lost to follow-up 
33 No abnormality Didn’t show up Left hydrocele Didn’t show up No abnormality 
33 No abnormality Didn’t show up Didn’t show up 
Enlarged, asymmetrical 
seminal vesicles 
Lost to follow-up 
39 No abnormality Didn’t show up Didn’t show up Left hydrocele Lost to follow-up 
44 No abnormality Left hydrocele Left hydrocele No abnormality Lost to follow-up 
53 No abnormality Didn’t show up Didn’t show up Didn’t show up 
Bladder thickening,  
left kidney mass 
 
 




Baseline (n = 130) 1-month (n = 29) 3-months (n = 32) 6-months (n = 38) 12-months (n = 17) 
Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative 
USS 
Positive 4 5 2 1 1 2 0 4 0 0 





To our knowledge, this is the first prospective ultrasonographic study of MGS in Malawi and 
south-eastern Africa on the fishermen cohort to determine its morbidity, through observations of 
pathological abnormalities in genital organs, as well as look at changes through time in men after 
standard dose-regimen of PZQ treatment.  
7.6.1 Detection of genital consequences of schistosomiasis on ultrasonography 
Genital manifestations like MGS are among the complications of schistosomiasis which 
remains unknown among local inhabitants frequently exposed in infective cercariae harbouring their 
freshwater bodies as well as health professionals working in the areas which result in undiagnosed, 
under- or mis-treating and underreporting of the disease, contributing further to morbidity among 
affected men. In some instances, people suffer from social prejudice and discrimination arising from 
the consequences of the genital complications, such as infertility, abnormal organ swelling, reduced 
sexual prowess, coital pain, genital bleeding among other with women severely and 
disproportionately (Yirenya-Tawiah, Ackumey and Bosompem, 2016; Kukula et al., 2019). 
In order to improve awareness and knowledge of MGS, other diagnostic methods can be 
added to help in detection of the disease. Radiological techniques have been observed to improve 
diagnosis of schistosomiasis at various stages, mostly with chronic complications. Ultrasonography is 
considered as an acceptable, safe and less-invasive tool in diagnosis, management and monitoring 
control of NTDs, including schistosomiasis. Recent advances in this technology has resulted in 
development of portable, high quality scanning devices which can be easily mobile to limited-
resource endemic areas and utilised in the available infrastructure, in detecting the genital 





7.6.2 Morbidity of MGS in Malawian fishermen 
Our MGS cohort study among local fishermen along the south shoreline of Lake Malawi 
observed a 17.1% baseline prevalence of UGS, 10.4% for MGS using semen microscopy and 26.6% by 
semen real-time PCR. Among those 130 participants who were scanned at baseline, the prevalence 
of UGS was 20.9%, 4.9% for possible intestinal S. mansoni schistosomiasis, 12.3% for MGS using 
semen microscopy and 28.1% by semen real-time PCR. 
Previous studies have described abnormalities observed in genital organs like prostate, 
seminal vesicles, ejaculatory ducts, vas deferens, epididymis, tests, scrotal sac among other 
structures, which include organ enlargement, shrinkage, dilatations, thickening, echogenic lesions, 
calcification, hydroceles among others, which can mimic other diseases. In schistosomiasis-endemic 
areas, detection of such pathological abnormalities together with classical genital symptoms like 
genital, coital or ejaculatory pain, haemospermia, abnormal ejaculates, reduced libido or suspected 
infertility, should suggests a diagnosis of MGS (Kayuni et al., 2019c). Since, similar clinical 
presentation and findings can be associated with other diseases prevalent in these endemic areas, 
affecting the genital organs such as sexually transmitted infections (STIs), tuberculosis (TB), 
malignant hypertension or cancer, proper clinical assessment and extensive diagnostic examinations 
are very important to be conducted to ensure appropriate diagnosis, treatment, care and 
management of affected men. 
The findings of this study showed that 10 participants had pathological abnormalities in their 
GU organs at baseline, of which nine participants (6.9%) having them in prostate, seminal vesicles 
and scrotum. These abnormalities suggest consequences of previous or current schistosomal 
infection acquired from their frequent exposure during fishing and other routine activities in the 
lake, which is known to harbour schistosomes. The abnormalities observed ranged from ‘mild’ ones 
present in majority of participants to severe ones, with three participants (3.1%) had abnormalities 
in multiple organs. Seminal vesicles had the most abnormalities on ultrasonography, with majority of 
participants having asymmetrical normal-sized vesicles and only three participants showing severely 
207 
 
enlarged vesicles. This is consistent with evidence from previous studies and literature which 
describes that seminal vesicles are among the frequent affected genital organs with schistosomiasis 
(Alves, Woods and Gelfand, 1955; Gelfand et al., 1970; Kayuni et al., 2019a).  
Further results show that urinary bladder had abnormal wall thickening, in some cases 
severe polypoid structures and associated bilateral hydronephrosis which required referral for 
further medical management at district hospital, unfortunately, participant was lost to follow-up. 
Such observations have been widely described in literature which originate from matured paired 
schistosome worms migrating from hepatic veins to reside in vesical plexus and continually deposit 
massive number of eggs, which get trapped in the bladder wall, causing granulomatous reactions, 
fibrosis, calcifications and architecture destruction, compromising bladder functioning (Bustinduy 
and King, 2014; Colley et al., 2014). As the infection progresses and bladder malfunctions, urine 
backflow compromises the ureters (hydroureter) which later affects the kidneys, resulting in 
hydronephrosis. Early diagnosis and management are critical in preventing such chronic and fatal 
consequences of schistosomiasis. 
Interestingly, schistosome worms have been thought to reside in venous plexus around 
genital organs like prostate, seminal vesicle and testes, with eggs being trapped in the tissues due to 
its tough architecture in comparison to the urinary bladder. This can result in echogenic lesions, 
calcifications, organ enlargement, atrophy, hydroceles among the pathological abnormalities in 
these genital organs which can be detected on ultrasonography (Richter, 2000; Al-Saeed et al., 2003; 
Richens, 2004). These abnormalities were observed in this study in the prostate, epididymis and 
testis, with some participants being positive on the urine and semen diagnostic tests. Prostate 
abnormalities were observed in 3 participants, of which two had grossly enlarged prostates and one 
had hyperechoic prostatic nodule and positive semen real-time PCR. These can be attributed to MGS 
after exclusion of other possible diseases like STIs, TB, benign prostatic hyperplasia or prostate 
malignancy. In addition, the lack of statistically significant differences among those with 
abnormalities in accordance to age, duration of stay and diagnostic tests’ results demonstrate that 
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the lesions can present at any age since they could have developed from a young age, as reported 
previously (Rambau et al., 2011; Ekenze et al., 2015).  
7.6.3 Long-term monitoring for MGS in line with regression of pathologies 
Monitoring of disease morbidity especially MGS is critical in controlling the disease and 
prevention of severe irreversible pathological abnormalities which later could contribute to 
mortality.  As a mainstay treatment, PZQ has shown to be effective in treating both forms of 
schistosomiasis, registering cure rates of over 90% in most endemic areas (Knopp et al., 2013; WHO, 
2013a). Currently, it is utilised by most national control programmes in endemic areas as one of the 
key control interventions through the MDA campaigns, which commonly targeted school-aged 
children. PZQ has also been used in treating MGS, clearing the schistosome eggs in semen and 
resolving some pathological abnormalities, while adjusting the standard dose of treatment in some 
cases to ensure complete cure (Kayuni et al., 2019a).  
From the study follow-up after PZQ treatment to the participants, most participants were 
observed to have resolved their pathological abnormalities at 1-month time-point, except two 
participants who had persistent abnormalities. This could illustrate the knowledge that early mild 
lesions will be resolved by standard PZQ treatment as it kills those adult-laying worms, hence 
reducing further damage to the organs. Chronic, long-standing abnormalities like hydroceles require 
further assessments, medical and surgical interventions to resolve these, as it was done in the study 
where such participants were referred to the bigger district hospital.  
During further follow-ups at the 3-, 6- and 12-months’ time-points, some participants 
developed new abnormalities, which highlighted the repeated exposure to the infested lake water. 
Other participants showed resolution of their abnormalities over time, supporting the need for 
repeated PZQ treatment to completely resolve the severe lesions which are reversible, while 
providing additional control interventions like adequate awareness and health education, provision 
of adequate, portable, safe and clean water, encouraging construction and utilisation of household 
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and community sanitation facilities, as well environmental control to reduce intermediate snail host 
population.  Only two participants were observed to have abnormalities at the last 12-months’ time-
point which shows the efficacy of praziquantel in resolving MGS pathologies.  
7.6.4 Study limitations and ultrasonographic diagnostic challenges in MGS 
The low number of participants undergoing the ultrasonography examinations limit the 
generalisation of the study results to male population in endemic region. This could be explained by 
lack of experience with the method as most participants reported this was their first time to undergo 
such examinations. Negative perceptions with regards to new techniques in rural communities and 
the longer time spent during the examination especially among those presenting with inadequate 
bladder filling could have deterred more study participants from taking part. Also, some participants 
could be reluctant to take part at health centres, due to poor health-seeking behaviour. More 
sensitisation and discussions which were done can help to address such and other concerns, thereby 
stimulate more participants to such important studies.  
The low sensitivity of transabdominal ultrasonography compared to TRUS, CT or MRI could 
result in missing some lesions in the genital organs, resulting in poorly described burden of genital 
diseases like MGS. However, cost implications associated with these sensitive techniques, their 
unavailability and inaccessibility as well as low acceptability among local participants could further 
jeopardise the implementations of such examinations in rural endemic areas. 
In addition, advanced radiological expertise and extensive training on genital 
ultrasonography are required in order to detect pathological lesions arising from MGS, which could 
be easily mistaken for those from other prevalent genital diseases such as STIs, TB or cancer. Also, 
further ultrasonography studies with larger cohort as well as inclusion of more advanced portable 




In conclusion, pathological abnormalities caused by MGS can be detected using portable 
transabdominal and scrotal ultrasonography, as demonstrated in our study, which could be used in 
describing the morbidity of MGS. This method could aid in improving diagnosing MGS among 
affected population, due to advances made in developing portable scanning devices which can be 
easily accessible in endemic areas especially SSA. Our study also showed good resolution of 
abnormalities at follow-up time-points, with only one participant having pathological abnormalities 
on ultrasonography at 12-months’ time-point, highlighting the role of this technique in monitoring 















This chapter presents the results of HIV-1 viral load analyses of the paired blood and semen 
plasma samples. Blood and semen samples were collected from all participants at entry into the 
study for analysis of plasma and semen HIV-1 viral load. Participants that were found to have 
schistosomiasis were treated with praziquantel (PZQ) and followed up. All participants had been on 
ART for six months or more at entry into the study.  
Fifteen participants with male genital schistosomiasis (MGS, cases) had their HIV blood and 
semen plasma viral loads compared with 16 participants without MGS (controls) at baseline, 1-, 3-, 
6- and 12-months after treatment with PZQ among the cases. At baseline, more cases (12/15, 80.0%) 
had detectable HIV-1 virus in plasma samples compared with the controls (5/16, 31.3%). Among the 
cases, there were three participants (20%) with detectable and quantifiable VL in semen plasma 
samples compared to two (12.5%) among the controls  
During follow-up at all time-points, HIV viral load declined among the cases. This may be 
attributable to the PZQ among the cases. We have demonstrated in this pilot study that men with 
MGS have higher viral loads in both blood and semen plasma compared with men without. We have 
also demonstrated that PZQ treatment in men with MGS results in reduction of HIV-1 viral load in 
both blood and semen plasma.  
To our knowledge, this is the first study in Malawi that has looked at seminal HIV-1 shedding 
in men with schistosomiasis. Although our data is limited by the small number of study participants, 
high loss to follow-up and not controlling for adherence to ART and other confounders that may 
increase HIV-1 viral load in both semen and blood including sexually transmitted illnesses, there is a 
possible significant role of MGS among men in fuelling this transmission, which suggest for further 






The SSA region remains at the epicentre of the HIV epidemic (Caldwell and Caldwell, 1996; 
Kopelman and van Niekerk, 2002; UNAIDS, 2019), as illustrated in Figure 12 in Chapter 2.  
The advent and effective use of highly active combined antiretroviral therapy (ART) in HIV 
infected people has shown greater ability to suppress viral load (VL) in blood plasma below detection 
threshold and reducing VL in genital secretions, thereby contributing significantly to decreased HIV 
transmission (Marcelin et al., 2008; Sheth et al., 2009). Despite the high rate of viral suppression and 
reduced HIV transmission, occasional HIV-1 transmission has occurred in those people on ART, with 
some men continuing to shed HIV-1 RNA in seminal secretion (Halfon et al., 2010; Cohen et al., 
2011).  
Schistosomiasis, which contributes significantly to the disease burden in SSA (Butterworth et 
al., 2013; McManus et al., 2018; WHO, 2018b), overlaps geographically with the HIV epidemic 
(Mbabazi et al., 2011; Ndeffo Mbah et al., 2013). Studies from East Africa among fisher folks have 
demonstrated increased prevalence of HIV among their communities (Allison and Seeley, 2004; 
Kissling et al., 2005; Seeley, Tumwekwase and Grosskurth, 2009), where urinary schistosomiasis is 
prevalent. Male genital schistosomiasis (MGS) remains a little known, underreported manifestation 
of schistosomiasis in endemic SSA areas (Leutscher et al., 2000; Kayuni et al., 2019a).  
A recent study in SSA demonstrated a reduction of seminal viral load shedding of newly 
diagnosed HIV-infected men coinfected with urogenital schistosomiasis (UGS) 10 weeks after 
praziquantel (PZQ) treatment (Midzi et al., 2017), highlighting a possible impact of schistosomiasis 
treatment on HIV control (Stecher et al., 2015).  
MGS and HIV-1 co-infection interactions within men in respect to the impact on VL is not 
fully understood in SSA, especially those on regular ART using the tenofovir disoproxil fumarate - 
lamivudine - efavirenz regimen (TNF/3TC/EFV). In order to evaluate the extent of relationship 
between MGS and HIV-1 VL in blood and semen, a pilot study was conducted among men with HIV 
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infection along Lake Malawi in Mangochi District, to assess the viral shedding in semen of those co-
infected with MGS. 
8.3. Methods 
8.3.1. Study area, population and sampling 
This study was conducted in the ART clinics of the health facilities located in the study area, 
(NSO and ICF, 2017), as described in Chapter 4. Men aged 18+ years who were HIV infected and 
taking ART were eligible to participate in the study, with those testing positive for schistosomiasis 
enrolled as study cases, and those negative regarded as study controls.  A minimum sample size of 
20 study cases and 20 study controls was planned for the pilot study.  
8.3.2. Data collection and analyses 
Data collection methods comprised of individual questionnaires, parasitological schistosome 
tests on urine and semen samples, transabdominal ultrasonography examination, as described in 
Chapter 4, blood for comparative HIV-1 RNA detection and molecular real-time PCR to detect 
schistosome DNA in semen and serological ELISA tests. Blood and semen plasma were analysed for 
HIV VL using Cepheid Xpert HIV-1 assay (Cepheid, 2019) as described in Chapter 4. 
8.3.3. Statistical analyses 
 After screening, and quality-control and data entry, descriptive statistics were calculated to 
explore the data and produce frequencies, medians and ranges of each study groups, including 
correlations and nonparametric tests.   
8.3.4. Ethical considerations 
Ethical clearance to conduct the study was provided by the National Health Sciences 
Research Committee (NHSRC) of Malawi and Liverpool School of Tropical Medicine (LSTM) Research 
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Ethics Committee (LSTM REC). Since this was a test-to-treat study, participants were offered PZQ 





8.4.1. Study population 
Seventy-four participants were invited to take part and were recruited into the study and 31 
participants submitted paired semen and blood samples for VL analyses, whose results are 
presented in this chapter (Figure 50).  
 
Figure 50: Diagram of the participants who took part in the study 
Fifteen participants had MGS on basis of schistosome eggs in semen and / or positive semen 
real-time PCR and categorised as cases while 16 were negative for schistosomiasis and categorised 
as controls.  
Inclusion criteria: 
• HIV positive, stable on ART 
• Men aged ≥ 18 years, 
including fishermen 
Participants on ART invited to the MGS – HIV study  
(n = 74) 
Participants recruited and had questionnaire interviews 
(n = 74) 
Participants invited to submit urine and blood samples  
(n = 51 [Cases: 18 + Controls: 33]) 
Those gave semen and received PZQ  
(n = 31 [Cases: 15 + Controls: 16]) 
Health facility (group criteria): 
• Cases: UGS / MGS on ART 
• Controls: on ART only 
• 23 didn’t submit samples  
Health facility: 
• All participants invited to 
submit semen & scanning 
• 20 didn’t submit semen 
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8.4.2. Demographic information of the study participants 
The median age of study cases was 42.0 years (interquartile range (IQR): 11.8), similar for 
study controls (median: 42.0 years, IQR: 17.3), with no statistical difference (Independent Mann-
Whitney test U = 120.0, p = 0.78) (Table 33). The median time after HIV diagnosis was 7.5 years 
(cases) and 7.8 years (controls) while duration on ART was 4.8 years (cases) and 6.1 years (controls) 
(Table 34), with no significant statistical difference.  
Table 33: Description of the study participants 
 
aData available from 13 cases; bData available from 12 controls; cData available from 14 cases; dData available 
from 14 controls; eData available from 14 cases and 14 controls; fData from commonly used first-line ART 
regimen.   
 
Table 34: Description of the study participants  
Characteristic Cases Controls p-value 
Total number of participants, n 15 16  
Age, median years (IQR, range) 42.0 (11.8, 43.0) 42.0 (17.3, 40.0) 0.78 
Time since HIV diagnosis, median years (IQR, range) 7.5 (11.0, 14.4)a 7.8 (6.3, 11.3)b 0.50 
ART duration, median years (IQR) 4.8 (10.3, 12.2)c 6.1 (7.1, 12.3)d 0.43 
Time on ARTe     
                                                      < 1 year (%) 4 (28.6) 1 (7.1) - 
                                                      > 1 year (%) 10 (71.4) 13 (92.9) - 
Current ART regimenf     
                                                     TDF/3TC/EFV 14 14 - 
                                                     TDF/3TC+NVP 1 0 - 
Characteristic Cases Controls 
Age 
N 15 16 
Median  42.0 42.0 
Range 25.0 – 65.0 22.0 – 65.0 
Interquartile Range (IQR) 11.8 17.3 
Time since HIV 
diagnosis 
N 13 12 
Median  7.8 7.5 




8.4.3. Schistosomiasis diagnosis in the study cases 
Of the 15 study cases, ten were positive for semen microscopy and / or real-time PCR at 
baseline, two for first-time at 1-month and three at 3-months’ time-point (Table 35). 
Table 35: Parasitological, serological and molecular results of the study cases  
UF = urine filtration, SEM = semen microscopy, IVD and DRG = serological ELISA tests, PCR = real-time PCR, “-“ = negative 
result, “+” = positive result. * positive real-time PCR on urine, not semen 
8.4.4. Patterns of HIV-1 viral detection in blood and seminal plasma of the study participants 
8.4.4.1. Study cases 
Seven cases (7/15 participants) had discrepant detectable HIV-1 VL in their paired samples at 
baseline of the study (Table 36). Two participants (2/7) had detectable but unquantifiable VL in 
Interquartile Range (IQR) 6.3 11.0 
Time on ART 
N 14 14 
Median  4.8 6.1 
Range 0.1 – 12.3 0.1 – 12.3 
Interquartile range (IQR) 10.3 7.1 
Study 
Case ID 
Baseline 1-month 3-months 6-months 12-months 
UF SEM IVD DRG PCR UF SEM PCR UF SEM PCR UF SEM PCR UF SEM PCR 
A - - + - +          - - - 
B - - + - - - - +          
C - + + + -             
D - + - - - - - - - - -    - - - 
E + - + + + - - - - - + - - + - - - 
G - + - - - - -  - - - - + - - - - 
H - - - - - - - - - - +    - - - 
I +  + +  + - + + + + - - + - - - 
J - - - - + - - -    + - -    
K - - + + +             
L + + + + -       - - - - - + 
M + - + -     + - + + + -    
N - - + - - + - + - - - - - - - - - 
O + + + + +          - - - 
P - - - + +             
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semen. Three cases had discrepant detectable and quantifiable VL in plasma, with a median VL of 
3.83 log 10 copies /ml (IQR: 4.65log 10 copies/ml).  
Table 36: Results of the HIV viral load analyses in the study cases 
D = detectable but not quantifiable in blood (VL: 1.34 – 1.59 log 10 copies/ml), UD = undetectable in blood 
(VL < 1.34 log 10 copies/ml); Dα = detectable but not quantifiable in semen (VL: 1.74 – 2.04 log 10 
copies/ml), Dβ = detectable but not quantifiable in semen (VL: 2.34 – 2.60 log 10 copies/ml), UD = 
undetectable in semen (VL < 1.74 log 10 copies/ml), UDα = undetectable in semen (VL < 2.04 log 10 
copies/ml), UDβ = undetectable in semen (VL < 2.34 log 10 copies/ml) 
 
In observing subsequent time-points after PZQ treatment, VL of two cases (J and L) showed a 
downward trend to undetectable level, while one (P) was lost to follow-up. One case (E) had 
detectable but unquantifiable VL at 1-month, quantifiable VL of 2.09 log 10 copies / ml at 3-months, 
reduced back to unquantifiable level at 6-months and undetectable VL at 12-months’ time-point. 
In all, 12 cases (80.0%) had detectable VL in either blood or semen plasma at some time-
point during the study. At baseline, out of 10 cases with positive schistosome tests, five had 
discrepant detectable VL Out of all study cases, five had detectable and quantifiable HIV VL (Table 
37) which were discrepant between blood and semen plasma samples during the longitudinal cohort 
study, demonstrating shedding of HIV viruses in blood among four participants with schistosomiasis 




Baseline 1-month 3-months 6-months 12-months 
BLOOD SEMEN BLOOD SEMEN BLOOD SEMEN BLOOD SEMEN BLOOD SEMEN 
A UD UDα       D UD 
B UD UD UD UD       
C UD Dβ         
D UD Dα UD UD UD UD   UD UD 
E UD UD UD Dα UD 2.09 UD Dα UD UD 
G UD UD UD UD UD UD UD UD UD UD 
H D UD UD UD D UD     
I UD  UD UD D UD UD UD UD UD 
J 2.32 UD 1.98 UD   D UD   
K UD UD         
L 3.32 UD     2.91 UD 2.44 UD 
M UD UDα   D UD     
N D UD D UD D UD UD UD   
O UD UDα       D UD 
P 4.75 UD         
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BASELINE 1-MONTH 3-MONTHS 6-MONTHS 12-MONTHS 
Schistosome HIV VL Schistosome HIV VL Schistosome HIV VL Schistosome HIV VL Schistosome HIV VL 
UF SEM IVD DRG PCR BLD SM UF SEM PCR BLD SM UF SEM PCR BLD SM UF SEM PCR BLD SM UF SEM PCR BLD SM 
E 2.1 0.0 0.32 0.61 36.1 UD UD 0.0 0.0 NEG UD Dα 0.0 0.0 22.5 UD 2.09 0.0 0.0 23.4 UD Dα 0.0 0.0 NEG UD UD 
F 0.0 0.0 0.10 0.12 NEG 4.06 UD 0.0 0.0 NEG 4.16 UD 0.0 0.0 NEG 4.15 UD      0.0 0.0 25.1 4.46 UD 
J 0.0 0.0 0.09 0.17 36.6 2.32 UD 0.0 0.0 NEG 1.98 UD      0.6 0.0 NEG D UD      
L 0.1 0.4 0.24 0.74 NEG 3.32 UD           0.0 0.0 NEG 2.91 UD 0.0 0.0 35.0 2.44 UD 
P 0.0 0.0 0.24 0.46 21.3 4.75 UD                     
Schistosome = schistosome parasitological, serological and molecular tests (  = positive result), HIV VL = HIV viral load analyses (in log 10 copies/ml,  = number of 
detected viral copies,  = detectable but unquantifiable viral copies); UF = urine filtration (eggs / 10ml urine), SEM = seminal microscopy (eggs /ml ejaculate), IVD and DRG 
= serological ELISA tests, PCR = seminal real-time polymerase chain reaction (PCR) analyses (Ct-value, NEG = negative), BLD = blood plasma, SM = seminal plasma. D = 
detectable but not quantifiable in blood (VL: 1.39 – 1.59 log 10 copies/ml), UD = undetectable in blood (VL < 1.39 log 10  copies/ml); Dα = detectable but not quantifiable in 
semen (VL: 1.74 – 2.04 log 10 copies/ml), Dβ = detectable but not quantifiable in semen (VL: 2.34 – 2.60 log 10 copies/ml), UD = undetectable in semen (VL < 1.74 log 10  





8.4.4.2. Study controls 
Of the 16 participants who were already on ART and recruited as study controls at baseline, 
three (I, VI and XV) had detectable HIV VL, with two (I and XV) having discrepant detectable VL in 
blood plasma, whilst one (VI) had concordant VL in blood and semen plasma (Table 38). Two other 
control participants had detectable and quantifiable VL, one (II) at 1-month in blood plasma only, 
and the other (V) at 3-months in both blood and semen plasma. 
Table 38: Results of the HIV viral load analyses in the study controls 
Study control 
ID 
Baseline 1-month 3-months 6-months 12-months 
IVD DRG BLOOD SEMEN BLOOD SEMEN BLOOD SEMEN BLOOD SEMEN BLOOD SEMEN 
I + + D UD       D UD 
II - - UD UD 1.81 UD     D UD 
III + - UD UDβ   UD UDβ     
IV + + UD UDβ         
V - - UD UDα   4.03 2.72 UD UD D UD 
VI + + 4.43 3.68         
Figure 51: Progression of HIV-1 viral levels of detectable cases at all the study time-points 
HIV VL from blood plasma from all cases except semen plasma for case E; blood plasma VL of 1.39 log
 10
 
copies/ml or less is classified as undetectable; semen plasma VL of 1.74 log
 10
 copies/ml or less is classified 
as undetectable, VL of 2.04 log
 10
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IVD and DRG = serological ELISA tests; D = detectable but not quantifiable in blood (VL: 1.34 – 1.59 log 10 
copies/ml), UD = undetectable in blood (VL < 1.34 log 10 copies/ml); UD = undetectable in semen (VL < 55 
copies/ml), UDα = undetectable in semen (VL < 2.04 log 10 copies/ml), UDβ = undetectable in semen (VL < 
2.34 log 10 copies/ml) 
8.4.5. Comparison of detectable HIV-1 viral levels between study cases and controls 
Twelve of 15 cases (80.0%) had detectable HIV VL compared to 5 of 16 controls (31.3%) in 
the study. Three cases (J, L and P) had detectable and quantifiable VL in blood plasma at baseline, 
ranging from 2.32 to 4.75 log 10 copies/ml (mean VL:  3.32 log 10 copies/ml), which was higher 
compared to that of two control participants, 1.61 and 4.43 log 10 copies/ml (mean VL: 3.02 log 10 
copies/ml).  
On follow-up after PZQ treatment, the VL showed a downward trend as the schistosome 
infection was clearing. The blood plasma VL of one case participant (J) present at 1-month time-
point reduced by 0.34 log 10 copies/ml, observed at 1.98 log 10 copies/ml, where all the schistosome 
tests were negative, and at 6-months’ time-point, had detectable but unquantifiable VL despite 
having UGS (schistosome eggs in urine). Similarly, blood plasma VL of the other MGS participant (L) 
followed up at 6- and 12-months’ time-points, declined to 2.91 and 2.4 log 10 copies/ml respectively. 
 
  
VII - + UD UD UD UD UD UD UD UD   
VIII + + UD UD         
IX + + UD UD         
X - - UD UD     UD UD   
XI - - UD UD         
XII - - UD UD         
XIII + + UD UD   UD UD     
XIV - - UD UD         
XV - - 1.61 UD         




This is the first epidemiological pilot study to measure the HIV-1 viral levels in blood and 
semen plasma of men on ART with MGS in endemic areas of SSA. It reveals a potential impact of 
MGS on HIV management and monitoring of viral suppression, from ART, and as a pilot study, 
suggests larger surveys are warranted to elucidate fully this relationship. 
It is recognised that the risk of HIV-1 sexual transmission among serodiscordant couples is 
zero when the infected partner is on effective ART regime and has a fully suppressed VL (Cohen et 
al., 2011; Rodger et al., 2016; Rodger et al., 2019).  
However, those on ART with suppressed VL in blood can have intermittent shedding and 
detectable HIV RNA in semen and genital tract fluids, even in absence of STIs and other 
inflammatory infections (Kalichman, Di Berto and Eaton, 2008; Lambert-Niclot et al., 2012), which 
raises significant concerns at a public health level. In this study, where more case participants with 
schistosomiasis, specifically MGS, had higher detectable and quantifiable VL at baseline compared 
with the control participants, it is suggestive of increased risk of HIV transmission. This is in line with 
evidence that schistosome egg excretion has been associated with increased HIV-1 VL in plasma 
(Karanja et al., 1997; Mwanakasale et al., 2003). 
This pilot study has detected a decline in VL on follow-up time-points after standard single-
dose PZQ treatment, where case participants also had reduced schistosome infections. Other 
prospective studies in SSA have reported similar results (Kallestrup et al., 2005a; Erikstrup et al., 
2008), coinciding with suggestions by a Cochrane review that treatment of helminth infections in HIV 
co-infected people may contribute to decline of their HIV-1 RNA VL (Means et al., 2016). A recent 
observation study on Zimbabwean men reported high VL in HIV-1 positives with UGS, which 
decreased 10 weeks after PZQ treatment (Midzi et al., 2017).  
In terms of longitudinal dynamics, further follow-up of the participants revealed rebound 
detectable VL among some case participants, despite continued long-term ART and PZQ treatment. 
This could be due to re-infection with schistosomes, incomplete cure of previous schistosome 
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infection, low ART adherence, presence of other infections like malaria, TB, other helminths or STIs, 
which were not detected in the study, as well as poorer ART performance (possible failure), other 
host or viral genetic factors.  
Although some case participants with MGS in our study were observed to have small 
amounts of VL reported as detectable but unquantifiable VL, it has been recognised not to correlate 
with HIV transmission risk due to negligible risk  achieved on fully suppressive ART consistently for at 
least 6 months (BHIVA, 2018). However, discrepant detectable VL suggest the different suppressive 
nature of ART in various body compartments especially TNF regimen which have been reported 
before (Ghosn et al., 2004; Lowe et al., 2006). Currently, the HIV treatment in Malawi has changed in 
2019 to dolutegravir regimen. 
Though this pilot study has shown the potential for a relationship between MGS, PZQ 
treatment and HIV VL, the study was limited in its statistical power by low number of participants 
submitting fewer samples during time-points, high numbers lost to follow up and meagre field 
resources, affecting the comparability of our results to previous studies and generalisation to the 
male population in the country and SSA region. This reaffirms the call for more prospective studies 
on co-infection of MGS and HIV with larger sample size of this high-risk male population in endemic 
areas. 
8.6. Conclusion 
 In conclusion, detectable VL was noted in some HIV-positive men who had MGS and 
displayed a downtrend after PZQ treatment on subsequent time-points while others had rebound 
detectable VL and schistosome re-infection. Therefore, PZQ treatment in endemic areas as multiple 
or repeated doses, bi-annual MDA is essential with synergising of schistosomiasis control strategies 
in the HIV program for cost-effective impact of both diseases among co-infected men, following 











This chapter discusses the main findings of the longitudinal cohort study on MGS, in line with 
the research hypothesis and objectives. Special focus is being put on the recommendations for 
diagnosis and management of MGS which reflects on a proposed algorithm, and role of other point-
of-care examination tools such as ultrasonography in determining the morbidity of MGS. This is 
critical to be incorporated in the activities for the national schistosomiasis control programme in 
Malawi and other endemic countries in SSA and globally.  
The interrelationship of HIV and MGS infections is also highlighted and possible role of both 
PZQ and ART together with regular viral load monitoring, adherence and treatment of other 
opportunistic infections, in controlling and managing both infections. Integration of control 
programmes in Malawi and other affected areas is very important in successful control of both 
diseases.  
Finally, suggestions for future work are presented to produce more evidence and improve 





9.2. Prevalence of MGS 
Schistosomiasis remains a prevalent parasitic disease affecting over 200 million people in 
tropical countries, especially SSA, where 85% inhabit, contributing to significant morbidity and 
considerable mortality in the world (WHO, 2018b). This neglected tropical disease (NTD) poses a 
significant public health challenge in most endemic rural and peri-urban areas, with its burden in 
2016 estimated at 2 543 364 disease-adjusted life years (DALYs) (WHO, 2018c), most arising for 
urogenital Schistosoma haematobium infections.  
The World Health Organisation (WHO) recommends preventive chemotherapy (PC) through 
periodic mass drug administration (MDA) of anthelmintic praziquantel (PZQ) as an appropriate 
measure for morbidity control, targeting at least 75% of school-aged children (SAC) in all 
schistosomiasis-endemic countries by 2020. In addition to PC, other recommended strategies 
include strengthening health systems, improving water and sanitation, hygiene education and snail 
control (WHO, 2012). Apart from SAC, other people considered for PC include adults at-risk such as 
fishermen, farmers and women in contact with infested waters, pre-school aged children (Pre-SAC) 
as well as entire communities in high-risk areas (WHO, 2006). As of 2017, 98.7 million people 
received PC globally, with the African region where 90.4% of those requiring PC live, treating 75 
million SAC and 12.4 million adults. Renewed commitments in accomplishing schistosomiasis control 
have been highlighted by various key stakeholders in NTDs.  
Despite the tremendous progress in delivery of PZQ treatments in endemic areas, the 
burden of schistosomiasis remains high with most people suffering the chronic consequences of the 
disease. These chronic consequences usually develop insidiously during childhood and present in 
later years of life as illustrated in Figure 52 (Bustinduy et al., 2014). In S. haematobium infection 
causing urogenital disease of which its complications have been described in literature, genital 
consequences have been understudied, and its epidemiology has been ignored in the recent 






Figure 52: Stages of schistosomiasis disease from infection with schistosome cercariae to chronic consequences and HIV interplay 
Photo credits: Dr Sekeleghe Kayuni, LSTM, June 2018. 
 
  
Infection with cercariae 
occur early in life 
Develops and present with symptoms of acute 
schistosomiasis 
Untreated infection or re-infection with schistosomiasis results in chronic schistosomiasis which include 
male genital schistosomiasis. Then, HIV infection may appear in late adolescent or adult age 
adolescence  growing into  adulthood 
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Among such chronic genital consequences, male genital schistosomiasis remains the most 
unknown, unrecognised and undertreated manifestation of chronic urogenital schistosomiasis 
(UGS), unlike female genital schistosomiasis (FGS) which has received increased attention (Kjetland, 
Leutscher and Ndhlovu, 2012; Christinet et al., 2016). This arises from undefined standard method 
for diagnosing MGS which result in under- and misdiagnosis as sexually transmitted infections (STIs) 
which are also prevalent in most schistosomiasis-endemic areas especially among young sexually 
active men.  
On the other hand, there have been advances in describing the definite standard tool and 
diagnostic algorithm for FGS (WHO, 2015a). By contrast, wet mount semen microscopy is the 
method commonly used for diagnosing MGS, however due to the logistical challenges with semen 
submission and handling, urine microscopy has been used as proxy method instead, which poses 
challenges with regards to its diagnostic sensitivity and specificity. 
This longitudinal cohort study on MGS which was conducted among local fishermen from a 
schistosomiasis-endemic area, along the south shoreline of Lake Malawi in Mangochi District, 
observed that 36 study participants had urine-patency S. haematobium eggs, giving a baseline 
prevalence of 17.1% for UGS. Also, twelve participants had S. haematobium eggs in semen, thus 
10.4% prevalence for MGS.  This highlights the existence of MGS in local male inhabitants of an 
endemic area in Malawi which has never been reported previously, at similar level as that of UGS. 
Furthermore, it was noted that a substantial proportion of participants (66.7%) had 
schistosome eggs in semen only but none in urine, which illustrate the possible locations of the 
schistosome worms in blood vessels surrounding genital organs like prostate, seminal vesicles, testes 
and scrotum. This also demonstrates that using urine filtration as a proxy technique in diagnosing of 
MGS is challenged by limited sensitivity and specificity as this will not detect all infected people. As 




In addition, the classical symptoms of MGS in literature were reported by less than 5% of 
participants and none of them had schistosome eggs in semen. This shows that local people in 
endemic areas with MGS do not commonly present with symptoms, which would likely result in 
underdiagnosis or mis-diagnosed as STIs (Ukwandu and Nmorsi, 2004; Yirenya-Tawiah, Ackumey and 
Bosompem, 2016). However, some of those with symptoms had schistosome eggs in urine, which 
highlights the underlying infection and unspecific symptomatology of MGS.  
Although S. mansoni eggs which cause intestinal schistosomiasis were not detected in semen 
of our study cohort as shown in previous studies and literature (Adisa et al., 2012; Lima et al., 2017; 
Abdel-Naser et al., 2018b), 3.8% of the study participants submitting urine had a positive POC-CCA 
test, showing possible intestinal schistosomiasis infection. Although stool Kato-Katz analysis done at 
subsequent follow-up time-points did not find any S. mansoni eggs, Biomphalaria pfeifferi snails 
were found on the shoreline in the study area, together with autochthonous transmission of 
intestinal schistosomiasis (Alharbi et al., 2019). This elucidates the possibility that S. mansoni 
infection may also contribute to MGS in men, located in the vicinity of the transmission spots. It is 
also worthy to note that S. mansoni-associated MGS usually occurs as co-infection with urogenital S. 
haematobium (Kayuni et al., 2019a).   
This study presented novel results from longitudinal analyses of seminal samples using 
molecular real-time polymerase chain reaction (PCR) in a local at-risk male population in an endemic 
area of SSA. The prevalence of MGS with the highly sensitive diagnostic technique increased by more 
than 2.5 times from 10.4% by semen microscopy to 26.5% using real-time PCR, showing that 
microscopy suffer from lower sensitivity and specificity as it misses out more infected men in the 
area.  
Interesting, some participants who had schistosome eggs in semen were noted to be 
negative on real-time PCR people, alluding to possibility of excretion of dead eggs or egg shells into 
urine and semen which could not be leaking schistosome DNA to be detected by PCR, thereby 
picking up active MGS infection, rather than chronic, controlled infection by host immunity, which is 
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established in adulthood. Although, this discrepancy could also arise from other components in the 
semen acting as inhibitors, thereby affecting the performance and depicting as a limiting factor for 
this molecular technique in diagnosis of MGS, it was observed that our real-time PCR did not suffer 
any inhibition during the analyses.  
Therefore, molecular techniques have a critical role to play in diagnosis of MGS where 
available, emphasizing the need for development of more accessible and affordable sensitive tools, 
such as point-of-care dipstick tests, utilising the relevant background scientific knowledge. At 
present, no single method can diagnose all possible cases of MGS, hence a combination of disease 
symptomatology, clinical findings of examination and current readily available methods is needed as 
proposed in a structured algorithm which will help in improving the diagnosis of MGS, as illustrated 




Figure 53: Suggested algorithm for investigating and managing a suspected MGS patient 
 
Positive Negative Negative 
Patient presenting with classical symptoms of MGS (pelvic, 
coital, ejaculatory or genital organs’ pain; haemospermia; 
abnormal ejaculates; scrotal swelling, infertility) 
Clinical examination including genital system 
Lab investigations to include POC-CCA and urine filtration 
Discharge and review after 4 weeks 
with POC-CCA and urine filtration 
Treat with single dose 
Praziquantel (40 mg/kg) and 
follow-up after 4 weeks with 
POC-CCA and urine filtration 
Repeat Praziquantel (40mg/kg) and 
follow-up after 4 weeks 
Request for semen sample for 
microscopy, possibly using the 
clean, transparent plastic bag 
Positive Negative 
If other conditions are 
excluded, perform pelvic and 
genital ultrasonography; 
repeat urine & semen analysis 
Conduct real-time PCR on semen 
and urine and treat if positive 
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9.3. Morbidity and treatment of MGS 
Chronic schistosomiasis such as MGS is associated with pathological lesions in various genital 
organs in infected men, arising from the inflammatory reactions, granulomata, fibrosis and 
calcifications. This is an on-going process which will arise from younger age progressing into later 
years of life, if no PZQ treatment is provided. These lesions have been reported to be detectable 
using radiological techniques such as ultrasonography (US), computerised tomography (CT) or 
magnetic resonance imaging (MRI) (Richter et al., 1996; Richens, 2004; Ramarakoto et al., 2008; 
Shebel et al., 2012).  
Specialised US such as transrectal US (TRUS) have been shown to be essential in definitively 
describe genital lesions associated with diseases affecting genital organs including tuberculosis, 
prostatitis, benign prostatic hyperplasia, malignancy, MGS among others. However, in rural endemic 
areas, portable transabdominal USS are seen to be useful in eliciting pathological lesions arising in 
genital organs from schistosomiasis. 
This cohort study utilised a portable Chison Q5 scanner with acceptable convex 3.5 MHz 
probe to perform transabdominal and scrotal ultrasonography on the consenting participants. At 
baseline, nine participants (6.9%) were observed to have abnormalities in prostate, seminal vesicles, 
epididymis and testes. The observed abnormalities which could suggest MGS include grossly 
enlarged prostates (3 with one having nodule), enlarged hyperechoic seminal vesicles (3), testicular 
nodule (1) while four had hydrocele which could arise from other infections. Excluding the four with 
hydroceles, four of these 5 participants had no schistosome eggs in urine or semen and were 
negative for semen real-time PCR. Three of the four who had hydrocele were also negative for MGS. 
Two of the 9 participants only reported experiencing pain of their genital organs in the month 
preceding the onset of the study, among the possible classical symptoms associated with MGS 
including haemospermia, coital or ejaculatory pain.  
These baseline findings illustrate that transabdominal and scrotal ultrasonography plays an 
important role in identifying genital lesions arising from MGS, as more diagnostic tests-negative 
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participants were observed to have such lesions. Radiological examination provided at first 
healthcare facility in the rural endemic area such as portable US scanner can contribute to improving 
detection of MGS. Furthermore, other possible diseases were excluded during the study from 
individual questionnaire interviews in lack of constitutional symptoms of diseases like tuberculosis, 
diagnostic tests such as prostatic specific antigen which were negative as well as long-term follow 
during the 12-months cohort study.  
Interestingly, follow-up of study participants revealed new lesions in previously normal 
participants, resolution of previous lesions as well as persistent lesions, which have also been 
described in published manuscript in Appendix 23 (Kayuni et al., 2019c). This was associated with 
clearance of infection due to PZQ which was provided at each time-point, especially at 1-month 
follow-up where none of the participants had schistosome eggs detected in semen but resurfaced at 
the subsequent time-points. Also, those chronic pathological lesions such as hyperechoic vesicles or 
hydroceles can be irreversible and not respond to PZQ treatment, let alone standard single dose, 
which explains the persistence in some participants. Such participants require additional medical 
management procedures such as surgical drainage of hydroceles to correct the pathology.  
Re-infections arising from re-exposure to same infested water bodies could contribute to 
new lesions developing despite previous treatment. This echoes the need for comprehensive control 
strategies including water, sanitation and health interventions which advocate for access to 
adequate, safe and clean water to deter people from re-exposing themselves to cercariae-infested 
waters. Another intervention is more involvement of men especially those at high-risk for 
schistosomiasis infection like fishermen in PC during MDA with PZQ. Malawi does conduct regular 
annual MDA campaigns which also targets adults in high risk areas such as along shoreline of Lake 
Malawi.  
However, from this study 34.8% of participants accessed PZQ treatment in the last 12 
months at baseline, with 61.7% reporting experiencing difficulties in accessing the treatment. There 
is need to elicit more information to understand factors contributing to this low access of PZQ in 
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men, and devise interventions to include men in this PC with MDA program. In addition, increasing 
the frequency of MDA especially in high-risk areas to all populations could be a way forward in 
arresting this infection and control its morbidity while introducing other strategies like snail control. 
Although transabdominal ultrasonography is a non-invasive diagnostic tool in 
schistosomiasis, it is neither sufficiently sensitive nor specific in detecting morbidity lesions of MGS 
as observed in this longitudinal cohort study as compared to transrectal ultrasonography, CT 
scanning and MRI. From this study, it remains unproven as a method for securing a clinical diagnosis 
for assessing prostate and seminal vesicles, affecting sensitivity, despite being only feasible method 
where available in this setting. 
Furthermore, the WHO developed practical guide to standardise use of ultrasonography for 
assessment of schistosomiasis-related morbidity, known as the ‘Ultrasound in Schistosomiasis 
Niamey protocol’ over two decades ago (WHO, 2000). However, this protocol in addition to recent 
manual of diagnostic ultrasound (WHO, 2011) does not provide detailed guidelines and descriptions 
of morbidity associated with genital schistosomiasis especially MGS. With regards to our novel 
findings on MGS lesions in genital organs, which resolve with PZQ treatment, updated standard 
guidelines on genital schistosomiasis is being advocated to aid in diagnosis of parasitological 






9.4. HIV and MGS co-infection 
Co-infections of HIV and schistosomiasis have been seldomly researched in endemic areas 
despite the two sharing geographical overlap in their epidemiology (Ndeffo Mbah et al., 2013). The 
risk of HIV infections has been observed to increase in women suffering from genital schistosomiasis 
by 2-3 fold , arising from mucosal structural breach which necessitate easier viral entry, 
inflammations triggering increased CD4+ receptor cells to the genital regions thereby increasing viral 
uptake in addition abnormal vasculature formation which increase blood flow and cells (Kjetland et 
al., 2006; Downs et al., 2011; Jourdan et al., 2011). On the other, schistosomiasis in men has been 
associated with some increased risk of HIV transmission through elevated inflammatory cells and 
cytokines which could increase viral load (VL) in semen (Leutscher et al., 2005; Leutscher et al., 
2008b; Downs et al., 2017a). In addition, men with both infections have been noted to have lower 
CD4+ cells levels as well as higher viral load which improve after PZQ treatment (Kallestrup et al., 
2005a; Midzi et al., 2017).  
Although, this evidence illustrates the critical role of schistosomiasis treatment on HIV 
disease progression and control, other studies have shown no beneficial or adverse effects of PZQ 
treatment on HIV infection, resulting in raising further reduction of CD4+ cells and increasing VL 
(Lawn et al., 2000). This has energised the need for more studies to understand the interactions 
between coinfections of HIV and MGS and impact of regular PZQ treatment and PC in at-risk men of 
endemic areas. 
Our longitudinal study recruited participants co-infected with HIV infections and active 
schistosomiasis especially MGS as cases and only HIV infections as controls in a pilot design due to 
the lack of previous studies and limited resources. At baseline, more study cases were observed to 
have discrepant detectable and quantifiable HIV VL in blood plasma which was higher than control 
participants. This suggest that the study participants had a larger number of viral copies in 
circulation which could means higher possibility of transmitting HIV to their sexual partners. 
Although these study cases had no detectable VL in semen, it is widely recognised that detectable 
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blood plasma VL is associated with increased HIV infectiousness and transmission. In this study, the 
cases with detectable VL were noted to have MGS as well, which allude to the point that despite the 
effective action of combined highly-active ART in suppressing HIV, schistosomiasis could have had 
resilient systemic immunomodulatory effect, compromising their effect.  
Furthermore, after providing PZQ treatment, follow-up showed some clearing of MGS 
infection as well as downward trend in the VL of those participants which supported the existing 
evidence of the important role played by this antihelminth in helping supress the virus, in addition to 
other factors like ART adherence. Antihelminth treatment have been advocated to co-infected with 
HIV and helminth in order to aid in managing the HIV disease, as such regular PZQ treatment 
through PC should be given at least twice a year to men and women on ART in schistosomiasis-
endemic areas. This should be provided alongside intermittent treatment where symptoms of 
schistosomiasis or MGS present or diagnosis of infection is made, in order to reduce the possibility of 
detectable viruses.  
The effects of active and past schistosome infections on HIV infection dynamics with regards 
to viral suppression in era of ART remain unknown. In this study, using results of two serological 
diagnostic tests, there was no direct association with detectable VL in the study cases although two 
of the 3 study controls with detectable blood plasma VL were seropositive at baseline. We 
considered active infection as a contributor to the immune effect on HIV infections. 
Re-infection arising from re-exposure to same cercariae infested waters could result in blips 
or rebound detectable VL after successful viral suppression, as observed in some study cases on long 
-term follow-up of 3-, 6- and 12-months’ time-points. Repeated treatments as well as other 
schistosomiasis control strategies described earlier could be useful in preventing these rebound VL 
as this propagate viral mutations and development of resistant viral copies which could not be 
completely suppressed as observed in one study case who remained unsuppressed despite being on 
treatment. Coordinating and synergizing control strategies of both infections can contribute towards 
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morbidity control of schistosomiasis, maintain viral suppression and arrest HIV disease progression, 






Figure 54: HIV and MGS co-infection and suggested management of an infected fishermen 
Health education, community awareness and self-help campaigns of both HIV and schistosomiasis should be provided at all stages of life. 
Photos credit: Dr Sekeleghe Kayuni, LSTM, June 2018. 
Frequent contact 
with infested water 
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• Testing & PZQ treatment 
• Annual MDA with PZQ, twice 
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• HIV testing 
• ART initiation 
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Infected with cercariae, 
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HIV-MGS co-infection 
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240 
 
9.5. Future work 
As highlighted earlier, this longitudinal cohort study had limitations of sample size, affecting 
the power of generalising its results to the male population in the region. However, the novel 
findings in this study advocate for further multi-site research study in deeper understanding of the 
pathogenesis of the MGS which will help in identifying specific key components including proteins, 
glycans in blood, urine or semen which could be useful in development of sensitive and specific 
point-of-care diagnostic tool, to be accessible and available in endemic areas.  
In addition, further research on point-of-care radiological diagnosis of MGS using accessible 
portable tools such android ultrasonography gadgets would be helpful to elicit pathological lesions 
earlier and drive earlier adequate treatment to clear the infection and achieve resolution of the 
lesions. This will aid in updating the available standard guidelines for ultrasonographic examination 
of MGS which is lacking despite huge advances in similar guidelines on FGS and acceptable Niamey 
protocol for urogenital and intestinal schistosomiasis where genital schistosomiasis in not included.     
Treatment dosing of PZQ in MGS need to be explored further to define the optimal dosage 
for treating acute cases of MGS, in order to prevent and resolve early pathologies elicited by the 
schistosomes. Also, there is need to assess whether the determined dose could prevent 
development of MGS after re-infections with cercariae. 
Furthermore, there is need to research psychosocial dynamics of MGS among at-risk and 
infected men, social determinants and economic implications in the communities in endemic areas, 
community perceptions on health with regards to MGS as well as FGS, applicable prevention and 
control strategies to the infection, and ascertain the best model on combined comprehensive 
strategies for managing both genital schistosome infections.   
In relation with HIV infection, there is need for a larger, prospective study to validate the 
observations in our novel pilot study on MGS potentially impacting the HIV-1 shedding in men’s 
plasma. Also, there is need to study further on the natural history of both infections, role of 
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preventive antihelminth treatments in HIV control by maintaining viral suppression by antiretroviral 
treatment, best time and frequency for PZQ treatment in prevention and / or resolution of early 
MGS morbidity and worsening especially in view of newer ART regimens like dolutegravir combined 
regimens recently incorporated in SSA countries like Malawi. Also, social determinants and 
community understanding of both infections and devise management approach form community to 
health facility level.  
Finally, developing educational tools for training for key health professionals and raising 
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I am Seke Kayuni. 
I would like to find out the level of genital 
schistosomiasis infection and possible HIV 
interactions in fishermen along Lake Malawi. 
Schistosomiasis is an infection caused by flatworms, 
present in parts of Malawi especially along Lake 
Malawi. HIV is a virus which cause AIDS, affecting 
people and causing deaths in Malawi. Some people 
can be infected with the two diseases at the same 
time. 
I will be working with fishermen in the area, to test 
for genital schistosomiasis in those HIV positive or 
negative.  You are being requested to take part in the 
Study. Your participation in this study is voluntary. 
What will you do? 
You will be asked questions about your health, 
knowledge and practices related to schistosomiasis 
and HIV. You will be requested to provide urine and 
semen samples for testing of the genital 
schistosomiasis at the health centre and LSTM 
laboratory in the UK. 
You will also be offered an ultrasound scan to see any 
effect of the schistosomiasis infection on your 
internal genital organs. You will be informed about 
the results and offered Praziquantel treatment for 
schistosomiasis. 
Are there any costs of the Study? 
The tests and treatment will be provided free-of-
charge. 
There will be no payment provided for participating in 
this study. 
What are the benefits and risks of the Study? 
The information you will provide, and the tests results 
are important in assisting the Ministry of Health and 
other organisations in improving treatment and 
control of schistosomiasis and HIV/AIDS. 
There is no risk or harm in taking part in the Study 
and you can opt-out from the Study at any time.  
Your name, answers and test results will be treated 
with privacy and confidentiality, will not be given to 
people not involved in the Study or medical care.  
Participation in this Study will be of great value to the 
healthcare delivery in Malawi. 
Further Information 
You can get more information about the Study, your 
rights or to report any harm or injury because of 
participating in this Study, from the following: 
District Health Officer, Mangochi District Hospital, 
P.O. Box, Mangochi. 
 
Dr. Sekeleghe Kayuni (+265 995 645 647) 
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Appendix 7: Participant information sheet for the MGS research study (in Chichewa)
 
Kafukufuku Wofuna Kuona 
Chiwerengero Cha Asodzi 
Amene Ali Ndi Likodzo Okhala 
M’bali Mwa Nyanja Ya 
Malawi. 
Ine dzina langa ndi Seke Kayuni. 
Ine ndikupanga kafukufuku ofuna kuona kuchuluka kwa 
matenda a Likodzo yokhuza njira yaumuna ndi EDZI mwa 
asodzi okhala m’madera oyandikana ndi Nyanja ya Malawi. 
Likodzo ndi matenda amene amayamba ndi tinyongolotsi 
timene tili m’madera ena mu Malawi, kwambiri mbali mwa 
Nyanja ya Malawi. HIV ndi kachilombo koyambitsa matenda 
a EDZI amene afalikira mu Malawi. Matenda awiriwa 
amapezeka pamodzi ndi anthu nthawi zambiri. 
Ine ndipanga Kafukufuku ndi asodzi omwe ali m’mderali, 
ndikuyeza za matenda a likodzo. Muli kufunsidwa kutenga 
nawo mbali pa Kafukufukuyu. 
Kodi ndidzapanga chiani? 
Inu mudzafunsidwa mafunso okhudza za umoyo wanu ndi 
zomwe mumadziwa za matenda a likodzo ndi EDZI. Kenako 
mudzapereka mkodzo ndi umuna kuti ukayedzedwe.  
Mudzafunsidwanso kujambulidwa ziwalo zachimuna poona 
za matendawa. Pamapeto mudzapatsidwa zotsatira ndi 
mankhwala. 
Kodi pali mtengo pa Kafukufukuyu 
Kuyezedwa ndi mankhwala ziperekedwa mwaulele.  
Ndipo simulandira malipiro potenga mbali pa Kafukufukuyu. 
Kodi pali mphindu kapena chiopsezo potenga mbali pa 
Kafukufukuyu 
Zomwe munganene pakafukufukuyu zidzathandiza unduna 
wa za Umoyo ndi mabungwe kupititsa patsogolo 
chithandizo cha mankhwala ndi kuchepetsa Likodzo ndi 
EDZI. 
Palibe choopsya chilichonse potenga nawo mbali pa 
Kafukufukuyu ndipo mutha kusiya kupanga nawo nthawi ina 
iliyonse.  
Dzina lanu, mayankho ndi zotsatira za kuyezedwa kwanu 
zidzasungidwa mwachinsinsi ndipo sidzizaperekedwa kwa 
anthu omwe sakupanga nawo Kafukufukuyu kapena 
opereka chithandizo cha chipatala.  
Kutenga mbali pa Kafukufukuyu kuthandiza kutukula ntchito 
za umoyo mu Malawi. 
Zambiri za Kafukufukuyu 
Ngati mukufuna kudziwa zambiri za Kafukufukuyu, ufulu 
wanu kapena kupereka chidandaulo mukutenga mbali, 
mutha kutero podziwitsa: 
District Health Officer, Mangochi District Hospital, P.O. Box, 
Mangochi. 




Appendix 8: Participant written informed consent form 
RESEARCH STUDY OF MALE GENITAL SCHISTOSOMIASIS AMONG ADULT FISHERMEN ALONG THE 
SOUTH SHORES OF LAKE MALAWI. 
Principal Investigator: Dr Sekeleghe Kayuni (LSTM), MASM, P.O. Box 1254, Blantyre. +265 995645647   
National Health Sciences Research Committee, Ministry of Health, P.O. Box 30377, Lilongwe 3.  
Introduction: Schistosomiasis (snail-borne disease) and AIDS (caused by a virus called HIV) are diseases which 
affect most people in Malawi, living along Lake Malawi.  
Purpose: This research study wilI look at the level of genital schistosomiasis and the effects of both diseases in 
adult fishermen males along Lake Malawi. 
Procedure: Individual questionnaire interviews will be done to find out about your health and issues about 
schistosomiasis and HIV. Urine and semen will be requested to test for genital schistosomiasis. You’ll be 
requested further if there will be needed to submit blood. Ultrasound scanning will be offered to you to look at 
your genital organs for effects of the infection. Some samples will be tested outside Malawi to get the results. 
You will be informed about the results and offered Praziquantel treatment. 
Benefits and risks: The information collected, and tests results are important in assisting the Ministry of Health 
and other organisations in improving treatment and control of schistosomiasis and HIV/AIDS. Participation in 
this Study will be of great value to the healthcare delivery in Malawi. There is no risk or harm in taking part in 
the Study and you can opt-out from the Study at any time.  
Privacy and confidentiality: You will be given a unique identifier (number) at the start of the study which will 
be used instead of your name. Your name, answers, testing including blood analysis and results will be treated 
with privacy and confidentiality, will not be given to people not involved in the Study or medical care. 
Study Approval:  
National Health Sciences Research Committee, Ministry of Health, P.O. Box 30377, Lilongwe 3. Malawi. 
Approval number: 1805  
Liverpool School of Tropical Medicine, Research Ethics Committee, Pembroke Place, Liverpool L3 5QA, 




I ................................................................................... have read the information leaflet which explains about 
schistosomiasis, what you are trying to find out, how you will find out and why you would like to talk to me. 
Please mark in the box if you think the statement is true: 
• I have asked all the questions I needed to and am happy with answers given    
• I understand that you will not tell anyone what I have told you       
• I allow you to write about what I have said and not using my real name     
• I understand that I don’t have to answer questions that I don’t want to talk about     
• I know that I can stop my participation at any time and without giving a reason    
• I understand that you wilI test my samples to a laboratory in the UK to get my results   
• I understand that I can get my test results and treatment where necessary if I want    
• I understand that I can look at the report for this study if I want to      
• I would like to take part in the Study. I can still change my mind any time     
 
My questions have been answered by ...................................................................................... 
 














Appendix 9: Participant written informed consent form (in chichewa) 
KAFUKUFUKU WOFUNA KUONA CHIWERENGELO CHA MATENDA A LIKODZO MWA AMUNA 
OKHALA M’BALI YA NYANJA YA MALAWI. 
Principal Investigator: Dr Sekeleghe Kayuni (LSTM), MASM, P.O. Box 1254, Blantyre. +265 995645647   
National Health Sciences Research Committee, Ministry of Health, P.O. Box 30377, Lilongwe 3.  
Mau oyamba: Likodzo ndi EDZI ndi matenda omwe amakhudza anthu ambiri m’madera a mbali mwa Nyanja ya 
Malawi.  
Cholinga cha kafukufukuyu: Kafukufukuyu akufuna kupeza kuchuluka kwa matenda aLikodzo pakati pa asodzi 
m’mderali, ndikuona zokhuzana ndi matenda a EDZI. 
Dongosolo la kafukufukuyu: mudzafunsidwa mafunso okhudza za umoyo wanu ndi zomwe mumadziwa za 
matenda a likodzo ndi EDZI. Kenako mudzapereka mkodzo ndi umuna kuti ukayedzedwe, kwa ena, 
muzafunsidwanso kepereka ndi magazi. Kuyezedwa kwina kudzapangidwa kunja kwa Malawi pofuna kupeza 
zotsatira zanu. Mudzafunsidwanso kuuninikidwa ziwalo zachimuna poona za matendawa. Pamapeto 
muzauzidwa zotsatila komanso mudzapatsidwa mankhwala.  
Ubwino ndi chiopsezo pa kafukufukuyu: Zomwe munganene pakafukufukuyu zidzathandiza unduna wa za 
Umoyo ndi mabungwe kupititsa patsogolo chithandizo cha mankhwala ndi kuchepetsa Likodzo ndi EDZI. 
Kutenga mbali pa Kafukufukuyu kuthandiza kutukula ntchito za umoyo mu Malawi. Palibe choopsya 
chilichonse potenga nawo mbali pa Kafukufukuyu ndipo mutha kusiya kupanga nawo nthawi ina iliyonse. 
Chinsinsi chanu pa kafukufukuyu: Muzapatsidwa nambala poyamba pa kafukufukuyu yomwe izagwiritsidwe 
mmalo mwa dzina lanu. Dzina lanu, mayankho, kuyezedwa ndi zotsatira zanu zidzasungidwa mwachinsinsi 
ndipo sizizaperekedwa kwa anthu omwe sakupanga nawo kafukufukuyu.  
Mabungwe Opereka Chilolezo cha kafukufukuyu:  
National Health Sciences Research Committee, Ministry of Health, P.O. Box 30377, Lilongwe 3. Malawi. 
Approval number: 1805  
Liverpool School of Tropical Medicine, Research Ethics Committee, Pembroke Place, Liverpool L3 5QA, 




Ine ................................................................................... ndawerenga chikalata chofotokoza za Likodzo, 
kafukufuku amene mukupanga, njira zomwe mugwiritse nchito ndi cholinga choyankhula nane. 
Chongani mu kabokosi ngati mwagwirizana ndi mawu ali m’munsimu: 
• Ndafunsa zonse zimene ndinafuna kudziwa ndipo ndakhutira ndi mayankho ndapatsidwa   
 
• Ndamvetsa kuti simuwudza munthu aliyense zomwe ndakuwudzani      
 
• Ndikulolani kulemba zomwe ndanena ndipo musagwiritse dzina langa     
 
• Ndamvetsa kuti nditha osayankha mafunso amene sindikufuna kuyankhulapo     
 
• Ndikudziwa kuti nditha kusiya Kafukufukuyu nthawi iliyonse, osapereka chifukwa     
 
• Ndamvetsa kuti zoyeza zina zikapangidwa kunja kwa Malawi kufuna kupeza zotsatira   
 
• Ndamvetsa kuti nditha kulandira zotsatira za kuyezedwa ndi chithandizo moyenera nditafuna  
 
• Ndamvetsa kuti nditha kuwerenga lipoti la Kafukufukuyu nditafuna      
 
• Ine ndikufuna kutenga nawo mbali pa Kafukufukuyu. Nditha kusintha nthawi iliyonse   
 
Mafunso anga ayankhidwa ndi ................................................................................................................ 
 














Appendix 10: Registration form for MGS participants in the study 
No. Name of Participant Study number Village Phone number Other contacts 
  BL/    
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      





Appendix 11: Registration form for HIV participants in the MGS study 
No. Name of Participant Study number Village Phone number Other contacts 
  H/    
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      





Appendix 12: Individual participant questionnaire 
Research study on Male genital schistosomiasis and HIV among Adult fishermen living in Southern 
shores of Lake Malawi (MGS Baseline & Follow-up Survey) 
Explanation: Put a tick () for the participant’s responses appropriately. If the boxes are not enough 
on one page, use another sheet. Return this and other sheets to the Study Investigator at the end.   
Date: (dd/mm/yy): __ __ / __ __ / __ __  Interviewer Name__________________________________ 
Consent checklist 
Has written consent been obtained?  Y      N      Only proceed if Y 
Section A:  Participant’s details 
1. Participant ID: __________________________________________________________________ 
2. Village: _______________________________________________________________________ 
3. T/A: __________________________________________________________________________ 
4. Name of nearest Health centre: ____________________________________________________ 
5. Gender: Male       Female       .  
6. Date of birth (dd/mm/yy): __ __ / __ __ / __ __  Age: _______________________________ 
7. Born where: ___________________________________________________________________  
8. How long have you been staying here: Years _____ Months: _____ Weeks: _____ Days: ______  
9. Weight (kg): ___________________________________________________________________  
10. Height (cm): ___________________________________________________________________ 
Section B:  General Health Information 
Are you experiencing the following symptoms now? In the last month? Put a tick () for Yes on all 
items mentioned or demonstrated: 
 Symptom Currently In last 
month 





11.  Fever      
12.  Headache      
13.  Fatigue      
14.  Abdominal cramping (pain)      
15.  Pain during urination (dysuria)      
16.  Frequency of urination      




Are you experiencing the following diseases now? In the last month? Put a tick () for Yes on all 
items mentioned or demonstrated: 
 
34. Did you take deworming medicine (albendazole) in the last month? Y         N      . 
35. Did you take schistosomiasis medicine (praziquantel) in the last month? Y         N      . 
36. Did you take antimalarial medicine in the last month? Y         N      . 
37. Did you take any other medicine in the last month? Y      N      . If Y, name _______________ 
_____________________________________________________________________________ 
The following questions are about HIV/AIDS: 
38. Did you attend any meetings about health education in the last month? Y         N      .  
39. Were any of the meetings about HIV/AIDS? Y         N      . 
40. Do you know what is HIV? Y         N      .  
41. Explain your answer in question 40._________________________________________________ 
_____________________________________________________________________________ 
42. Do you know what is AIDS? Y         N      .  
43. Explain your answer in question 42._________________________________________________ 
_____________________________________________________________________________ 
44. Do you know how HIV is transmitted? Y         N      .  
18.  Blood in urine (haematuria)      
19.  Blood in stool      
20.  Blood in semen      
21.  Pains during and / or after coitus      
22.  Pains on ejaculation      
23.  Pains of the genital organs      
24.  Other (please specify):      
 Disease Currently In last 
month 





25.  Malaria      
26.  Diarrhoea      
27.  Dysentery      
28.  Skin disease      
29.  Respiratory disease      
30.  Worm infestation      
31.  Schistosomiasis      
32.  Sexually transmitted infection (STI)      




45. Explain your answer in question 44._________________________________________________ 
_____________________________________________________________________________ 
46. Do you know how HIV is prevented? Y         N      .  
47. Explain your answer in question 46._________________________________________________ 
_____________________________________________________________________________ 
48. Have you been tested for HIV? Y         N      .  
49. If Y in question 48, can you tell us the results? Y         N      .  
If Y in question 49, tell us the HIV test results? Tick () for the relevant answer below: 
50. Positive (+)        .       
51. Negative (-)        .       
52. Do not remember       .  
53. If N in question 48, will you be willing to go for an HIV test? Y         N      .  
54. If N in question 53, may you tell us the reason(s)?______________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
Section C:  Hygiene and Sanitation Information 
55. Do you swim, walk or work in the Lake? Y         N      . (If N, go to question 57).   
56. If Y in question 55, how many times in a week?______________________________________ 
57. Do you bathe or wash in the Lake? Y         N      .  
58. If Y in question 57, how many times in a week?______________________________________ 
59. If Y in question 57, why do you bathe or wash in the Lake? ______________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
60. Do you wear shoes or long protective wear when in the Lake? Y         N      .  
61. If Y in question 60, how many times when in the Lake?__________________________________ 






63. Where is the main place you go to urinate?___________________________________________ 
64. Where is the main place you go to defecate?__________________________________________ 
65. Does your house have a toilet? Y         N      .  
66. If Y in question 65, do you use it? Y         N      .  
67. If Y in question 66, how many times in a week?________________________________________ 
68. If N in question 66, why do you not use it? ____________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
69. If N in question 66, where do you use the toilet?_______________________________________ 
_____________________________________________________________________________ 
Do you have access to treatments for schistosomiasis? Tick () for the relevant answer below: 
70. No, not at all        .       
71. Yes       .       
72. Do not know       .  
73. Refused to answer       .  
 
Section D:  Socio-economic characteristics 
What is your highest level of education? Put a tick () for Yes on only one option: 
 Level of Education Option 
74.  Never went to school  
75.  Not finished primary school (6 years)  
76.  Completed primary school  
77.  Not finished secondary school  
78.  Completed secondary school   
79.  Not finished tertiary/professional school  
80.  Completed tertiary/professional school  
81.  Don’t know  
82.  Refused  
 




If Y to question 83, can you tell us the job? Put a tick () for Yes on all items mentioned or 
demonstrated: 
 Type of Employment / Job Yes 
84.  Self-employed. Specify:  
85.  Fishing  
86.  Farming/agriculture  
87.  Clerk/administration  
88.  Health worker  
89.  Selling at market  
90.  Other. Specify:  
91.  Refused  
 
Other employment status, 
 Other Job Yes  
92.  Doing housework   
93.  Student  
94.  Retired  
95.  Long-term disabled  
96.  Unemployed  
97.  Don’t know  
98.  Refused  
 
If Y to question 85 (fishing), can you tell us more about your work by answering the following: 
99. How long have you been doing this job? __________________________________________ 
100. How often do you go for fishing? ________________________________________________ 
101. What kind of fish do you catch? _________________________________________________ 
102. Is the job (fishing) seasonal? Y         N      .  
103. If Y to question 102, when is the season? ______________________ 
104. If Y to question 102, what else do you do during off-season period? ____________________ 
__________________________________________________________________________ 
105. Do you migrate to other places during / after fishing? Y         N      . _____________________ 
106. If Y to question 105, how often do you migrate in a year?_____________________________ 
107. If Y to question 105, where do you migrate to? _____________________________________ 






109. Do you own a boat? Y         N      .  
110. What kind of boat? ___________________________________________________________  
111. Are you planning of getting a new boat? Y         N      .  
112. What kind of boat? ___________________________________________________________ 
__________________________________________________________________________  
Regarding marriage and family, 
Can you tell us about your relationship status: 
 Relationship Yes 
113.  Married   
114.  Co-habiting / engaged  
115.  Divorced  
116.  Single  
117.  Other. Specify:  
118.  Refused  
 
119. Do you have children? Y         N      . 
120. If Y to question 119, how many? ________________________________________________ 
121. If N to question 119, why? _____________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
122. Has your spouse / partner experienced stillbirth / abortion? Y         N      . 
123. Have you or your spouse / partner had childlessness after marriage/engaged? Y         N      . 
124. Have you or your spouse / partner experienced infertility? Y         N      . 











Does your spouse or partner experience the following symptoms: 
127. Lower abdominal pain? Y         N      . For how long _________________________________ 
128. Pain during / after coitus? Y         N      . For how long _______________________________ 
129. Bleeding during / after coitus? Y         N      . For how long ____________________________ 
130. Pain during menstruation? Y         N      . For how long ______________________________ 
131. Changes of menstrual flow / flow? Y         N      . For how long ________________________ 


















Appendix 13: Individual participant questionnaire (in chichewa) 
Kafukufuku wa matenda a Likodzo la amuna ndi HIV pakati pa Asodzi okhala m’mbali mwa nyanja 
ya Malawi (MGS Baseline & Follow-up Survey) 
Chidziwitso: Chongani () pa mayankho operekedwa ndi opangidwa kafukufuku. Pitilizani kulemba 
mayankho pa tsamba lina ngati malo oyankhira achepa. Mukamaliza, perekani mayankho onse kwa 
mkulu wa Kafukufukuyu.   
Tsiku: (dd/mm/yy): __ __ / __ __ / __ __  Opangitsa Kafukufuku ______________________________ 
Chilolezo cha opangidwa Kafukufuku 
Opangidwa kafukufuku apereka chilolezo cholemba?  Inde       Ayi       
Pitirizani Kafukufuku ngati avomera Inde 
Gawo A:  Mbiri ya Opangidwa Kafukufuku 
1. Nambala ya Opangidwa Kafukufuku: ________________________________________________ 
2. Mudzi: ________________________________________________________________________ 
3. Mfumu Yaikulu: _________________________________________________________________ 
4. Chipatala chapafupi: _____________________________________________________________ 
5. Ndinu: Mwamuna       Mkazi       .  
6. Tsiku lobadwa (dd/mm/yy): __ __ / __ __ / __ __  Zaka : ______________________________ 
7. Munabadwira kuti: ______________________________________________________________  
8. Mwakhala nthawi yaitali bwanji kuno: Zaka _____ Miyezi: _____ Sabata: _____ Masiku: ______  
9. Thupi kulemera (kg):____________________________________________________________  
10. Msinkhu kutalika (cm): __________________________________________________________ 
Gawo B:  Mbiri ya Zaumoyo wanu 
Kodi mwakhala ndi zizindikiro monga izi? Tsopano? Kapena mu mwezi wapitawu? (Kwa ofunsa: 
Chongani () ngati Inde pa zizindikiro zonse zimene zayankhidwa ndi kusonyezedwa): 








11.  Kutentha thupi      
12.  Mutu kupweteka      
13.  Kufooka      





Kodi mwadwala matenda awa? Tsopano? Kapena mu mwezi wapitawu? (Kwa ofunsa: Chongani () 
ngati Inde pa matenda onse zimene zayankhidwa ndi kusonyezedwa): 
 
34. Kodi munamwa mankhwala a njoka zammimba (albendazole) mu miyezi 12 yapita? Inde    Ayi    . 
35. Kodi munamwa mankhwala a likodzo (praziquantel) mu miyezi 12 yapita? Inde         Ayi      . 
36. Kodi munamwa mankhwala a malungo mu miyezi 12 yapita? Inde         Ayi      . 
37. Kodi munamwa mankhwala ena aliwonse mu miyezi 12 yapita? Inde         Ayi      . Ngati Inde,  
tchulani dzina la mankhwala ___________________________________________________ 
Mafunso awa ndi okhudzana ndi kachilombo ka HIV ndi matenda a EDZI: 
38. Kodi munakhalapo nawo pa misonkhano ya zaumoyo mu miyezi 12 yapita? Inde      Ayi      .  
39. Kodi mmisonkhanoyi ina inalipo yokhudza za matenda a EDZI? Inde         Ayi      . 
40. Kodi mukudziwa kuti HIV ndi chiani? Inde         Ayi      . 
41. Longosolani kayankhidwe kanu pa funsoli (40): _______________________________________ 
_____________________________________________________________________________ 
42. Kodi mukudziwa kuti EDZI ndi chiani? Inde         Ayi      .  
43. Longosolani yankho lanu pa funsoli (42). ____________________________________________ 
15.  Kupweteka pokodza      
16.  Kukodza pafupi-pafupi      
17.  Kusinthika kwamtundu wa mkodzo      
18.  Magazi mu mkodzo      
19.  Magazi mu chimbudzi      
20.  Magazi mu umuna      
21.  Kupweteka pogonana      
22.  Kupweteka potulutsa umuna      
23.  Kupweteka kwa ziwalo za umuna      
24.  Zizindikiro zina (nenani)      








25.  Malungo      
26.  Kutsegula m’mimba      
27.  Kutsegula kwa kamwazi      
28.  Matenda a pakhungu      
29.  Chifuwa      
30.  Njoka za mmimba      
31.  Likodzo      
32.  Matenda opatsana pogonana      





44. Kodi mukudziwa mmene HIV imafalikira? Inde         Ayi      .  
45. Longosolani yankho lanu pa funsoli (44). ____________________________________________ 
_____________________________________________________________________________ 
46. Kodi mumadziwa mmene HIV ingapewedwele? Inde         Ayi      .  
47. Longosolani yankho lanu pa funsoli (46). ____________________________________________ 
_____________________________________________________________________________ 
48. Kodi munayezetsa za HIV? Inde         Ayi      .  
49. Ngati Inde pa funsoli (48), mungafotokoze za zotsatira zake? Inde         Ayi      .  
Ngati Inde pa funsoli (49), fotokozani za zotsatira za kuyeza kwa HIV? Ikani () pa yaknho loyenera: 
50. Ndili ndi HIV (+)        .       
51. Ndilibe HIV (-)        .       
52. Sindikukumbuka       .  
53. Ngati Ayi ku funso 48 (simunayezetse HIV), mungalore kuyezedwa za HIV? Inde         Ayi      .  
54. Ngati Ayi pa kuyezedwa, mungalongosole zifukwa zake? _______________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
Gawo C:  Zaukhondo ndi Kudzisamalira 
55. Kodi mumasambira, kuyenda kapena kugwira ntchito mu nyanja? Inde     Ayi      (pitani funso 57). 
56. Ngati Inde pa funsoli (55), mumatero kangati pa sabata? ________________________________ 
57. Kodi mumasamba kapena kuchapa mu nyanja? Inde         Ayi      (pitani funso 60).  
58. Ngati Inde pa funsoli (57), mumatero kangati pa sabata? ________________________________ 
59. Ngati Inde pa funsoli (57), chifukwa chiani? __________________________________________ 
_____________________________________________________________________________ 
60. Kodi mumavala nsapato kapena malaya otalika mu nyanja? Inde     Ayi     (pitani funso 63).  
61. Ngati Inde pa funsoli (61), mumatero kangati mukakhala mu nyanja? ______________________ 





63. Kodi mumakodza kuti?___________________________________________________________ 
64. Kodi mumachita chimbudzi kuti?____________________________________________________ 
65. Kodi nyumba yanu ili ndi chimbudzi? Inde         Ayi      (pitani funso 70).  
66. Ngati Inde pa funsoli (65), kodi mumagwiritsa ntchito Inde         Ayi      (pitani funso 68).  
67. Ngati Inde pa funsoli (66), mumagwiritsa ntchito kangati pa sabata? _______________________ 
68. Ngati Ayi pa funsoli (66), chifukwa chiani simugwiritsa ntchito? ___________________________ 
_____________________________________________________________________________ 
69. Ngati Ayi pa funsoli (66), mumagwiritsa ntchito chimbudzi chakuti? ________________________ 
_____________________________________________________________________________ 
Kodi mumatha kupeza mankhwala a likodzo? (Kwa ofunsa: Chongani () ngati Inde pa mayankho 
oyenera): 
70. Ayi        .       
71. Inde       .       
72. Sindikudziwa       .  
73. Sindiyankha       .  
 
Gawo D:  Zachikhalidwe ndi chuma 
Kodi munaphunzira pakana kalasi yanji? (Kwa ofunsa: Chongani () ngati Inde pa yankho limodzi 
loyenera): 
 Maphunziro Yankho 
74.  Sindinapiteko ku sukulu  
75.  Sindinamalize sukulu ya Pulaimale  
76.  Ndinamaliza sukulu ya pulaimale  
77.  Sindinamalize sukulu ya Sekondale  
78.  Ndinamaliza sukulu ya sekondale  
79.  Sindinamalize maphunziro a kukoleji  
80.  Ndinamaliza maphunziro a Koleji  
81.  Sindikudziwa  
82.  Sindiyankha  
 




Ngati Inde pa funsoli (83), mungafotokoze ntchito yanu? (Kwa ofunsa: Chongani () ngati Inde pa 
mayankho oyenera: 
 Mtundu wa ntchito Inde 
84.  Mumazilipila nokha. Nenani:  
85.  Usodzi  
86.  Ulimi  
87.  Ukalaliki  
88.  Ntchito ya chipatala  
89.  Kugulutsa mu msika  
90.  Ntchito zina, Nenani:  
91.  Sindiyankha  
 
 Ntchito ina Inde  
92.  Ntchito ya pakhomo  
93.  Mwana wa sukulu  
94.  Ndinapuma ntchito  
95.  Olumala  
96.  Sindili pantchito iliyonse  
97.  Sindikudziwa  
98.  Sindiyankha  
 
Ngati Inde pa funsoli (85) la zausodzi, mungafotokoze zambiri za ntchito yanu: 
99. Kodi mwagwira nthawi yayitali bwanji pa ntchito ya usodzi? ____________________________ 
100. Kodi mumachita usodzi kangati? ________________________________________________ 
101. Mumagwira nsomba za tundu wanji? ____________________________________________ 
102. Kodi mumapanga usodzi mwaka nyengo? Inde       Ayi     .(pitani funso xxx)  
103. Nyengo yake? _______________ 
104. Ngati Inde pa funsoli (102), mumapanga chiani nthawi yomwe simuweza? _______________ 
__________________________________________________________________________ 
105. Kodi mumapita madera ena nthawi ya usodzi? Inde         Ayi      . ______________________ 
106. Ngati Inde pa funsoli (104), mumapita kangati pa chaka? _____________________________ 
107. Ngati Inde pa funsoli (104), mumapita kuti? _______________________________________ 
108. Ngati Inde pa funsoli (104), mumayenda chifukwa chiani? ____________________________ 
__________________________________________________________________________ 
109. Muli ndi bwato lanu? Inde       Ayi     .  




111. Muli ndi ma pulani ogula bwato latsopano? Y         N      .  
112. Mtundu wa bwato lanu? _______________________________________________________ 
__________________________________________________________________________  
Zokhudzana ukwati ndi banja lanu, mungafotokoze zambiri, 
 Ukwati Inde 
113.  Okwatira  
114.  Unapanga unkhoswe  
115.  Banja linatha  
116.  Simunakwatirepo  
117.  Zina, nenani  
118.  Sindiyankha  
 
119. Kodi muli ndi ana? Inde         Ayi      .  
120. Ngati Inde, alipo angati? ______________________________________________________ 
121. Ngati Ayi pa funsoli (119), chifukwa chiani? _______________________________________ 
__________________________________________________________________________ 
122. Kodi akazi anu anapita padera ali woyembekezera? Inde         Ayi      . 
123. Kodi inu kapena akazi anu mukakhala opanda mwana m’banja? Inde         Ayi      . 
124. Kodi inu kapena akazi anu anakhalapo ndi vuto losabereka? Inde         Ayi      . 








Kodi akazi anu amaona zizindikiro izi: 
127. Kupweteka mmimba? Inde         Ayi      . Ngati inde, Kwa nthawi yaitali bwanji ____________ 




129. Kutaya magazi pogonana? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji ________ 
130. Kupweteka posamba? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji ___________ 
131. Kusintha kwa kusamba? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji __________ 




















Appendix 14: Individual HIV participant questionnaire 
Research study on Male genital schistosomiasis and HIV among Adult fishermen living in Southern 
shores of Lake Malawi (MGS-HIV Baseline Survey) 
Explanation: Put a tick () for the participant’s responses appropriately. If the boxes are not enough 
on one page, use another sheet. Return this and other sheets to the Study Investigator at the end.   
Date: (dd/mm/yy): __ __ / __ __ / __ __  Interviewer Name__________________________________ 
Consent checklist 
Has written consent been obtained?  Y      N      Only proceed if Y 
Section A:  Participant’s details 
1. Participant ID: __________________________________________________________________ 
2. Village: _______________________________________________________________________ 
3. T/A: __________________________________________________________________________ 
4. Name of nearest Health centre: ___________________________________________________ 
5. Gender: Male       Female       .  
6. Date of birth (dd/mm/yy): __ __ / __ __ / __ __  Age: _______________________________ 
7. Born where: ___________________________________________________________________  
8. How long have you been staying here: Years _____ Months: _____ Weeks: _____ Days:______   
9. Weight (kg):___________________________________________________________________  
10. Height (cm):___________________________________________________________________ 
Section B:  General Health Information 
Are you experiencing the following symptoms now? In the last month? Put a tick () for Yes on all 
items mentioned or demonstrated: 
 Symptom Currently In last 
month 





11.  Fever      
12.  Headache      
13.  Fatigue      
14.  Abdominal cramping (pain)      
15.  Pain during urination (dysuria)      
16.  Frequency of urination      




Are you experiencing the following diseases now? In the last month? Put a tick () for Yes on all 
items mentioned or demonstrated: 
 
34. Did you take deworming medicine (albendazole) in the last month? Y         N      . 
35. Did you take schistosomiasis medicine (praziquantel) in the last month? Y         N      . 
36. Did you take antimalarial medicine in the last month? Y         N      . 
37. Did you take any other medicine in the last month? Y      N      . If Y, name _______________ 
_____________________________________________________________________________ 
The following questions are about HIV/AIDS: 
38. Did you attend any meetings about health education in the last month? Y         N      .  
39. Were any of the meetings about HIV/AIDS? Y         N      . 
40. Have you experienced any problems after starting ART? Y         N      .  
41. Did you had any problems also related to genitourinary organs in last 12 months? Y      N     .  
42. If Y in question 41, may you tell the problems?_________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
43. Did you seek any help on the problems said in question 42? Y         N      .  
44. If Y in question 43, where did you get help?___________________________________________ 
18.  Blood in urine (haematuria)      
19.  Blood in stool      
20.  Blood in semen      
21.  Pains during and / or after coitus      
22.  Pains on ejaculation      
23.  Pains of the genital organs      
24.  Other (please specify):      
 Disease Currently In last 
month 





25.  Malaria      
26.  Diarrhoea      
27.  Dysentery      
28.  Skin disease      
29.  Respiratory disease      
30.  Worm infestation      
31.  Schistosomiasis      
32.  Sexually transmitted infection (STI)      




45. If Y in question 43, what help were you given?_________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
46. If N in question 43, may you tell the reason(s)?________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
47. Will you accept to do a full clinical examination including the genitourinary system? Y         N      .  
Section C:  Hygiene and Sanitation Information 
48. Did you swim, walk or work in the Lake? Y         N      . (If N, go to question 50).  
49. If Y in question 48, how many times in a week?______________________________________ 
50. Did you bathe or wash in the Lake? Y         N      .  
51. If Y in question 50, how many times in a week?______________________________________ 
52. If Y in question 50, why do you bathe or wash in the Lake? ______________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
53. Do you wear shoes or long protective wear when in the Lake? Y         N      .  
54. If Y in question 53, how many times when in the Lake?__________________________________ 
55. If N in question 53, why do you not wear them? _______________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
56. Where is the main place you go to urinate?___________________________________________ 
57. Where is the main place you go to defecate?__________________________________________ 
58. Does your house have a toilet? Y         N      .  
59. If Y in question 58, do you use it? Y         N      .  
60. If Y in question 59, how many times in a week?________________________________________ 






62. If N in question 59, where do you use the toilet?_______________________________________ 
_____________________________________________________________________________ 
Do you have access to treatments for schistosomiasis? Tick () for the relevant answer below: 
63. No, not at all        .       
64. Yes       .       
65. Do not know       .  
66. Refused to answer       .  
Section D:  Socio-economic characteristics 
What is your highest level of education? Put a tick () for Yes on only one option: 
 Level of Education Option 
67.  Never went to school  
68.  Not finished primary school (6 years)  
69.  Completed primary school  
70.  Not finished secondary school  
71.  Completed secondary school   
72.  Not finished tertiary/professional school  
73.  Completed tertiary/professional school  
74.  Don’t know  
75.  Refused  
76. Do you have a job or are you employed? Y         N      .  
If Y to question 76, can you tell us the job? Put a tick () for Yes on all items mentioned or 
demonstrated: 
 Type of Employment / Job Yes 
77.  Self-employed. Specify:  
78.  Fishing  
79.  Farming/agriculture  
80.  Clerk/administration  
81.  Health worker  
82.  Selling at market  
83.  Other. Specify:  
84.  Refused  
 
Other employment status, 
 Other Job Yes  
85.  Doing housework   
86.  Student  




88.  Long-term disabled  
89.  Unemployed  
90.  Don’t know  
91.  Refused  
 
If Y to question 78 (fishing), can you tell us more about your work by answering the following: 
92. How long have you been doing this job? ____________________________________________ 
93. How often do you go for fishing? ___________________________________________________ 
94. What kind of fish do you catch? ____________________________________________________ 
95. Is the job (fishing) seasonal? Y         N      .  
96. If Y to question 95, when is the season? _________________________ 
97. If Y to question 95, what else do you do during off-season period?_________________________ 
_____________________________________________________________________________ 
98. Do you migrate to other places during / after fishing? Y         N      .  
99. If Y to question 98, how often do you migrate in a year? _________________________________ 
100. If Y to question 98, where do you migrate to? ______________________________________ 
101. If Y to question 98, why do you migrate? __________________________________________ 
__________________________________________________________________________ 
102. Do you own a boat? Y         N      .  
103. What kind of boat? _______________________________ 
104. Are you planning of getting a new boat? Y         N      .  
105. What kind of boat? ___________________________________________________________ 
Regarding marriage and family, 
Can you tell us about your relationship status: 
 Relationship Yes 
106.  Married   
107.  Co-habiting / engaged  
108.  Divorced  
109.  Single  
110.  Other. Specify:  
111.  Refused  




113. If Y to question 112, how many? ________________________________________________ 
114. If N to question 112, why? _____________________________________________________ 
__________________________________________________________________________ 
115. Has your spouse / partner experienced stillbirth / abortion? Y         N      . 
116. Have you or your spouse / partner had childlessness after marriage/engaged? Y         N      . 
117. Have you or your spouse / partner experienced infertility? Y         N      . 
118. What do you think about pains of genital organs or during / after coitus if you experience it?  
__________________________________________________________________________ 
__________________________________________________________________________ 
119. What do your spouse think about pains of your genital organs or during / after coitus?____ 
__________________________________________________________________________ 
__________________________________________________________________________ 
Does your spouse or partner experience the following symptoms: 
120. Lower abdominal pain? Y         N      . For how long _________________________________ 
121. Pain during / after coitus? Y         N      . For how long _______________________________ 
122. Bleeding during / after coitus? Y         N      . For how long ____________________________ 
123. Pain during menstruation? Y         N      . For how long ______________________________ 
124. Changes of menstrual flow / flow? Y         N      . For how long ________________________ 
125. If Y to any of the symptoms above, what does your spouse think about them? ____________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
126. If Y to any of the symptoms above, what do you think about them?_____________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
127. Any other comments related to issues above? _____________________________________ 
__________________________________________________________________________ 




Appendix 15: Individual HIV participant questionnaire (in chichewa) 
Kafukufuku wa matenda a Likodzo la amuna ndi HIV pakati pa Asodzi okhala m’mbali mwa nyanja 
ya Malawi (MGS-HIV Baseline & Follow-up Survey) 
Chidziwitso: Chongani () pa mayankho operekedwa ndi opangidwa kafukufuku. Pitilizani kulemba 
mayankho pa tsamba lina ngati malo oyankhira achepa. Mukamaliza, perekani mayankho onse kwa 
mkulu wa Kafukufukuyu.   
Tsiku: (dd/mm/yy): __ __ / __ __ / __ __  Opangitsa Kafukufuku ______________________________ 
Chilolezo cha opangidwa Kafukufuku 
Opangidwa kafukufuku apereka chilolezo cholemba? Inde       Ayi       
Pitirizani Kafukufuku ngati avomera Inde 
Gawo A:  Mbiri ya Opanga Kafukufuku 
1. Nambala ya Opangidwa Kafukufuku: ________________________________________________ 
2. Mudzi: _______________________________________________________________________ 
3. Mfumu Yaikulu: _________________________________________________________________ 
4. Chipatala chapafupi: ____________________________________________________________ 
5. Ndinu: Mwamuna       Mkazi       .  
6. Tsiku lobadwa (dd/mm/yy): __ __ / __ __ / __ __  Zaka : _____________________________ 
7. Munabadwira kuti: _____________________________________________________________  
8. Mwakhala nthawi yaitali bwanji kuno: Zaka _____ Miyezi: _____ Sabata: _____ Masiku: _____  
9. Thupi kulemera (kg):___________________________________________________________  
10. Msinkhu kutalika (cm): __________________________________________________________ 
Gawo B:  Mbiri ya Zaumoyo wanu 
Kodi mwakhala ndi zizindikiro monga izi? Tsopano? Kapena mu mwezi wapitawu? (Kwa ofunsa: 
Chongani () ngati Inde pa zizindikiro zonse zimene zayankhidwa ndi kusonyezedwa): 








11.  Kutentha thupi      
12.  Mutu kupweteka      
13.  Kufooka      




Kodi mwadwala matenda awa? Tsopano? Kapena mu mwezi wapitawu? (Kwa ofunsa: Chongani () 
ngati Inde pa matenda onse zimene zayankhidwa ndi kusonyezedwa): 
 
34. Kodi munamwa mankhwala a njoka zammimba (albendazole) mu miyezi 12 yapita? Inde    Ayi    . 
35. Kodi munamwa mankhwala a likodzo (praziquantel) mu miyezi 12 yapita? Inde         Ayi      . 
36. Kodi munamwa mankhwala a malungo mu miyezi 12 yapita? Inde         Ayi      . 
37. Kodi munamwa mankhwala ena aliwonse mu miyezi 12 yapita? Inde         Ayi      . Ngati Inde,  
tchulani dzina la mankhwala ___________________________________________________ 
Mafunso awa ndi okhudzana ndi matenda a EDZI: 
38. Kodi munakhalapo nawo pa misonkhano ya zaumoyo mu miyezi 12 yapita? Inde      Ayi      .  
39. Kodi mmisonkhanoyi ina inalipo yokhudza za matenda a EDZI? Inde         Ayi      . 
40. Kodi mwakumana ndi mavuto chiyambire kumwa ma ARVs? Inde         Ayi      .  
41. Munakumana ndi mavuto okhudza ziwalo za umuna pa miyezi 12 yapita? Inde         Ayi      .  
42. Ngati Inde pa funsoli (41), fotokozani mavutowo?_____________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
15.  Kupweteka pokodza      
16.  Kukodza pafupi-pafupi      
17.  Kusinthika kwamtundu wa mkodzo      
18.  Magazi mu mkodzo      
19.  Magazi mu chimbudzi      
20.  Magazi mu umuna      
21.  Kupweteka pogonana      
22.  Kupweteka potulutsa umuna      
23.  Kupweteka kwa ziwalo za umuna      
24.  Zizindikiro zina (nenani)      








25.  Malungo      
26.  Kutsegula m’mimba      
27.  Kutsegula kwa kamwazi      
28.  Matenda a pakhungu      
29.  Chifuwa      
30.  Njoka za mmimba      
31.  Likodzo      
32.  Matenda opatsana pogonana      




43. Munalandira chithandizo chilichonse oa funsoli (42)? Inde         Ayi      .  
44. Ngati Inde pa funsoli (43), munalindira chithandizo kuti? ________________________________ 
45. Ngati Inde pa funsoli (43), thandizo munalira ndi lotani? ________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
46. Ngati Ayi pa funsoli (43), fotokozani zifukwa zanu?____________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
47. Kodi mukuvomera kuyezedwa mthupi limodzi ndi ziwalo za umuna? Inde         Ayi      .  
Gawo C:  Zaukhondo ndi Kudzisamalira 
48. Kodi mumasambira, kuyenda kapena kugwira ntchito mu nyanja? Inde     Ayi      (pitani funso 50). 
49. Ngati Inde pa funsoli (48), mumatero kangati pa week _________________________________ 
50. Kodi mumasamba kapena kuchapa mu nyanja? Inde         Ayi      .  
51. Ngati Inde pa funsoli (50), mumatero kangati pa week? ________________________________ 
52. Ngati Inde pa funsoli (50), chifukwa chiani? _________________________________________ 
_____________________________________________________________________________ 
53. Kodi mumavala nsapato kapena Malaya otalika mukakhala mu Nyanja? Inde         Ayi      .  
54. Ngati Inde pa funsoli (53), mumatero kangati mukakhala mu nyanja? _____________________ 
55. Ngati Ayi pa funsoli (53), chifukwa chiani simuvala? __________________________________ 
_____________________________________________________________________________ 
56. Kodi mumakodza kuti?__________________________________________________________ 
57. Kodi mumachita chimbudzi kuti?___________________________________________________ 
58. Kodi nyumba yanu ili ndi chimbudzi? Inde         Ayi      .  
59. Ngati Inde pa funsoli (58), kodi mumagwiritsa ntchito? Inde         Ayi      .  
60. Ngati Inde pa funsoli (59), mumagwiritsa ntchito kangati pa week?_ _______________________ 





62. Ngati Ayi pa funsoli (59), mumagwiritsa ntchito kuti chimbudzi?__________________________ 
_____________________________________________________________________________ 
Kodi mumatha kupeza mankhwala a likodzo? (Kwa ofunsa: Chongani () ngati Inde pa 
mayankho oyenera): 
63. Ayi        .       
64. Inde       .       
65. Sindikudziwa       .  
66. Sindiyankha      .  
Zachikhalidwe ndi chuma 
Kodi munaphunzira pakana kalasi yanji? (Kwa ofunsa: Chongani () ngati Inde pa yankho limodzi 
loyenera): 
 Maphunziro Yankho 
67.  Sindinapiteko ku sukulu  
68.  Sindinamalize sukulu ya Pulaimale  
69.  Ndinamaliza sukulu ya pulaimale  
70.  Sindinamalize sukulu ya Sekondale  
71.  Ndinamaliza sukulu ya sekondale  
72.  Sindinamalize maphunziro a kukoleji  
73.  Ndinamaliza maphunziro a Koleji  
74.  Sindikudziwa  
75.  Sindiyankha  
 
76. Kodi muli pa ntchito? Inde         Ayi      (pitani funso 92).  
Ngati Inde pa funsoli (76), mungafotokoze ntchito yanu? (Kwa ofunsa: Chongani () ngati Inde pa 
mayankho oyenera: 
 Mtundu wa ntchito Inde 
77.  Mumazilipila nokha. Nenani:  
78.  Usodzi  
79.  Ulimi  
80.  Ukalaliki  
81.  Ntchito ya chipatala  
82.  Kugulutsa mu msika  
83.  Ntchito zina, Nenani:  
84.  Sindiyankha  
 
 Ntchito ina Inde  
85.  Ntchito ya pakhomo  
86.  Mwana wa sukulu  




88.  Olumala  
89.  Sindili pantchito iliyonse  
90.  Sindikudziwa  
91.  Sindiyankha  
 
Ngati Inde pa funsoli (78) la zausodzi, mungafotokoze zambiri za ntchito yanu: 
92. Kodi mwagwira nthawi yayitali bwanji pa ntchito ya usodzi? ______________________________ 
93. Kodi mumachita usodzi kangati? __________________________________________________ 
94. Mumagwira nsomba za mtundu wanji? _____________________________________________ 
95. Kodi mumapanga usodzi mwaka nyengo? Inde       Ayi     .  
96. Nyengo yake? __________________ 
97. Ngati Inde pa funsoli (96), mumapanga chiani nthawi yomwe simuweza? __________________ 
_____________________________________________________________________________ 
98. Kodi mumapita madera ena nthawi ya usodzi? Inde         Ayi      . _______________________ 
99. Ngati Inde pa funsoli (97), mumapita kangati pa chaka? _______________________________ 
100. Ngati Inde pa funsoli (97), mumapita kuti? ________________________________________ 
101. Ngati Inde pa funsoli (97), mumayenda chifukwa chiani? _____________________________ 
__________________________________________________________________________ 
102. Mtundu wa bwato lanu? ________________________  
103. Muli ndi ma pulani ogula bwato latsopano? Y         N      .  
104. Mtundu wa bwato lanu? _______________________________________________________ 
__________________________________________________________________________ 
Zokhudzana ukwati ndi banja lanu, mungafotokoze zambiri, 
 Ukwati Inde 
105.  Okwatira  
106.  Unapanga unkhoswe  
107.  Banja linatha  
108.  Simunakwatirepo  
109.  Zina, nenani  
110.  Sindiyankha  
111. Kodi muli ndi ana? Inde         Ayi      .  




113. Ngati Ayi pa funsoli (110), chifukwa chiani? _______________________________________ 
__________________________________________________________________________ 
 __________________________________________________________________________ 
114. Kodi akazi anu anapita padera ali woyembekezera? Inde         Ayi      . 
115. Kodi inu kapena akazi anu mukakhala opanda mwana m’banja? Inde         Ayi      . 
116. Kodi inu kapena akazi anu anakhalapo ndi vuto losabereka? Inde         Ayi      . 
117. Kodi munganene zotani pa kupweteka kwa ziwalo za umuna mukanamagonana? _________ 
__________________________________________________________________________ 
__________________________________________________________________________  
118. Kodi akazi anu anaganiza bwanji pa kupweteka kwa ziwalo za umuna kukamagonana?  ____ 
__________________________________________________________________________ 
__________________________________________________________________________  
Kodi akazi anu amaona zizindikiro izi: 
119. Kupweteka mmimba? Inde         Ayi      . Ngati inde, Kwa nthawi yaitali bwanji ____________ 
120. Kupweteka pogonana? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji ___________ 
121. Kutaya magazi pogonana? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji ________ 
122. Kupweteka posamba? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji ___________ 
123. Kusintha kwa kusamba? Inde         Ayi      . Ngati Inde, Kwa nthawi yaitali bwanji __________ 
124. Ngati Inde pa zizindikiro izi, akazi anu amaganiza chiani? ____________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
125. Ngati Inde pa zizindikiro izi, inu amaganiza chiani? _________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________  
126. Muli ndi maganizo ena pa zomwe zakambidwa? ___________________________________ 
__________________________________________________________________________ 
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EXAMINATION OF URINE FOR EGGS OF Schistosoma haematobium 
1. PRINCIPLE AND CLINICAL SIGNIFICANCE OF THE EXAMINATION  
1.1 Schistosoma haematobium causes urogenital schistosomiasis, which is endemic in sub-
Saharan African countries including Malawi, especially along water bodies like Lake Malawi. 
Infected people pass the parasites in urine, 12 weeks after exposure and present with 
symptoms like fever, fatigue, dysuria, haematuria 
1.2 Laboratory diagnosis of S. haematobium infection is by detection of the S. haematobium 
eggs through microscopic examination of the urine. A quantitative report of the laboratory 
diagnosis is number of eggs per 10ml of urine.  
1.3 The excretion of S. haematobium eggs in urine varies throughout the day with highest 
output between 10:00 hrs and 14:00 hrs, peaking around midday. It may also be necessary 
to examine several specimens collected on different days due to the irregular pattern of 
egg excretion. 
2. SPECIMEN REQUIREMENTS 
2.1 The type of specimen to be examined is urine, using filtration technique. 
2.2 The materials required to conduct the urine examination include: 
120ml urine container, 60ml syringe and forceps, Urine card for macrohaematuria, 
Urinalysis reagent strips, Schistosoma CCA strips, Filter holder and membrane, Microscope, 
slides and coverslips, Lugol’s iodine, Examination gloves, Laboratory coat. 
2.3 The participant will submit urine in the clean container between 10:00 hrs and 14:00 hrs 
and then immediately give it to the study team member. 
2.4 The urine will be analysed immediately or where not possible, transferred to a designated 
laboratory in a cooler box to prevent Schistosoma eggs from hatching. 
2.5 The results will be recorded on the data collection tool and thereafter given to the 
participant. 




3.1. Safety precautions will be ensured always to prevent exposure to hazards. The study team 
will wear laboratory coats, gloves and acceptable protective wear throughout the 
technique.  
3.2. Once the urine is submitted, the study team member will record the volume and then its 
appearance using the urine card to assess for macrohaematuria. 
3.3. The urine will be analysed for microhaematuria using reagent strips and the result will be 
recorded. 
3.4. Then a drop of urine will be drawn and put on the CCA strip, a drop of the buffer will be 
added, and the result will be recorded. 
3.5. Thereafter, the entire amount of urine will be drawn by the 60ml syringe and filtered 
through a disinfected filter holder containing a clean polycarbonate filter membrane to 
trap as many eggs in the urine. 
3.6. The filter membrane will be removed, placed on a microscope slide labelled with 
participant’s unique identifier and examined under microscope. Iodine will be added to 
visualise S. haematobium eggs distinctly.  
3.7. The number of eggs will be counted and recorded per 10ml of urine. 
3.8. The microscope slide will be stored for quality control. 
4. SPECIMEN AND WASTE DISPOSAL 
4.1. The urine will be discarded in accordance with the aseptic practices and Infection 
prevention procedures set by Ministry of Health in Malawi. 
4.2. The used gloves, disposable protective wear and other waste will be disposed in 
accordance with Infection prevention procedures set by Ministry of Health in Malawi. 
5. QUALITY CONTROL PROCEDURES 
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EXAMINATION OF SEMINAL FLUID FOR EGGS OF Schistosoma haematobium 
1. PRINCIPLE AND CLINICAL SIGNIFICANCE OF THE EXAMINATION  
1.1 Schistosoma haematobium causes urogenital schistosomiasis, which is endemic in sub-
Saharan African countries including Malawi, especially along water bodies like Lake Malawi. 
Infected people pass the eggs in urine and/or semen, and present with symptoms like 
fever, fatigue, dysuria, haematuria, haemospermia, pain of the genital organs, pain during 
or after sexual intercourse. 
1.4 Laboratory diagnosis of S. haematobium infection is by detection of the S. haematobium 
eggs through microscopic examination of the semen. A quantitative report of the diagnosis 
is number of eggs per ejaculate (semen provided).  
1.5 Like the variation of S. haematobium eggs in urine, excretion of eggs in semen is very 
variable and unpredictable, with eggs present in semen and not in urine. Therefore, it is 
essential to examine several specimens collected on different days to detect eggs in 
semen, even in absence of eggs in urine. 
 
2. SPECIMEN REQUIREMENTS 
2.1 The type of specimen to be examined is semen / seminal fluid. 
2.2 The materials required to conduct the semen examination include: 
• Clear, self-sealing plastic bag 
• Heat sealer 
• 2ml microtubes 
• Centrifuge and Microscope  
• Microscope slides and coverslips 
• Pasteur pipettes 
• Exam gloves 




2.3 The participant will be counselled to abstain from sexual activity for at least 2 days prior to 
semen submission. 
2.4 On the day of submission, the participant will be given a clear, self-sealing plastic bag for 
submitting semen, labelled with their unique identifier. This bag will be used instead of the 
traditional container or nonspermicidal condoms commonly used in other similar studies. 
2.5 The participant will be directed to a separate, quite private room where they submit semen 
through masturbation. 
2.6 For those who will fail to submit semen, they will be asked to either try the following day 
or ejaculate into the bag during intercourse by coitus interruptus on the next morning and 
delivered to the study team within three hours of ejaculation. 
2.7 The semen will be analysed within 3 hours of submission and results be given to the 
participant and recorded on the data collection tool. 
3. STEPS OF THE SPECIMEN EXAMINATION 
3.1. Safety precautions will be ensured always to prevent exposure to hazards. The study team 
will wear laboratory coats, gloves and acceptable protective wear throughout the 
technique.  
3.2. Once the semen is submitted, the study team member will report the appearance (watery, 
lumpy) and colour (clear/colourless, white, yellowish/straw, red/bloody). 
3.3. Thereafter, the semen should be placed on a bench at room temperature for 20-45 
minutes to allow liquefication if not already done. 
3.4. The semen should be pushed gently to one corner of the plastic bag and the bag should be 
heat sealed to evenly concentrate the semen for easy visualisation during microscopy. 
3.5. Then the heat-sealed bag should be placed in a clean petri-dish and examined directly 
under microscope to check for S. haematobium eggs, presence of blood cells and other 




3.6. The semen should be then transferred into 2ml microtube using the Pasteur pipettes and 
the volume measured and recorded. 
3.7. The semen should be centrifuged at 3,000 xg for 5 minutes to collect the pellet and 
seminal plasma which should be stored at -80c before shipment to Liverpool.  
3.8. Normal saline (2.5ml) and ethanol (0.1 ml) should be added to the pellet in the microtube 
and mixed thoroughly well. Thereafter, a drop of the pellet should be placed on a slide and 
examined under microscope for S. haematobium eggs.  
3.9. The seminal plasma should be analysed for molecular HIV viral load where necessary after 
shipment to Liverpool. 
3.10. The microscope slide should be labelled with the participant’s unique identifier and stored 
for quality control. 
4. SPECIMEN AND WASTE DISPOSAL 
4.1. The semen bag should be discarded in accordance with the aseptic practices and Infection 
prevention procedures set by Ministry of Health in Malawi. 
4.2. The used gloves, disposable protective wear and other waste will be disposed in 
accordance with Infection prevention procedures of the Ministry of Health in Malawi. 
5. QUALITY CONTROL PROCEDURES 
5.1. The P.I. and/or Fieldwork Advisor will perform microscopy on slides of the semen, random 
selected on daily basis as part of quality control. 
 
6. REFERENCES 
• Cheesbrough, M. (2005). District Laboratory Practice in Tropical Countries - Part 2. The 
Edinburgh Building, Cambridge, UK, Cambridge University Press. 





• WHO (2010). WHO Laboratory manual for the examination and processing of human semen 






Appendix 18: Post-semen submission questionnaire 
INDIVIDUAL PARTICIPANT QUESTIONNAIRE 
Research study on Male genital schistosomiasis and HIV among Adult fishermen living in Southern 
shores of Lake Malawi (Post-semen submission Survey) 
Explanation: Put a tick () for the participant’s responses appropriately. If the boxes are not enough 
on one page, use another sheet. Return this and other sheets to the Study Investigator at the end.   
Date: (dd/mm/yy): __ __ / __ __ / __ __  Interviewer Name__________________________________ 
Consent checklist 
Has written consent been obtained?  Y      N      Only proceed if Y 
Section A:  Participant’s details 
1. Participant ID: __________________________________________________________________ 
2. Village:_______________________________________________________________________ 
3. T/A: __________________________________________________________________________ 
4. Name of nearest Health centre:____________________________________________________ 
5. Gender: Male       Female       .  
6. Date of birth (dd/mm/yy): __ __ / __ __ / __ __  Age: : ______________________________ 
7. Weight (kg):___________________________________________________________________  
8. Height (cm):___________________________________________________________________ 
Section B:  After Semen collection 
9. Did you experience any challenges or problems in submitting the semen sample? Y         N      .  
10. If Y to question 9, may you tell us the challenges or problems___________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
11. Would you have preferred a collection bottle instead of a collection bag given? Y         N      . 
12. If Y to question 11, may you tell us the reason(s)______________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 




Appendix 19: Post-semen submission questionnaire (in chichewa) 
INDIVIDUAL PARTICIPANT QUESTIONNAIRE (in Chichewa) 
Kafukufuku wa Matenda a Likodzo la njira yaumuna ndi Edzi mwa Asodzi okhala m’bali mwa 
Nyanja ya Malawi (Post-semen collection survey) 
Chidziwitso: Ikani () pa mayankho operekedwa ndi opanga kafukufuku. Pitirizani mayaknho anu pa 
tsamba lina ngati malo oyankhira achepa. Perekani mayankho onse kwa mkulu wa Kafukufukuyu.   
Tsiku: (dd/mm/yy): __ __ / __ __ / __ __  Opangitsa Kafukufuku ______________________________ 
Chilolezo cha opanga nawo Kafukufuku 
Opanga kafukufuku apereka chilolezo?  Inde       Ayi      Pitirizani Kafukufuku ngati avomera Inde 
Gawo A:  Mbiri ya Opanga Kafukufuku 
1. Participant ID: __________________________________________________________________ 
2. Mudzi:________________________________________________________________________ 
3. T/A: __________________________________________________________________________ 
4. Chipatala chapafupi:_____________________________________________________________ 
5. Ndinu: Mwamuna       Mkazi       .  
6. Tsiku lobadwa (dd/mm/yy): __ __ / __ __ / __ __  Zaka :______________________________ 
7. Thupi kulemera (kg):____________________________________________________________  
8. Thupi kutalika (cm):_____________________________________________________________ 
Gawo B:  Mutatha kupereka Umuna wanu 
9. Munakumana ndi vuto lililonse popereka umuna wanu? Inde         Ayi      .  
10. Ngati Inde, fotokozani mavuto munakumana nawo _____________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
11. Mukanakonda kupereka umuna mu botolo mmalo mwa pepala munapatsidwa? Inde      Ayi      . 
12. Ngati Inde, fotokozani maganizo anu pa yankho lanu ___________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 




Appendix 20: Standard operating procedure for ultrasonography 
ULTRASOUND EXAMINATION FOR MALE GENITAL SCHISTOSOMIASIS (MGS) 
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ULTRASOUND EXAMINATION FOR MALE GENITAL SCHISTOSOMIASIS (MGS)  
1. PRINCIPLE AND CLINICAL SIGNIFICANCE OF THE EXAMINATION  
1.1 Schistosoma haematobium causes urogenital schistosomiasis, which is endemic in sub-
Saharan African countries including Malawi, especially along water bodies like Lake Malawi. 
Infected people pass the eggs in urine and/or semen, and present with symptoms like 
fever, fatigue, dysuria, haematuria, haemospermia, pain of the genital organs, pain during 
or after sexual intercourse. 
1.2 Laboratory diagnosis of S. haematobium infection is by detection of the S. haematobium 
eggs through microscopic examination of the urine, semen and other affected tissues 
excised.  
1.3 Ultrasonography of urinary and genital organs is an important examination for morbidity 
assessment related to S. haematobium infection, useful for appropriate participants’ 
management. 
2. REQUIREMENTS 
2.1 The participant for this ultrasound examination is the fishermen in the study. 
2.2 The requirements for the ultrasonography of the male genital organs include: 
• Bed/Couch: participant will lie in supine position for the exam, with the examiner on 
his right side. 
• Ultrasound machine. 
• Probes: curved array transducer – 3.5 MHz. 
• Ultrasound Gel: used every-time as conductive medium between the patient’s skin and 
the ultrasound transducer. 
• Tissue paper for cleaning the probe and participants after examination. 






3. STEPS OF THE ULTRASONOGRAPHY EXAMINATION 
3.1. Safety precautions will be ensured always to prevent exposure to hazards. The study team 
will wear gloves and appropriate protective wear during examination.  
3.2. Participants will be asked to present to the examination room with a full bladder. 
3.3. The ultrasound procedure will be explained to the patient and/or caregiver. 
3.4. The lights in the room will be turned off and the room darkened, if possible. 
3.5. The patient will be placed in a lying position and the ultrasound machine set up on the 
right side of the patient. 
3.6. The ultrasound machine will be put on the appropriate urology preset for the examination. 
3.7. The participant’s study number will be registered in the ultrasound machine and report 
form prior to starting the examination. 
3.8. A reasonable amount of ultrasound gel will be put on the probe. 
3.9. The ultrasound examination will be conducted in the following procedure:  
a. Urinary bladder:  
i. Probe position: The probe is placed transverse (TS) above the pubic symphysis 
with probe orientation projecting the right side of the patient on the left side of 
the screen.  Transverse sweeps through the bladder are performed to assess the 
shape (distension) and wall thickness of the bladder, as well as the distal ureters 
where possible. Care should be taken to adjust depth and gain settings 
appropriately for anterior and then posterior bladder wall/ureters to avoid 
artefacts and reduced visibility of bladder wall. Longitudinal (LS) sweeps will also 
be performed in similar way. 
ii. Normal finding: The bladder is fully distended and has a regular, rectangular 
shape. The bladder wall is of regular thickness and not thicker than 5 mm. Normal 




iii. Pathological findings: Schistosomiasis-related urinary pathologies include a 
rounded or irregular shape of the bladder, wall thickening with diffuse or focal 
thickening of > 5 mm, bladder wall calcifications and masses or pseudopolyps 
protruding in the bladder lumen. The distal ureters are considered pathological 
when dilated. 
iv. Bladder wall thickness will be measured in mm and stored as a separate still 
image. Storing of images and clips: After having performed several sweeps 
through the bladder, the best representative sweep will be stored under the label 
“bladder”. In case of any pathologic findings additional still images with relevant 
measurements will be stored.  
v. Once the bladder wall thickness is abnormal, the kidneys will be scanned for 
evidence of hydronephrosis.  
vi. Reporting: The visualization conditions will be documented first. Subsequently, 
the absence/presence of pathological findings is documented on the report form. 
b. Prostate: 
i. The prostate will be visualised with the probe directed deep into the pelvis, after 
scanning the bladder. Care should be taken to adjust depth and gain settings 
appropriately to clearly and fully visualise the prostate.  
ii. Normal finding: The prostate is normal when volume is 30 mm3 or less with 
smooth outline. 
iii. Pathological findings: Schistosomiasis-related pathologies include nodules or 
masses above 1 cm, and calcifications of the prostate. 
iv. The prostate will be measured in cm3 or ml and stored as a separate still image. 
Storing of images and clips: After having performed several sweeps through the 




In case of any pathologic findings additional still images with relevant 
measurements will be stored.  
v. Reporting: The visualization conditions will be documented first. Subsequently, 
the absence/presence of pathological findings is documented on the report form. 
c. Seminal vesicles: 
i. The seminal vesicles will be visualised adequately with several sweeps, just after 
scanning the prostate. 
ii. Normal finding: The seminal vesicles will be symmetrical, measuring 15 mm or 
less in antero-posterior (AP) plane with smooth outline. 
iii. Pathological findings: Schistosomiasis-related pathologies include enlarged and or 
asymmetrical vesicles with nodular, echogenic appearance. 
iv. If the vesicles measure larger than 15 mm in AP plane, their measurement will be 
stored as a separate still image. Storing of images and clips: After having 
performed several sweeps through the vesicles, the best representative sweep 
will be stored under the label “SV”. In case of any pathologic findings additional 
still images with relevant measurements will be stored.  
v. Reporting: The visualization conditions will be documented first. Subsequently, 
the absence/presence of pathological findings is documented on the report form. 
d. Scrotum: 
i. Probe position: The probe is placed transverse on the scrotum with probe 
orientation projecting the right side of the patient on the left side of the screen.  
Axial sweeps on the scrotum are performed to assess both testes. Care should be 
taken to adjust depth and gain settings appropriately.  
ii. Testis: if abnormal, describe whether there are nodules, masses, atrophy or 
calcifications. 




iv. Other: describe whether hydrocele is present or not; and other abnormalities not 
mentioned earlier.  
v. Reporting: Pathological findings should be documented on the report form. 
3.10. All clips and images saved as described above, will be transferred from the ultrasound 
machine to an external hard drive, for a random second reading by the P.I. and quality 
control. 
3.11. The used gloves, disposable protective wear and other waste will be disposed in 
accordance with the Infection prevention procedures set by the Ministry of Health in 
Malawi.  
3.12. Probe hygiene: the probe will be cleaned with tissue paper to remove the gel, and with 
methylated spirit after each participant. 
4. QUALITY CONTROL PROCEDURES 
4.1 The P.I. and/or Specialist Radiologist will review at least 15% of the stored images / clips, 
randomly selected as part of quality control. 
REFERENCES 
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genital tract: transrectal sonographic findings." J Urol 158(4): 1491-1493. 
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Appendix 21: Data collection form for field laboratory examinations 
Multidisciplinary studies of Male genital schistosomiasis (MGA) along Lake Malawi 
Date of Study Name of the Study Name of Health centre Study Lab personnel 



















         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         





Appendix 22: Data collection form for field ultrasonography examinations 
ULTRASOUND SCAN REPORT 
Research study on Male genital schistosomiasis and HIV among Adult fishermen living in Southern 
shores of Lake Malawi (MGS Baseline & Follow-up Survey) 
Explanation: Put a tick () for the appropriate result. If the boxes are not enough on one page, use another 
sheet. Return this and other sheets to the Study Investigator at the end.   
Date: (dd/mm/yy): __ __ / __ __ / __ __  Sonographer name: ________________________________ 
Consent: Has written consent been obtained?  Y      N      Only proceed if Y 
Participant ID: _____________________________________________________________________ 
Weight (Kg): ____________________________  Height (cm): _______________________________ 
Section A:  Urinary Bladder 
1. Filling:       Adequate      Inadequate (go to Section B). 
2. Shape:       Normal       Abnormal. 
3. Wall thickness:      Normal (≤ 5 mm)       Abnormal, mild (5-10 mm) 
4. Wall thickness, abnormal (go to Kidneys):      ≥ 11 mm/polypoid/flat;      mass (possible cancer)  
5. Kidneys:       Normal       hydronephrosis (transverse pelvis > 10 mm);      Right            Left 
 
Section B:  Prostate 
6. Visualisation:      Adequate       Inadequate 
7. Organ:       Normal       Abnormal 
8. Size: W_____  X H_____  X D_____ X 0.52  = _____ OR _____ ml3 
9. Outline:       Smooth       Irregular 
10. Nodules / Mass:      Absent       Present      Multiple. If present,  
a. Hypo-echoic:      : Size:      ≤1 cm; W___  X H___  X D___ X 0.52  = _____ OR ____ ml.  
b. Hyper-echoic:      : Size:      ≤1 cm; W___  X H___  X D___ X 0.52  = _____ OR ____ ml.  
c. Mixed echogenicity:    ; Size:     ≤1 cm; W___  X H___  X D___ X 0.52  = ___ OR ___ ml.  




Section C:  Seminal vesicles 
12. Visualisation:      Adequate       Inadequate 
13. Symmetry:      Normal      Abnormal. 
14. Size: _____mm;      Normal (≤15 mm)      Enlarged (>15 mm).  If enlarged,  
a. Right     , Size: _____mm;  Left      , Size: _____mm.  
b. Hypo-echoic:     ;   Right        Left      . 
c. Hyper-echoic:     ;   Right        Left      . 
 
Section D:  Scrotum 
Testis: 
15. Right: Normal       Abnormal     .  If abnormal,   
a. Nodules      ;  Mass      Size: _____cm;  Atrophy     ;  Calcifications     .  
16. Left: Normal        Abnormal     .  If abnormal,   
a. Nodules      ;  Mass      Size: _____cm;  Atrophy     ;  Calcifications     .  
 
Epididymis: 
17. Right: Normal       Enlarged     . 
18. Left: Normal       Enlarged     .  
 
Other: 
19. Hydrocele: Present       Absent     .  If present,  
a. Right        Left       .      
 
20. Other abnormalities:     . Describe__________________________________________________ 
_____________________________________________________________________________ 




Appendix 23: Research output – Manuscript published in the American Journal of Tropical 



















































































































Appendix 26: Research output – Contribution to Emerging Infectious Diseases (for 

















Appendix 27:  Research output – Contribution to the Emerging Infectious Diseases (for S. 




























BLOG: Parasitology paper of the month 
 
by 
Dr. Sekeleghe Kayuni 
About the author: Seke is a medical doctor working with MASM Medi Clinics Limited in Blantyre City, Malawi 
and currently a Commonwealth PhD Scholar studying at the Liverpool School of Tropical Medicine and 
University of Liverpool. His twitter account is @sekekayuni. 
 
Our paper on diagnostics originates from my soon-to-be-completed PhD study that has 
focused on developing a better understanding of the interplay between schistosomiasis and HIV in 
Malawian fishermen.  In my country, Malawi, schistosomiasis is well known especially along the 
shoreline of Lake Malawi, where through my professional medical duties and research studies, I have 
encountered many people seeking for praziquantel treatment. The disease, also known as Bilharzia 
and grouped within the neglected tropical disease (NTDs), employs a preventative chemotherapy 
approach with praziquantel as its first foundation of disease control.  
Across sub-Saharan Africa, schistosomiasis can be particularly common. Millions of young 
children, through to older adults, are affected by this disease, which may be life-threatening upon 
advanced disease progression like abdominal pain, blood or difficulties in passing urine, enlarged 
liver and spleen, liver fibrosis or bladder cancer. Schistosome infections are acquired through direct 
contact with freshwater sources that contains infective schistosome larvae, which penetrate the 
skin. Most often, daily activities such as bathing and swimming, or drawing water for domestic 
chores, places people of all ages at risk. Around Lake Malawi, adult men engaged in fishing are an 
especially well-known high-risk group, and having often had insufficient praziquantel treatment, 




In Africa, Schistosoma haematobium and Schistosoma mansoni are responsible for the two 
forms of schistosomiasis urogenital or intestinal, respectively. Accurate diagnosis of schistosomiasis 
in all its stages and forms remains a challenge despite scientific advances in general recognition of 
NTDs as a global public health concern. Several diagnostic methods for detection of urogenital 
schistosomiasis (UGS) have been developed over the years but we still do not have a reliable rapid 
point-of-care (POC) test. This is in contrast with intestinal schistosomiasis where a urine-based point 
of care circulating cathodic antigen (POC-CCA) strip assay test is commercially available and also 
advocated within WHO guidelines for disease mapping.  
Although more efforts have been put into raising awareness in general, the treatment, 
control and prevention of schistosomiasis, and specific genital complications arising especially in 
male genital schistosomiasis (MGS) have been overlooked and underreported for decades. This 
perceived lack of interest has resulted in under-diagnosis, 
non-treatment and poor awareness in endemic areas; MGS 
is a gender-specific manifestation of schistosomiasis, 
associated with schistosome eggs and pathologies in genital 
fluids and organs most commonly observed with S. 
haematobium infection. This complication, first described 
in 1911 by Professor Madden in Egypt, causes genital or 
ejaculatory pain, abnormal ejaculates, infertility, enlarged organs, and tissue abnormalities observed 
on diagnostic examinations. Perhaps as the largest chronic parasitic public health burden in Africa, 
there is also a direct connection with HIV transmission as schistosome eggs in the genital tracts often 
are associated with raised viral loads in semen. 
Unlike the recent advances in defining a clinical standard protocol for female genital 
schistosomiasis (FGS), MGS remains inadequately defined as there is no ‘gold-standard’ diagnostic 
test. Semen microscopy remains the recommended test for MGS, although its acceptability and 
applicability in endemic areas with limited laboratory capacity poses a significant challenge in the 




management of MGS. Urine filtration with microscopic examination for S. haematobium eggs has 
been utilised in such settings as a convenient but unfortunately error-prone proxy of MGS.  
Through a recent longitudinal cohort study conducted among fishermen along the south 
shoreline of Lake Malawi in Mangochi district, my work described a novel low-cost sampling and 
direct visualisation method for enumeration of ova in semen, which helped to diagnose MGS, 
showing a prevalence of MGS was 10% using seminal microscopy and 27% on seminal real-time 
polymerase chain reaction (PCR), with UGS prevalence of 17%. With such diagnostic challenges 
regarding MGS highlighted, there is need to improve diagnostic tests as well as raise adequate 
professional awareness for comprehensive clinical assessment, treatment and inclusion of men in 
preventive chemotherapy programs like mass drug administration (MDA) campaigns with PZQ. I 
hope my paper on diagnostics draws attention to the importance of increased research on MGS 
diagnostics, and that an intricate knowledge on circulating schistosome glycans has application in 





























































Appendix 31: Research output – Description of the planned fieldwork studies through 






















































REPORT ON THE REAL-TIME POLYMERASE CHAIN REACTION (PCR) FOR MALE GENITAL 
SCHISTOSOMIASIS (MGS) AT LABORATORY FOR MEDICAL MICROBIOLOGY AND IMMUNOLOGY, ST. 
ELISABETH TWEESTEED HOSPITAL IN TILBURG, NETHERLANDS. 
1. Background introduction 
Schistosomiasis is caused by snail-borne parasites Schistosoma spp, causing urogenital 
disease (S. haematobium) and hepato-intestinal disease (S. mansoni, etc) (McManus et al., 2018). 
Male genital schistosomiasis (MGS), a specific manifestation due to eggs and pathologies in genital 
fluids and tissues, remains underreported despite its first report in 1911 and possible association 
with Human immunodeficiency virus (HIV) (Kayuni et al., 2019a). Advanced diagnostics tests for 
schistosomiasis using circulating cathodic antigen (CCA) and circulating anodic antigen (CAA), include 
point-of-care (POC) CCA urine dipsticks (van Dam et al., 2004), up-converting phosphor-lateral flow 
assay (UCP-LF CAA) (Corstjens et al., 2008) and real-time polymerase chain reaction (PCR) (Kenguele 
et al., 2014). Despite these diagnostic advances, MGS remain undiagnosed and untreated among 
men in endemic areas. 
2. Cohort study on Male genital schistosomiasis (MGS) in Malawi 
A longitudinal cohort study was conducted among fishermen along south-western shores of 
Lake Malawi from October 2017 to December 2018. At baseline, 17.1% of the study participants had 
urogenital schistosomiasis (n = 210), 3.8% were positive on POC-CCA test (possible hepato-intestinal 
schistosomiasis), 35.7% had detectable CAA levels on UCP-LF CAA while 10.4% had MGS, thus S. 
haematobium eggs in semen (n = 114). Preserved semen samples in ethanol were shipped to 
Laboratory for Medical Microbiology and Immunology (LMMI) in St. Elisabeth Tweesteed Hospital in 
Tilburg, Netherlands, for real-time PCR, showing a higher MGS prevalence of 26.5%. 
3. Specific aims  




a. Undergo training in real-time PCR for detecting low-intensity schistosome infections. 
b. Novel application of semen real-time PCR to diagnose undetectable MGS infection.  
4. Activities and outcomes of the visit to LMMI  
The following activities were done during the period of my visit to LMMI: 
a. Training by Dr Jaco Verweij on real-time PCR and novel semen application for MGS. 
b. Tutorial on developing primers for real-time PCR. 
c. Oral presentation on the Cohort study on Male genital schistosomiasis in Malawi. 
d. Compilation of real-time PCR results from 12-months follow-up of our cohort study. 
e. Preliminary analysis, interpretation and discussion of the preliminary PCR results. 
5. Outcomes of the visit to LMMI 
The training on real-time PCR and its novel semen application emphasised the role of PCR in 
improving MGS diagnosis in our study. Real-time PCR was conducted on the samples which showed 
rise in MGS prevalence from 2% observed in the field, to 28% (Table below). We observed that some 
positive PCR participants had no Schistosoma eggs in semen and urine, which highlights the 
diagnostic challenges in MGS and need for improved, multiplex diagnostic platform for MGS to pick 
up more possible cases.  
Sample 
Microscopy Real-time PCR 
Number Positive Prevalence Number Positive Prevalence 
Urine 61 6 9.8% 61 4 6.6% 
Semen 50 1 2.0% 50 14 28.0% 
6. Conclusion  
I am very grateful to Burroughs-Wellcome Fund for the Collaborative Research Travel Award, 




novel application in MGS diagnosis. Also, to Dr Jaco Verweij and his team at LMMI for the warm 
reception, training, expertise and advice on the cohort study and real-time PCR results. Finally, to my 
supervisors Professor J.R. Stothard and Dr E.J. LaCourse for their overwhelming support throughout 





































Appendix 40: Research output – Reports in the local media in Malawi 
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